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ABSTRACT 
 
The peroxisome proliferator-activated receptor (PPAR) δ is a ligand-dependent 
transcription factor that has been implicated in metabolic and inflammatory regulation. 
The molecular and physiological mechanisms by which PPARδ activation regulates 
lipid metabolism, inflammatory signaling and protection from atherosclerosis in states of 
metabolic disturbance such as insulin resistance and dyslipidemia, were investigated in 
a series of in vitro and in vivo studies. In vitro experiments were performed in THP-1 
human macrophages. These studies demonstrated that PPARδ activation inhibits 
atherogenic lipoprotein-induced lipid accumulation and the associated proinflammatory 
responses. Specifically, treatment of macrophages with the synthetic PPARδ agonists 
GW0742 or GW1516 attenuated triglyceride (TG) accumulation and cytokine 
expression induced by very low-density lipoprotein (VLDL). The primary mechanisms 
for these effects were increased fatty acid β-oxidation, decreased lipoprotein lipase 
(LPL) activity, reduced MAPK signaling and improved insulin signaling. With regard to 
cholesteryl ester (CE)-rich low-density lipoprotein (LDL), the PPARδ activators 
stimulated cholesterol efflux via ABCA1 to apoAI, resulting in the inhibition of native and 
modified LDL-induced CE accumulation. In vivo studies were conducted in high fat, 
high cholesterol (HFHC)-fed low-density lipoprotein receptor null (Ldlr-/-) mice. 
Following a 4-week induction phase of HFHC-feeding to stimulate early atherosclerotic 
lesion development, dietary supplementation with GW1516 for a subsequent 8-weeks 
prevented further plaque progression. This prevention was linked to inhibition of 
dyslipidemia, hyperinsulinemia, and glucose and insulin intolerance. Furthermore, 
GW1516 strongly attenuated aortic inflammation, insulin resistance and endoplasmic 
reticulum (ER)-stress, which likely contributed to inhibition of lesion progression.  
iii 
 
Additional studies in the liver showed that PPARδ activation inhibits hepatic TG 
accumulation induced by HFHC-feeding. To further probe the mechanism for this effect, 
experiments were conducted in primary mouse hepatocytes isolated from wild-type 
(WT) or adenosine monophosphate-activated protein kinase (AMPK) β1-/- mice. These 
studies revealed that PPARδ activation in the liver stimulates fat oxidation due to 
upregulation of the PPARδ-target gene carnitine palmitoyl transferase (Cpt) 1a, which 
occurred independent of AMPK activation. Furthermore, GW1516 inhibited de novo 
lipogenesis, which was partially dependent on AMPK activation. The residual inhibitory 
effect on fatty acid synthesis was associated with correction of selective hepatic insulin 
resistance. 
In summary, these studies provide significant insight and support for PPARδ 
activation as a therapeutic strategy to treat the dysregulation of lipid homeostasis, 
inflammatory signaling, metabolic disease, and their cardiovascular complications. 
Keywords: PPARδ, macrophage foam cells, intervention, inflammation, 
atherosclerosis, insulin resistance, mouse model 
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Chapter 1* 
Thesis topics review 
 
1.1 GENERAL INTRODUCTION 
 Cardiovascular disease (CVD) represents the leading cause of death in the 
industrialized world, and will likely soon achieve this status worldwide (Lloyd-Jones et 
al., 2010). The underlying cause of most cardiovascular events is atherosclerosis, a 
decades-long chronic inflammatory disease of large and medium sized arteries, 
ultimately resulting in the formation of complex lesions known as plaques (Glass and 
Witztum, 2001, Moore and Tabas, 2011). Unstable plaques are prone to rupture, 
resulting in the formation of thrombi that can subsequently induce the acute clinical 
manifestations of myocardial infarction or stroke (Libby et al., 2011). Major risk factors 
for the development of atherosclerosis include age, hypertension, smoking, obesity, 
diabetes and increased plasma concentrations of cholesterol and triglycerides (TG) 
(Libby et al., 2011). Despite the success of pharmacological treatment of many of these 
risk factors, the prevalence of CVD in all groups of Canadians has continued to rise (Lee 
et al., 2009). The class of drugs known as statins effectively lower plasma cholesterol 
levels and CVD (Cannon et al., 2004). However, significant residual risk remains, 
possibly due to the fact that statins do not improve other cardiometabolic risk factors 
such as high plasma TG, obesity and diabetes. Consequently, novel therapeutic 
strategies to alleviate these unmet medical needs are highly sought-after. 
 This thesis focuses on defining the mechanism of action and therapeutic 
potential of peroxisome proliferator-activated receptor (PPAR) δ activation in the 
regulation of lipid metabolism, inflammatory signaling and protection from 
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atherosclerosis in states of metabolic disturbance such as insulin resistance and 
dyslipidemia.  
1.2 DYSLIPIDEMIA AND CARDIOVASCULAR DISEASE 
Cholesterol is an essential precursor in the synthesis of all steroid hormones, bile 
acids and the myelin sheath that surrounds axons (Goldstein and Brown, 2009). 
Furthermore, cholesterol is a major component of all cellular membranes, providing 
barrier functions between microenvironments and modulating membrane fluidity 
(Goldstein and Brown, 2009). Cells acquire cholesterol from a number of sources 
including de novo cholesterol synthesis, as well as uptake of cholesteryl ester (CE)-rich 
apoB100 containing lipoproteins, namely low-density lipoprotein (LDL) in the periphery, 
and CE-rich high-density lipoprotein (HDL) in the liver. 
Since 1913 when Anitschkow and Chalatow first experimentally demonstrated 
the link between plasma cholesterol and atherosclerosis (Chatalow, 1983), clinical 
studies have clearly shown that a 2-fold increase in plasma cholesterol is associated 
with a 6-fold increase in CVD risk (Neaton and Wentworth, 1992). The fact that the 
cholesterol biosynthetic pathway was a regulated process that could be manipulated to 
modulate plasma cholesterol was well established in the 1950s and 1960s, which 
launched the search for cholesterol synthesis inhibitors (Vance and Van den Bosch, 
2000). Three-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase converts 3-hydroxy-
3-methylglutaryl-coenzyme A to mevalonate, the rate-limiting step in the production of 
cholesterol, which subsequently became the major target for the treatment of 
hypercholesterolemia using the class of drugs called statins (Tobert, 2003). Although 
compactin (mevastatin), isolated from Penicillium citrinum, was the first potent inhibitor 
of HMG-CoA reductase reported by Akiro Endo in 1976 (Endo et al., 1976), the first 
statin to be approved for use in the clinical arena was lovastatin, discovered by Alberts 
and colleagues at Merck Research Laboratories (Alberts et al., 1980). Since these early 
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studies, statins have become the standard of care in reducing plasma LDL-cholesterol 
(LDL-C) in a variety of patient populations, yielding primary and secondary prevention 
against CVD (Mills et al., 2008). Despite the overwhelming evidence from large 
randomized controlled trials demonstrating the success of statins in reducing morbidity 
and mortality in high risk CVD patients, about 50-75% of cardiovascular events are not 
prevented with these drugs (Mazzone et al., 2008). In addition to high plasma LDL-C, 
atherogenic dyslipidemia is now characterized by increased plasma TG-rich very low-
density lipoprotein (VLDL) and low plasma HDL, neither of which are appreciably 
affected by statin treatment (Musunuru, 2010). Therefore, additional therapeutic 
strategies are required to complement existing medical therapies in CVD risk 
management. 
Fasting hypertriglyceridemia is strongly associated with elevated rates of 
atherosclerotic CVD, particularly in patients with type 2 diabetes (Talayero and Sacks, 
2011). The extent of atherosclerosis in this patient population is positively correlated with 
plasma concentrations of TG-rich lipoproteins, namely VLDL as well as intermediate 
density lipoprotein (IDL), also known as VLDL-remnants (Reyes-Soffer et al., 2013). 
Importantly, individuals with type 2 diabetes are at significantly higher risk for developing 
CVD, even if LDL-C has been reduced to the therapeutic goal (Talayero and Sacks, 
2011). Since each of VLDL, IDL and LDL harbors one apoB100 molecule, measuring 
total apoB reflects the total number of potentially atherogenic particles in plasma and is 
therefore a stronger predictor of CVD risk than simply measuring LDL-C (Walldius and 
Jungner, 2006). As such, targeting apoB100 specifically represents an attractive 
therapeutic target in the treatment of dyslipidemia. Antisense oligonucleotides (ASO) 
against apoB100 successfully reverse diet-induced dyslipidemia in mice without affecting 
intestinal lipid absorption or accumulation, and without causing hepatic steatosis (Crooke 
et al., 2005, Mullick et al., 2011). Furthermore, apoB100 ASOs profoundly inhibit the 
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development of murine atherosclerosis (Mullick et al., 2011). Preliminary trials in humans 
have shown that apoB100 ASOs are generally well-tolerated, and effectively lower all 
plasma apoB100-containing lipoproteins (Lippi and Favaloro, 2011). Future trials are 
required to determine whether apoB ASOs will reach the clinical arena. Nevertheless, 
reducing plasma apoB100 may confer protection from development of CVD. 
Raising plasma HDL-cholesterol (HDL-C) has been given considerable attention 
as a potential therapeutic strategy based on a substantial body of evidence suggesting 
the cardioprotective capacity of these lipoproteins. HDL is responsible for reverse 
cholesterol transport, the process by which cholesterol is drawn from peripheral tissues, 
and is transported to the liver for biliary excretion (Rader et al., 2009). Furthermore, 
epidemiological evidence reproducibly shows an inverse correlation between plasma 
HDL-C levels and CVD (Nicholls et al., 2012). As a result, this has led to the 
development of the HDL hypothesis: interventions to raise HDL-C will confer reduced 
CVD risk (Rader and Tall, 2012). However, recent human trials have suggested that 
simply raising total HDL-C levels may not be the appropriate goal. Torcetrapib, the first 
generation cholesteryl ester transfer protein (CETP) inhibitor, successfully raised plasma 
HDL-C levels yet cardiovascular events and all cause mortality were significantly higher 
in the treatment arm of the phase III clinical trial (Barter and Rye, 2012). The increased 
mortality in torcetrapib-treated individuals was attributed to off-target effects of the drug 
(Barter and Rye, 2012), prompting further evaluation of CETP inhibition as therapeutic 
approach to treating CVD. The next major phase III clinical trial involving a CETP 
inhibitor (dalcetrapib-OUTCOMES) was conducted by Roche and was halted early due 
to interim analyses demonstrating that the drug was not providing reduced CVD risk, 
despite significantly raising HDL-C (Schwartz et al., 2012). These results suggest that 
the HDL-C hypothesis may require replacement by the „HDL flux hypothesis‟, in which 
interventions to raise HDL reverse cholesterol transport capacity and HDL turnover may 
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confer protection from CVD (Rader and Tall, 2012). Although the application of this 
hypothesis is in its infancy, interventions that increase reverse cholesterol transport and 
not simply bulk HDL-C are in development (Nicholls et al., 2012). 
In summary, therapeutic interventions that lower LDL-C beyond statin 
monotherapy, decrease plasma apoB100 concentrations, decrease plasma triglycerides 
or increase the capacity of HDL to promote reverse cholesterol transport may prove to 
be effective in reducing CVD. 
1.2.1 ATHEROSCLEROSIS 
Atherogenesis begins with the entry and retention of apoB-containing lipoproteins 
within the arterial intima of susceptible regions of large and medium sized arteries 
(Tabas et al., 2007). Subsequent to lipoprotein retention, a series of biological and 
maladaptive immune responses ensue (Tabas et al., 2010). Complex interactions 
between the endothelium, vascular smooth muscle cells and immune cells such as 
macrophages, drive plaque progression through a non-resolving expansion of the 
arterial intima which protrudes into the arterial lumen (Moore and Tabas, 2011). 
Although this protrusion can eventually lead to tissue ischemia, the predominant acute 
clinical events are myocardial infarction or stroke caused by rupture of unstable plaques 
generating thrombi that can occlude local or distal arteries (Libby et al., 2011).  
 An artery consists of three morphologically distinct layers: the intima, media and 
adventitia (Figure 1.1). The intima is the innermost layer, which is defined by an 
endothelial cell monolayer on the luminal side, the internal elastic lamina on peripheral 
side and extracellular matrix collagen and proteoglycans in between (Lusis, 2000). 
Endothelial cells of the intima regulate vascular tone via the production of vasoactive 
mediators (Sudano et al., 2006). The medial layer consists of vascular smooth muscle 
cells that participate in the regulation of vascular tone as well as the synthesis and 
secretion of elastin, collagen and sulfated glycosaminoglycans. The intimal side of the 
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Figure 1.1: Composition of the arterial wall.  
Arteries contain three distinct layers: (1) the intima which which is defined by an 
endothelial cell monolayer on the luminal side that protects the subendothelial intima 
from entry of atherogenic lipoproteins, (2) the media which consists of vascular smooth 
muscle cells that participate in the regulation of vascular tone as well as the synthesis 
and secretion of elastin, collagen and sulfated glycosaminoglycans and (3) the 
adventitia which is comprised of connective tissue with sporadic fibroblasts, smooth 
muscle cells and progenitor cells. 
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arterial media is defined by the internal elastic lamina, while the adventitial side is 
defined by the external elastic lamina (Lusis, 2000). Finally, the adventitia, the outermost 
arterial layer, is comprised of connective tissue with sporadic fibroblasts, smooth muscle 
cells and progenitor cells. 
 Normally the endothelial monolayer provides a protective barrier between the 
arterial lumen and the subendothelial intima (Libby et al., 2011). However, in curvatures 
and bifurcations of the arterial tree, blood flow is disturbed, characterized by retrograde 
and oscillatory shear stress which promotes a proinflammatory endothelial cell 
phenotype (Cybulsky and Jongstra-Bilen, 2010). In turn, these regions of the endothelial 
monolayer exhibit increased adhesiveness and permeability to atherogenic lipoproteins. 
Upon entry into the intima, apoB100 interacts with extracellular matrix 
glycosaminoglycans resulting in lipoprotein trapping which in turn leads to oxidative and 
hydrolytic modification of apoB by secretory phospholipase A2 and secretory 
sphingomyelinase, both of which are produced by macrophages (Moore and Tabas, 
2011). In response to retention and modification of apoB, the proinflammatory phenotype 
of endothelial cells is extended to the upregulation of adhesion molecules such as P-
selectin, intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule 
(VCAM), which collectively promote the endocytosis of monocytes into the 
subendothelial space (Moore and Tabas, 2011).  
Once resident in the intima, monocytes give rise to a heterogeneous population 
of cells that regulate immune responses (Becker et al., 2012). Monocyte-derived 
dendritic cells internalize, process and present antigens (such as lipid or modified apoB 
fragments) to T-cells, potentiating immune cell recruitment (Becker et al., 2012). 
Monocyte-derived macrophages engulf lipoprotein-derived lipids in attempt to clear the 
atherogenic substrate, and are hence considered atheroprotective in early lesions 
(Moore and Tabas, 2011). However, overwhelming accumulation of apoB100-containing 
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lipoproteins in the intima renders macrophage lipid uptake and efflux mechanisms 
dysregulated, which generates lipid-laden macrophage foam cells (Libby et al., 2011). 
The accumulation of foam cells coupled with the inflammatory response contributed by 
both dendritic cells and macrophages defines the unresolving nature of a growing 
atheroma (Libby et al., 2011).  
1.2.2 CHOLESTEROL-RICH MACROPHAGE FOAM CELLS 
 Macrophage cholesterol homeostasis is regulated by uptake, storage and efflux 
(Figure 1.2). The development of CE-rich lipoprotein-induced “macrophage foam cells” - 
a histological term that reflects the microscopic appearance of lipid-laden macrophages - 
is initiated by the ingestion and processing of LDL in both its native and modified forms 
(Libby et al., 2011). Native LDL uptake occurs via the LDL receptor (LDLR), which 
undergoes negative feedback regulation under high intracellular sterol concentrations 
(Goldstein and Brown, 2009). Although this pathway certainly contributes to foam cell 
development (Goldstein and Brown, 2009), the predominant LDL uptake pathway by 
macrophages in lesions is that of modified LDL via the scavenger receptors cluster of 
differentiation (CD) 36 and scavenger receptor A I/II (SRAI/II). Upon entry into the intima, 
LDL particles undergo oxidative modification rendering them high-affinity scavenger 
receptor ligands (Moore and Freeman, 2006). Unlike the native LDLR, scavenger 
receptors do not undergo negative feedback regulation in response to intracellular sterol 
accumulation (Moore and Freeman, 2006). Consequently, macrophage uptake of 
modified LDL particles in lesions can persist indefinitely, and is only limited by substrate 
availability and cell viability.  
Once internalized, lipoprotein derived cholesteryl esters are hydrolyzed in the 
late endosomes to free cholesterol and fatty acids (Maxfield and Tabas, 2005). Through 
mechanisms that are poorly understood, the late endosomal protein Niemann Pick C1 
(NPC1) traffics late endosomal free cholesterol to the endoplasmic reticulum (ER), 
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Figure 1.2: Cholesterol homeostasis in macrophages. 
The LDL receptor (LDLR) mediates the uptake of native LDL particles through receptor-
mediated endocytosis. Modified LDL, namely oxLDL is also taken up via receptor 
mediated endocytosis by the scavenger receptors CD36 and SRAI/II. Upon 
internalization, CE is hydrolyzed in the late endosomes/early lysosomes into free 
cholesterol and transferred to the endoplasmic reticulum for processing. The two major 
pathways for this free cholesterol are: (1) efflux via the cholesterol efflux transporters 
ABCA1 (to apoAI) and ABCG1 (to HDL3), and (2) re-esterification by ACAT into 
cholesteryl ester for storage in cytoplasmic lipid droplets. 
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where acyl-CoA:cholesterol acyltransferase (ACAT) re-esterifies free cholesterol to 
cholesteryl fatty acid esters for storage in cytoplasmic lipid droplets (Brown et al., 1980, 
Ikonen, 2008). Lipid droplet CE is a defining feature of LDL-induced macrophage foam 
cells in atherosclerotic plaques. However, it has been suggested that as lesions 
progress, ACAT activity diminishes (Rong et al., 2013). As proof-of-concept, the ablation 
of macrophage ACAT1 in hypercholesterolemic mouse models of atherosclerosis results 
in increased atherosclerotic lesion area (Accad et al., 2000, Fazio et al., 2001). 
Subsequent studies demonstrated that the increase in atherosclerosis in ACAT-deficient 
settings is due to enrichment of free cholesterol in ER membranes, which initiates the 
ER-stress response and promotes a proinflammatory, apoptosis-susceptible 
macrophage (Li et al., 2005, Seimon et al., 2009). As a result, hyperlipidemia coupled to 
diminishing ACAT activity in advanced plaques contributes to the potentiation of plaque 
progression. Under these circumstances, it is critical that the rate of cholesterol efflux 
maintains intracellular free cholesterol content below inflammatory and cytotoxic levels.  
Normally free cholesterol released from the late endosomal pathway, as well as 
free cholesterol mobilized from cytoplasmic lipid droplets, can traffic to the plasma 
membrane via the Golgi-to-membrane vesicular pathway to become accessible for 
cholesterol efflux out of the cell (Tall et al., 2008). The removal of plasma membrane 
cholesterol from macrophages is the predominant pathway for cholesterol mobilization 
from plaques during atherosclerosis regression (Fisher et al., 2012), and occurs via 
ATP-binding cassette (ABC) A1- and ABCG1-mediated free cholesterol transport to 
apolipoprotein A1 (apoA1) and HDL respectively (Tall et al., 2008). HDL particles are 
also recognized by the scavenger receptor, class B type I (SR-BI) in the periphery as 
well as the liver (Trigatti et al., 2003). Increasing the cholesterol efflux pathway has very 
clear cardioprotective effects (Fisher et al., 2012). Intravenous injection of apoAI into 
hypercholesterolemic rabbits successfully delayed lesion progression, and intravenous 
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infusion of a recombinant form of apoAI induced significant regression of atherosclerosis 
in apoE deficient mice (Miyazaki et al., 1995, Shah et al., 2001). Conversely, as 
predicted, combined deletion of ABCA1 and ABCG1 in macrophages significantly 
increases lesion development in mice (Yvan-Charvet et al., 2007). Interestingly, ABCG1 
deletion alone is atheroprotective due to compensatory upregulation of ABCA1 (Tarling 
et al., 2010). 
In summary, dynamic regulation of cholesterol uptake, storage and efflux 
requires a fine balance in plaque macrophages, and ultimately dictates the fate of 
atherosclerotic lesions. 
1.2.3 INFLAMMATION AND APOPTOSIS IN CHOLESTEROL-RICH FOAM CELLS 
As alluded to in sections 1.1 and 1.2.1, a major characteristic of atherosclerosis 
is chronic low-grade inflammation. Although it has recently been challenged (Spann et 
al., 2012), the generally accepted paradigm is that cholesterol-treated macrophages 
exhibit a proinflammatory phenotype (Moore and Tabas, 2011). Specifically, oxidized 
LDL (oxLDL) has been reported to stimulate proinflammatory cytokine expression 
through CD36 in concert with the pattern recognition toll-like receptors (TLR) (Moore and 
Tabas, 2011). The assembly of CD36-TLR complexes leads to the activation of nuclear 
factor kappa B (Nfκb) signal transduction to simulate expression of inflammatory 
mediators (Stewart et al., 2010). In macrophages isolated from CD36 deficient patients, 
oxLDL fails to stimulate cytokine expression (Janabi et al., 2000), and loss of this 
scavenger receptor protects mice against diet-induced atherosclerosis and aortic 
inflammation (Febbraio et al., 2000, Manning-Tobin et al., 2009). Furthermore, specific 
deletion of TLR4 or TLR6 abrogates oxLDL-induced inflammatory responses in vitro 
(Stewart et al., 2010), while TLR1, TLR2 and TLR6 deletion attenuates atherogenesis in 
a variety of atherosclerosis mouse models (Curtiss et al., 2012, Mullick et al., 2005).  
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In addition to lipoprotein-mediated cell-surface stimulation of inflammatory signal 
transduction, intracellular cholesterol accumulation can also lead to macrophage 
inflammation. In particular, free cholesterol loading stimulates an ER-stress pathway 
known as the unfolded protein response (UPR), which serves as a repair pathway during 
times of ER perturbation (Martinet et al., 2012, Tabas and Ron, 2011). However, 
prolonged ER-stress leads to the induction of a specific branch of the UPR involving 
C/EBP homologous protein (CHOP), which in turn stimulates Nfκb signaling, and 
eventually apoptosis and secondary necrosis. These latter consequences of free 
cholesterol-induced ER-stress are central features of advanced atherosclerotic lesions 
that are vulnerable to rupture (Li et al., 2005, Thorp et al., 2009). Increased ER-stress 
markers have been visualized in plaques isolated from hypercholesterolemic mice (Zhou 
et al., 2005). Furthermore, Chop/apoE double knockout mice background exhibit 
substantially smaller atherosclerotic lesions than Chop+/+;apoE-/- mice (Thorp et al., 
2009). Moreover, the global deletion of Chop reduced plaque macrophage apoptosis 
and necrosis, thus resulting in more stable atherosclerotic lesions (Thorp et al., 2009). 
Subsequently it was shown that macrophage-specific deletion of Chop also reduced 
plaque vulnerability (Tsukano et al., 2010). Importantly, free cholesterol loaded 
macrophages with ER-stress-induced inflammation and apoptosis are significant 
contributors to the accelerated atherosclerosis progression observed in the insulin 
resistant state (Tabas et al., 2010). 
Despite the overwhelming evidence that cholesterol-treated and cholesterol-
loaded macrophages are proinflammatory the data are not consistent across all 
experimental settings. THP-1 human monocytes that are differentiated into 
macrophages and treated with LDL that has been mildly or extensively oxidized 
displayed reduced expression of a panel of proinflammatory cytokines (Qiu et al., 2007). 
In a subsequent study, addition of the TLR2/TLR4 ligand lipopolysaccharide (LPS) 
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stimulated an Nfκb-mediated inflammatory response in primary human monocytes, 
which was completely inhibited by the addition of oxLDL (Kannan et al., 2012). Recently, 
Spann et al. demonstrated that cholesterol loading of mouse peritoneal macrophages 
results in downregulation of cholesterol biosynthesis, which consequently increases 
intracellular concentrations of a very specific oxysterol, desmosterol. Importantly, 
desmosterol is a potent activator of the liver X receptor (LXR), a nuclear hormone 
receptor that is known to mediate anti-inflammatory processes (Spann et al., 2012). 
Collectively, these studies suggest that understanding macrophage inflammatory 
responses in the context of hypercholesterolemia requires further study. This 
controversy will be further elaborated on in Chapter 3 of this thesis. 
1.2.4 TRIGLYCERIDE-RICH MACROPHAGE FOAM CELLS 
The canonical atherogenic lipoprotein is CE-rich LDL. However, elevated plasma 
TG-rich VLDL is now regarded as a significant contributor to the development of 
cardiovascular disease, particularly in the context of insulin resistance and type 2 
diabetes (Talayero and Sacks, 2011). Although a causal relationship between TGs and 
atherosclerosis has been difficult to establish (Goldberg et al., 2011), TG-rich apoB-
containing lipoproteins have been localized in plaques isolated from humans as well as 
animal models of disease (Proctor and Mamo, 1998, Rapp et al., 1994), justifying further 
investigation of the impact of these lipoproteins on macrophage foam cell formation. 
It is well established that VLDL readily stimulates TG accumulation in 
macrophages (Figure 1.3), which is initiated by cell-surface bound lipoprotein lipase 
(LPL) hydrolyzing the TG-rich core of VLDL particles (Bates et al., 1984, Huff et al., 
1991). The liberated fatty acids (FAs) are subsequently taken up by cells either via 
passive diffusion or via protein-mediated uptake by the FA translocase (FAT)/CD36. 
Upon internalization, FA binding proteins transport FAs to the outer mitochondrial 
membrane for activation to fatty acyl-CoAs by acyl-CoA synthetases (Yen et al., 2008). 
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Figure 1.3: VLDL-induced foam cell formation. 
The interaction between VLDL and cell-surface bound lipoprotein lipase (LPL) results in 
the hydrolysis of the VLDL TG-rich core to free fatty acids (FFAs). These FFAs are 
internalized either via passive diffusion or protein-mediated uptake by the fatty acid 
translocase (FAT) CD36. Upon internalization, FFAs are either re-esterified into TG by 
the DGAT enzymes for storage in cytoplasmic lipid droplets, or transported into the 
mitochondria by CPT1α for fatty acid β-oxidation. Excessive fatty acid uptake without 
sufficient β-oxidation results in the development of TG-rich macrophage foam cells. 
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This activation step is a requirement for further FA trafficking within the cell. For 
example, the acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymes catalyze the re-
esterification of FAs into triaclyglycerol for storage in cytoplasmic lipid droplets, and use 
activated fatty acyl-CoAs as the acyl donors (Yen et al., 2008). Although the exact 
process by which TG is deposited into lipid droplets is not fully understood, it is believed 
that the DGAT enzymes synthesize TGs mainly at the lipid bilayer of the ER (Walther 
and Farese, 2012). Nevertheless, macrophage exposure to VLDL stimulates foam cell 
formation due to substantial accumulation of cytoplasmic TG. It is therefore important 
that the process of FA β-oxidation maintains TG homeostasis to prevent excessive 
accumulation of lipid-laden macrophages in the arterial intima. Fatty acid oxidation will 
be discussed in detail in section 1.4.4. 
1.2.5 INFLAMMATION IN TRIGLYCERIDE-RICH FOAM CELLS 
 Although TG-rich macrophages are by definition foam cells, the induction of 
inflammatory responses does not occur in response to TG accumulation per se. Rather, 
the stimulation of macrophage inflammation and cytotoxicity is thought to occur as a 
consequence of VLDL-derived free fatty acid (FFA) exposure to cells. Inhibition of LPL 
resulted in complete abrogation of the VLDL-stimulated inflammatory response in mouse 
peritoneal macrophages (Saraswathi and Hasty, 2006). Additionally, peritoneal 
macrophages and bone marrow-derived macrophages isolated from Dgat1 transgenic 
mice fed a high fat diet accumulate a significant amount of TG, but were protected from 
an inflammatory response (Koliwad et al., 2010), which further demonstrates that FFAs 
are responsible for an inflamed macrophage phenotype rather than TGs themselves. A 
number of groups independently suggested that FFAs activate TLR-dependent signaling 
to generate macrophage inflammation and lipotoxicity (Lee et al., 2004a, Shi et al., 
2006). However, this claim has more recently been cast in doubt by other studies 
(Anderson et al., 2012, Erridge and Samani, 2009).  
19 
 
 
 VLDL-derived FAs elicit macrophage inflammatory responses, at least in part due 
to stimulation of MAPK signaling. The MAP kinases extracellular signal-related kinase 
(ERK)1/2 and p38 cooperatively regulate the activated protein (AP)-1 transcription factor 
(Figure 1.4), which is known to participate in the induction of a host of proinflammatory 
cytokines (Eferl and Wagner, 2003). VLDL not only stimulates ERK1/2 activation 
(Saraswathi and Hasty, 2006), but it also potentiates LPS-induced cytokine expression 
(Stollenwerk et al., 2005), attributable to the simultaneous activation of parallel pathways 
by each stimulus. In addition to inducing MAPK signaling, VLDL-derived FAs can also 
promote an insulin-resistant macrophage phenotype, which can potentiate the 
inflammatory response (Su et al., 2009). The impact of macrophage insulin resistance 
on inflammation, apoptosis and atherosclerosis will be further discussed in section 
1.5.3.2 of this thesis. Interestingly, in contrast to free cholesterol-induced macrophage 
inflammation, FFA-induced cytokine expression does not require Nfκb activation (Erridge 
and Samani, 2009).  
 The induction of macrophage foam cell formation and the inflammatory response 
by VLDL, as well as the ability of peroxisome proliferator-activated receptor (PPAR)-δ 
activation to attenuate these effects is the topic of Chapter 2 of this thesis (Bojic et al., 
2012).  
1.2.6 ATHEROSCLEROTIC LESION PROGRESSION 
The stages of atherosclerosis are numerically classified based on histological 
features at each stage of the disease (Stary, 2000). Initial lesions, classified as Type I 
(Stary et al., 1994), are characterized by thickening of the arterial intima due to the 
accumulation of lipoproteins and increased cellularity (Figure 1.5), with development of 
isolated groups of macrophage foam cells. In many cases, Type I lesions can be 
detected during infancy (Stary et al., 1994). As foam cell accumulation persists to the 
point of gross microscopic detection, the lesion becomes classified as Type II, also 
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Figure 1.4: VLDL-induced MAPK signaling in macrophage foam cells.  
VLDL-derived FAs stimulate the phosphorylation of the MAP kinases extracellular signal-
related kinase (ERK)1/2 and p38 via mechanisms that remain to be elucidated. 
Phosphorylated ERK1/2 and p38 cooperatively stimulate the activation of the activated 
protein (AP)-1 transcription factor. Activated AP-1 translocates into the nucleus where it 
binds to AP-1 response elements (AP-1RE) within promoter regions of proinflammatory 
cytokine genes. 
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Figure 1.5: Atherosclerotic Lesion Progression. 
Endothelial dysfunction and build up of arterial lipids and lipoproteins stimulate the 
recruitment of macrophages to the site of vascular insult. Macrophages of the arterial 
intima scavenge lipoprotein-derived lipids, resulting in foam cell formation. Excessive 
macrophage foam cell accumulation results in the development of a lipid core associated 
with proinflammatory immune responses. To stabilize the expanding lipid core, smooth 
muscle cells are stimulated by inflammatory effectors from the lesion to proliferate into 
the plaque and deposit extracellular matrix proteins such as collagen. This results in the 
formation of a fibrous plaque. Consequences of unresolved atherogenesis include 
vessel occlusion, rupture and thrombosis, all of which can induce an acute 
cardiovascular event such as myocardial infarction or stroke.  
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referred to as a fatty streak. At this stage, smooth muscle cells indigenous to the lesion 
location can also take up lipid resulting in a smooth muscle cell-foam cell phenotype 
(Stary et al., 1994). The bridge between Type II lesions and advanced plaques are Type 
III intermediate lesions, for which the major histological feature is microscopically visible 
extracellular pools of lipid, namely cholesterol crystals (Stary et al., 1994). This is most 
likely due to the onset of ER-stress-induced apoptosis of macrophage foam cells as a 
consequence of unresolved inflammation in the plaque, coupled to defective clearance 
of dead cells and debris by phagocytic immune cells (Moore and Tabas, 2011). Despite 
monocyte recruitment persisting at all stages of lesion development in efforts to clear the 
atherogenic substrates and debris (Swirski et al., 2006), the presence of extracellular 
cholesterol crystals and debris disrupts and displaces extracellular matrix within the 
lesion. Consequently, the classification extends to Type IV lesions, or atheromas, which 
are characterized by the presence of a defined lipid core causing severe intimal 
disorganization (Stary et al., 1995). Secondary necrosis is also a major feature of Type 
IV lesions as a result of continued ER-stress-induced apoptosis as discussed in section 
1.2.3. It is important to note that Type I to III lesions are clinically silent, and it is at the 
Type IV lesion stage that blood flow may begin to be significantly disrupted and lead to 
compromised arterial function (Stary, 2000). Intimal and newly recruited medial smooth 
muscle cells increase the presence of fibrotic tissue in the plaque, which consists of 
elastin, collagen, proteoglycans and glycoproteins that forms a fibrous cap as an effort to 
stabilize the necrotic lipid core. The presence of this cap is the prominent new feature 
that defines the progression to Type V lesions (Stary et al., 1995). Despite increased 
fibrous cap formation, local immune cells produce matrix-metalloproteinases that 
degrade the deposited extracellular matrix, which eventually leads to fibrous cap thinning 
(Weber et al., 2008). The resultant lesions are prone to neovascularization, which 
increases leakage, hemorrhage, and rupture (Weber et al., 2008). All of these processes 
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contribute to the contact of plaque debris with the circulation, triggering coagulation and 
thrombus formation, thereby increasing likelihood of arterial occlusion leading to 
myocardial infarction or stroke. Therefore, whether lesion progression, stabilization or 
regression occurs is determined by the complex interactions between the physical and 
environmental factors within the lesion. 
1.3 LIPOPROTEIN METABOLISM 
 Whole body lipid homeostasis is maintained through a balance between 
exogenous uptake and endogenous synthesis of fatty acids and cholesterol, as well as 
the trafficking of these lipids in macromolecular complexes called lipoproteins. 
1.3.1 LIPOPROTEINS 
 All lipoproteins are spherical, soluble lipid carriers comprised of a hydrophobic 
TG and CE rich core encased by a hydrophilic monolayer of phospholipids, free 
cholesterol and apolipoproteins (Hegele, 2009). The classification of lipoproteins is 
based on their density, lipid composition and apolipoprotein association (Table 1.1). In 
addition to providing structural support to lipoprotein complexes, apolipoproteins also 
determine the interaction of lipoproteins with cell surface receptors as well as their rate 
of catabolism.  
The largest lipoproteins are chylomicrons which are formed in the intestine and 
transport dietary TGs on an apoB48 backbone, with trace amounts of dietary cholesterol. 
Very low-density lipoproteins (VLDL), secreted by hepatocytes, carry endogenous TG 
with modest amounts of endogenous as well as exogenous CE on an apoB100-
backbone, and are associated with apoEs and apoCs. The catabolism of VLDL results in 
VLDL-remnant lipoproteins called intermediate density lipoproteins (IDL), which transport 
roughly equal partitions of TG and CE. Further catabolism of IDL followed by a series of 
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modifications and lipid exchanges with various lipoproteins, results in the formation of 
CE-rich LDL particles (Hegele, 2009).  
 Cholesteryl Ester is also transported by HDL, the smallest lipoprotein type. The 
protein backbone of HDL particles is apoAI, which is predominantly secreted from the 
liver and initially lipidated by hepatic ABCA1 (Timmins et al., 2005). This lipidation 
results in the formation of nascent HDL which enters the plasma and undergoes a series 
of enzymatic lipid transfer modifications to form mature HDL (Sorci-Thomas and 
Thomas, 2012). Cholesterol is effluxed to HDL as free cholesterol and is re-esterified 
into the hydrophobic core of the particles by HDL-associated lecithin-cholesterol 
acyltransferase (LCAT). Once HDL becomes CE-enriched, it can be remodeled by 
cholesteryl ester transfer protein (CETP) in plasma which facilitates the movement of CE 
from HDL to VLDL in exchange for TG. In turn, HDL particles become better substrates 
for hepatic lipase (HL). Mature HDL particles serve as carriers of cholesterol from the 
periphery to the liver, where cholesterol is converted to bile acids for subsequent 
excretion (Repa and Mangelsdorf, 2000). 
1.3.2 EXOGENOUS LIPOPROTEIN METABOLISM 
 Absorption of dietary lipids occurs in the jejunal portion of the small intestine. 
Cholesterol is absorbed via protein-mediated uptake by the transporter Niemann-Pick 
C1-like1 (NPC1L1) on the brush-boarder membrane of the intestinal lumen (Huff et al., 
2006), whereas dietary TG requires hydrolysis by pancreatic lipase before it can be 
taken up by soluble passive diffusion. Upon internalization into intestinal enterocytes, 
fatty acids are sequentially re-esterified into TG by the MGAT and DGAT enzymes. It is 
dietary TG, rather than cholesterol, which determines the rate of formation of the 
exogenously derived TG-rich chylomicron particles (Karpe, 2002). The apoB48 
backbone of chylomicrons is derived from editing of full-length APOB mRNA by the apoB 
mRNA editing enzyme (APOBEC1), which deaminates cytidine 6666 of the APOB 
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transcript to a uridine (Rosenberg et al., 2011). This results in a change at position 2153 
of the apoB protein from glutamine to a stop codon, yielding a translated protein that is 
the N-terminal 48% of the 550kDa polypeptide apoB100 chain (Chen et al., 1987). In 
humans, APOBEC1 is expressed exclusively in the intestine, whereas mice express this 
enzyme in both intestine and liver. ApoB48 is cotranslationally lipidated with TG, CE and 
phospholipids by microsomal triglyceride transfer protein (MTP) within the ER of 
intestinal enterocytes prior to secretion into the lymphatic system as a chylomicron 
(Figure 1.6).  
 Chylomicrons, upon entry into the lymphatics and into plasma, become 
associated with apoEs and apoCs, both of which are required for the metabolism of 
chylomicron particles. Specifically, apoCII is required for the activation of TG hydrolysis 
by LPL, an enzyme which is secreted by parenchymal cells of muscle and adipose 
tissue, and is anchored to capillary endothelial cells by heparin sulfate proteoglycans. 
Chylomicron-derived FFAs and glycerols are taken up predominantly by adipose tissue 
and re-esterified into TGs for storage. The resultant chylomicron remnant particles are 
efficiently taken up by the liver through LDLR- and LDL receptor related protein (LRP)-
mediated uptake by recognition of apoE (Blasiole et al., 2007), concluding the 
exogenous lipid metabolism pathway. 
1.3.3 ENDOGENOUS LIPOPROTEIN METABOLISM 
 The endogenous lipoprotein pathway begins with the recycling of TG and 
cholesterol from chylomicron remnants in the liver, intersecting with the hepatic de novo 
synthesis of these lipids. Approximately 80% of circulating cholesterol is produced by the 
body, mostly in hepatocytes, making the liver the primary regulator of whole body 
cholesterol and lipid homeostasis (Hegele, 2009). 
 Synthesis of both cholesterol and TG begins with the formation of acetyl-CoA 
derived from the metabolism of glucose or fatty acids. The 32-step cholesterol 
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Figure 1.6: Endogenous and Exogenous Lipoprotein Metabolism. 
Dietary triglycerides and cholesterol are packaged onto apoB48 within the intestinal 
enterocytes. The resultant chylomicron particles are secreted into the lymphatics, which 
subsequently enter the blood stream. Lipoprotein lipase (LPL) hydrolyzes triglycerides 
(TGs) which allows uptake of free fatty acids (FFAs) into peripheral tissues. The remnant 
cholesteryl ester (CE)-rich particle is taken up by the liver through LDL receptor (LDLR)- 
and LDLR related protein (LRP)-mediated endocytosis. Dietary and newly synthesized 
lipids are packaged onto apoB100, which is secreted by the liver as VLDL. These 
particles also undergo hydrolysis by LPL. The CE-rich VLDL-remnant particles (IDL), 
and IDL modified to LDL particles, can be taken up by the liver or peripheral tissues 
through the LDLR. The reverse cholesterol transport pathway involves the removal of 
cholesterol from peripheral tissues via efflux to HDL. This lipoprotein particle is efficiently 
cleared by SR-BI in the liver, where cholesterol is converted to bile acids for excretion in 
bile. 
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biosynthetic pathway is initiated by the condensation of two acetyl-CoA molecules to 
produce acetoacetyl-CoA, which is the substrate for HMG-CoA-synthase in the formation 
of HMG-CoA. Subsequently, HMG-CoA-reductase, the rate-limiting enzyme in the 
cascade and target of statins, catalyzes the generation of mevalonate, which through a 
series of condensation reactions yields squalene. The cyclization of squalene produces 
lanosterol, which is converted to cholesterol through a further 19-step process with the 
final reaction being the conversion of desmosterol to cholesterol by dehydrocholesterol 
reductase (DHCR) 24.  
 Fatty acid synthesis is initiated by the carboxylation of acetyl-CoA by acetyl-CoA 
carboxylase (ACC) to malonyl-CoA, which is subsequently elongated to palmitic acid by 
fatty acid synthase (FAS). Fatty acids can then be further elongated and/or 
monounsaturated prior to subsequent esterification into TG by the MGAT and DGAT 
enzymes in the ER. 
 The availability of both cholesterol and TG is required for the formation of VLDL 
particles. The apoB100 backbone of VLDL is cotranslationally lipidated by MTP 
exclusively in the liver prior to its secretion into the bloodstream. Within capillary beds of 
target tissues such as adipose and muscle, endothelial cell LPL hydrolyzes the TG-rich 
VLDL core liberating FFAs and glycerol which are taken up via soluble passive diffusion 
or CD36-mediated uptake. Re-esterification into TGs in adipose or fatty acid oxidation in 
muscle ensues. Following LPL-mediated hydrolysis of VLDL particles, VLDL-remnants 
or IDLs are formed, which can be taken up by recognition of apoE by the LDLR or the 
LRP following HL modification (Hu et al., 2008). Alternatively, IDL can become further 
enriched in CE from HDL via CETP, and can be further modified by HL, consequently 
resulting in the formation small sense CE-rich LDL particles. In humans, IDL modification 
leading to LDL formation is the predominant pathway. 
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 The final lipoprotein in the endogenous pathway is CE-rich LDL, which is mainly 
taken up receptor-mediated endocytosis. The LDLR is expressed ubiquitously, 
recognizes apoB100 and mediates the principal mechanism of LDL uptake. It accounts 
for approximately one third of LDL uptake by extrahepatic tissues. However, the liver is 
the primary site of LDLR expression and therefore regulates most of the clearance of 
circulating LDL particles. 
1.4 REGULATION OF FATTY ACID AND CHOLESTEROL METABOLISM 
1.4.1 STEROL REGULATORY ELEMENT BINDING PROTEINS 
 The sterol regulatory element binding proteins (SREBPs) are the master 
transcriptional regulators of lipid homeostasis (Horton et al., 2002). The three isoforms of 
the SREBP family are encoded by two genes; SREBP1, which generates the SREBP-1a 
and SREBP-1c isoforms through the use of different promoters to produce alternate 
forms of exon 1, and SREBP2 (Horton et al., 2002). The three members of the SREBP 
family have distinct but overlapping transcriptional programs. SREBP-1c is expressed 
predominantly in hepatocytes, where it directly activates the expression of genes 
involved in fatty acid synthesis and elongation in response to increases in plasma insulin 
levels. SREBP-1a and SREBP-2 are expressed ubiquitously where they regulate genes 
involved in cholesterol homeostasis in response to intracellular sterol concentrations 
(Shao and Espenshade, 2012). 
 All three SREBPs contain three basic domains: (i) an N-terminal basic helix-loop-
helix (bHLH) leucine zipper DNA binding motif for binding to sterol response elements 
(SREs) within promoter regions of their target genes, (ii) two hydrophobic 
transmembrane domains separated by a short loop that projects into the lumen of the 
ER and (iii) a regulatory C-terminal domain that interacts with the SREBP cleavage 
activating protein (SCAP) (Horton et al., 2002). The SREBPs are synthesized as inactive 
precursors, retained in the ER due to their interaction with SCAP through the MELADL 
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peptide sequence (Sun et al., 2005). Under conditions of high intracellular sterols, SCAP 
also interacts with the insulin induced genes (INSIG) 1/2; ER-anchor proteins that retain 
the SCAP/SREBP complex in the ER. When sterols are depleted, SCAP undergoes a 
conformational change resulting in the dissociation from INSIG, which allows access of 
COPII vesicles containing a Sar-1/Sec23/Sec24 complex to SCAP/SREBP. In turn, the 
SCAP/SREBP complex is trafficked to the Golgi for processing to active transcription 
factors (Sun et al., 2005). Depletion of hepatic SCAP results in the complete absence of 
processing of all three SREBPs, concomitant with normalization of lipogenesis and 
hypertriglyceridemia (Moon et al., 2012), demonstrating a lack of redundancy for SCAP-
mediated SREBP transport to the Golgi. Once the SCAP/SREBP complex reaches the 
Golgi, SREBPs undergo sequential cleavage by the Site 1 and Site 2 proteases (Shao 
and Espenshade, 2012). The Site 1 protease is a serine protease that cleaves the ER-
luminal loop separating the SREBP transmembrane domains. Subsequently, the Site 2 
zinc metalloproteinase releases the N-terminal bHLH leucine zipper fragment, allowing 
for its translocation into the nucleus where it binds to SREs within target gene promoters 
(Figure 1.7) (Shao and Espenshade, 2012). SREBP-1a and SREBP-2 activate 
transcription of genes involved in cholesterol uptake and cholesterol synthesis such as 
LDLR and HMG-CoA reductase, to restore sterol balance (Shao and Espenshade, 
2012). SREBP-1c on the other hand, stimulates the expression of genes involved in fatty 
acid synthesis and elongation, including ACC, FAS and stearoyl-CoA desaturase (SCD) 
(Moon et al., 2012). 
 In addition to SCAP, the INSIGs provide another layer of trafficking regulation to 
the SREBPs, owing to a convergent feedback loop (Goldstein et al., 2006). The two 
INSIG isoforms (INSIG-1 and INSIG-2) are protein products of separate genes and are 
differentially regulated. INSIG-1 transcription is activated by SREBP-1c in a feed forward 
mechanism to regulate the amount of cholesterol being restored. INSIG-2 produces two 
34 
 
 
 
 
 
 
 
Figure 1.7: Regulation of the Sterol Regulatory Element Binding Proteins. 
The sterol regulatory element binding proteins (SREBP) reside in the endoplasmic 
reticulum (ER) membrane as inactive precursors. During periods of high intracellular 
sterol, SREBPs interact with SREBP cleavage activating protein (SCAP), which in turn 
interacts with Insig to retain SREBPs within the ER membrane. Upon depletion of 
intracellular sterol, or insulin-mediated degradation of Insig, the dissociation of SCAP 
from Insig results in the trafficking of the SCAP-SREBP complex to the Golgi where 
sequential processing by Site 1 (S1P) and Site 2 proteases (S2P) releases the active 
nuclear SREBP transcription factor. SREBP transcription factors translocate into the 
nucleus and bind to sterol regulatory elements (SREs) within promoter regions of genes 
required for lipogenesis.  
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Adapted from (Shao and Espenshade, 2012). Cell Metab, 16, 414-9. 
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transcripts that encode the same protein, but are differentially regulated. INSIG-2a is a 
liver-specific isoform whereas INSIG-2b is ubiquitously expressed, yet has very low liver 
expression (Goldstein et al., 2006). Evidence that the INSIGs are required for the 
regulation of lipid homeostasis in liver was provided by Engelking and colleagues, when 
they simultaneously disrupted hepatic INSIG-1 and -2 (Engelking et al., 2005). The 
resultant phenotype was profound hepatic steatosis on a chow diet as a result of 
hyperactive SREBP-mediated lipogenesis, demonstrating that the INSIG proteins are 
essential for SREBP feedback regulation (Engelking et al., 2005). 
  The INSIGs are also regulated by plasma insulin, which sets the stage for 
reciprocal regulation during fasting and feeding cycles (Goldstein et al., 2006). As 
mentioned above, SREBP-1c is activated in response to increases in circulating insulin. 
During the fasted state, plasma insulin is low. In turn, SREBP-1c is inactive meaning that 
INSIG-1 expression is low. However, INSIG-2a levels are high, which contributes to 
SREBP-1c retention in the ER during the fasted state. As plasma insulin rises during 
feeding, INSIG-2a is rapidly degraded by Akt-dependent mechanisms allowing for 
SREBP-1c processing and translocation into the nucleus (Yecies et al., 2011). As a 
result, INSIG-1 levels increase owing to convergent feedback regulation, resulting in the 
prevention of SREBP-1c hyperactivity. In mice overexpressing hepatic Insig1, normal 
fasting/re-feeding regulation of INSIG-2 ensues, yet the livers of these animals are 
resistant to acute lipogenesis in the fed state (Engelking et al., 2004). This suggests that 
insulin-mediated suppression of INSIG-2 is required for insulin-induced SREBP-1c 
lipogenesis during feeding. In states of insulin resistance, hyperinsulinemia persists 
during fasting, resulting in the chronic downregulation of INSIG-2, which in part 
contributes to the hyperactivity of SREBP-1c-mediated lipogenesis (Yecies et al., 2011).  
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1.4.2 DE NOVO LIPOGENESIS 
Lipolysis of adipose tissue TG is the major contributor of FAs to VLDL-TG during 
periods of fasting (Zechner et al., 2012), while de novo lipogenesis is a minor contributor 
(Barrows and Parks, 2006). However during feeding, adipose tissue lipolysis is 
suppressed whereas hepatic de novo lipogenesis is simultaneously increased by insulin. 
Consequently, a major contributor to the pool of FAs for VLDL-TG in the fed state is de 
novo lipogenesis. 
 The synthesis of FAs begins with the carboxylation of acetyl-CoA to malonyl-CoA 
by ACC. Subsequently, malonyl-CoA provides two carbon units to FAS for the synthesis 
of 16 and 18 carbon saturated fatty acids. The resultant fatty acids require activation by 
long chain acyl-CoAs synthetase to fatty acyl-CoA before they can become substrates 
for subsequent processing or partitioning (Walther and Farese, 2012). Fatty acyl-CoAs 
are stearoyl CoA-desaturase (SCD) substrates for desaturation and subsequent 
esterification to cholesterol in the production of cholesteryl esters. Additionally, activated 
fatty acids are also used by CPT1α and DGAT for entrance into the mitochondria for 
fatty acid oxidation and for re-esterification of fatty acids into TGs, respectively (Walther 
and Farese, 2012).  
 The generation of TG is the major mechanism for metabolic fuel storage in living 
organisms (Yen et al., 2008). Two convergent pathways contribute to TG production, 
both of which utilize fatty acyl-CoAs as acyl donors. The canonical glycerol phosphate 
pathway occurs in most tissues and begins with the acylation of glycerol-3-phosphate by 
acyl-CoA:glycerol-3-phosphate acyltransferase to yield lysophosphatidic acid. 
Subsequently, lysophosphatidic acid is further acylated and dephosphorylated to 
produce diacylglycerol (DG) (Liu et al., 2012). In the monoacylglycerol pathway, which 
occurs mainly in the intestine, liver and adipose tissue, fatty acyl-CoAs are esterified to 
the 2-position of monoacylglycerol by acyl-CoA:monoglycerol acyltransferase (MGAT) to 
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produce DG (Liu et al., 2012). In the final step of TG synthesis, fatty acyl-CoAs are 
esterified to the 3-position of the resultant DG from either pathway by the DGAT 
enzymes (Liu et al., 2012). Newly synthesized TGs from both pathways are then 
transferred to cytoplasmic lipid droplets for storage via mechanisms that are not 
completely understood (Walther and Farese, 2012), or become incorporated into apoB-
containing lipoproteins via MTP in the liver and intestine for secretion. 
 The esterification of fatty acyl-CoAs onto DG occurs via sequential reactions in 
the ER by the resident DGAT enzymes DGAT1 and DGAT2. Despite having similar 
function, the two DGAT isoforms differ in gene family as well as protein sequence, with 
DGAT1 encoding a polypeptide chain approximately 35% longer than DGAT2 (Liu et al., 
2012). Nevertheless, DGAT1 is ubiquitously expressed but is most abundant in the small 
intestine and adipose tissue and is least abundant in the liver. Gene knockout studies 
revealed that Dgat1-/- mice are resistant to diet-induced dyslipidemia, obesity and insulin 
resistance (Smith et al., 2000), whereas Dgat2-/- mice die soon after birth due to 
lipopenia (Stone et al., 2004). Together these studies suggest that DGAT2 is responsible 
for the majority of TG synthesis required for survival.  
Interestingly, overexpression of Dgat1 specifically in white adipose tissue results 
in protection from diet-induced insulin resistance despite increased adiposity (Chen et 
al., 2002). Furthermore, overexpression of either form of DGAT in the liver results in a 
similar phenomenon. Dgat1 or Dgat2 liver-transgenic mice develop profound hepatic 
steatosis in the complete absence of insulin resistance. In addition, these mice do not 
accumulate any appreciable fat in skeletal muscle or adipose tissue and surprisingly 
display substantially reduced plasma triglycerides (Monetti et al., 2007). As discussed in 
section 1.2.5, macrophages isolated from Dgat1 transgenic mice display significant TG 
accumulation without an overt inflammatory phenotype (Koliwad et al., 2010). 
Collectively these studies suggest that the efficient synthesis of TG by DGAT1 results in 
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the partitioning of fat into cytoplasmic lipid droplets which protects cells from FA 
overload, lipotoxicity and lipoprotein overproduction thus conferring protection from 
metabolic disturbance (Monetti et al., 2007).  
1.4.3 CHOLESTEROL ESTERIFICATION 
 The ACAT enzymes are another group within the superfamily of membrane 
bound acyltransferases. ACAT1 and ACAT2 utilize fatty acyl-CoA donors and 
cholesterol as substrates in the esterification of cholesterol to generate CE for storage in 
cytoplasmic lipid droplets and lipoprotein secretion. The two isoforms are encoded by 
different genes and also differ in their tissue distribution. ACAT1 is ubiquitously 
expressed, whereas ACAT2 is found exclusively in the small intestine and liver. 
Knockout of Acat1 results in normal cholesterol absorption as well as normal intestinal, 
hepatic and plasma lipids due to the compensation of cholesterol esterification by 
ACAT2. The most significant change in Acat1-/- mice compared to their wild-type 
counterparts was virtually undetectable CE in the adrenal cortex and in isolated 
peritoneal macrophages (Meiner et al., 1996). In contrast, Acat2-/- mice cannot 
synthesize CE within the intestine and as a result, have reduced capacity to absorb 
cholesterol from the diet. Additionally, these mice cannot synthesize CE in the liver and 
therefore do not become hypercholesterolemic when fed a high-fat high-cholesterol diet 
(Buhman et al., 2000). 
 The different physiological roles of the ACAT isoforms become more readily 
apparent when examining atherosclerosis. Breeding Acat1-/- mice to either 
atherosclerosis susceptible apoE-/- or Ldlr-/- background does not protect from 
atherosclerosis (Accad et al., 2000). In fact, lesion complexity is exacerbated compared 
to Acat1 WT on either background. In addition, bone marrow transplantation from Acat1-
/- mice to these atherogenesis models also worsens atherosclerosis lesion pathology 
(Fazio et al., 2001). As discussed in section 1.2.2, this is likely due to FC-induced ER-
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stress, apoptosis and secondary necrosis as a result of the inability of macrophages to 
sequester cholesterol as metabolically inert CE. Subsequently, Acat2-/- mice were bred 
to both Ldlr-/- and apoE-/- mice. In contrast to the Acat1-/- crosses, Acat2 deficiency 
protects against atherosclerosis (Lee et al., 2004b, Willner et al., 2003), probably owing 
to the lack of hypercholesterolemia in these animals as outlined above (Buhman et al., 
2000). Finally, tissue-specific targeting of Acat2 attenuates atherogenic dyslipidemia 
(Zhang et al., 2012). Collectively, these studies demonstrate that pharmacological 
inhibition of ACAT2 would likely be beneficial for treatment of atherosclerosis. 
1.4.4 FATTY ACID OXIDATION 
A critical process in maintaining lipid homeostasis and generating ATP is the 
oxidation of fatty acids. In hepatocytes, stimulation of fat oxidation also limits TG 
availability for VLDL assembly and secretion, in turn contributing to reduced plasma TG 
levels. In the muscle and heart, fatty acid oxidation is vital for the generation of ATP 
required for contractility. In macrophages, activation of fat oxidation is crucial to 
maintaining intracellular TG in balance with uptake and storage, which can contribute to 
reduced foam cell formation.  
The rate-limiting step in the oxidation of fatty acids is CPT1-mediated entry into 
the mitochondria (Figure 1.8) (Bonnefont et al., 2004). CPT1 is an outer mitochondrial 
membrane enzyme that uses activated fatty acyl-CoA donors in the production of 
acylcarnitine. Subsequently, acylcarnitine can freely translocate across the outer and 
inner mitochondrial membranes. Upon entry into the mitochondrial matrix, CPT2, which 
is localized on the inner mitochondrial membrane, catalyzes the reformation of fatty acyl-
CoA, and liberates carnitine for subsequent CPT1-mediated reactions (Bonnefont et al., 
2004). Fatty acyl-CoA processing via four enzymatic steps ensues in the mitochondrial 
matrix to generate acetyl-CoA groups that can enter the Kreb‟s cycle to be oxidized for 
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Figure 1.8: The carnitine palmitoyl-transferase system. 
Carnitine palmitoyl-transferase (CPT) 1 is located on the outer mitochondrial membrane, 
and uses activated fatty acyl-CoA donors in the production of acylcarnitine. The 
production of this intermediate allows for fatty acyl-carnitine to freely translocate across 
the outer and inner mitochondrial membranes. Upon entry into the mitochondrial matrix, 
CPT2, which is localized on the inner mitochondrial membrane, catalyzes the 
reformation of fatty acyl-CoA, and liberates carnitine for subsequent CPT1-mediated 
reactions. Fatty acyl-CoA processing via four enzymatic steps ensues in the 
mitochondrial matrix to generate acetyl-CoA groups which enter the Kreb‟s cycle to be 
oxidized for the production of ATP, CO2 and water. 
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the production of ATP, CO2 and water. In most tissues, CPT1α is the predominant 
isoform that regulates fat oxidation. However, a CPT1β isoform also exists, which is 
mainly expressed in the skeletal muscle, adipose tissue and heart (Bonnefont et al., 
2004). 
Regulation of fat oxidation occurs via multiple mechanisms. CPT1 is regulated at 
a transcriptional level by a series of complex transcription factors including PPARγ-
coactivator 1 α (PGC1α), PPARα and PPARδ. Additionally, CPT1 is also allosterically 
regulated by malonyl-CoA (Rasmussen et al., 2002). During periods of feeding, malonyl-
CoA levels are high due to increased flux through the ACC de novo lipogenesis pathway 
as outlined above. Conversely, during periods of fasting, malonyl-CoA levels drop due to 
decreased ACC activity, alleviating the impediment on CPT1-mediated fatty acid 
oxidation (O'Neill et al., 2013). Animal models in which malonyl-CoA levels are 
manipulated can vastly alter metabolic phenotypes. Liver-specific deletion of fatty acid 
synthase results in substantially increased hepatic malonyl-CoA content, reduced 
CPT1α-mediated oxidation and as a result, hepatic steatosis (Chakravarthy et al., 2005). 
On the other hand, hepatic overexpression of malonyl-CoA decarboxylase (which 
degrades malonyl-CoA to acetyl-CoA) resulted in depletion of hepatic malonyl CoA. 
Consequently, fat oxidation was increased, and dyslipidemia and insulin resistance were 
normalized (An et al., 2004). Collectively, these studies highlight the importance of fatty 
acid β-oxidation in whole body lipid homeostasis, and suggest that therapeutic 
interventions to increase fat oxidation may confer protection from metabolic disease. 
1.4.4.1 FATTY ACID OXIDATION – PPAR REGULATION 
 The PPARs are a class of ligand-dependant transcription factors that regulate 
whole body lipid homeostasis (Harmon et al., 2011). Two members of this family, namely 
PPARα and PPAR δ, stimulate transcriptional programs that initiate fat oxidative 
machinery. In the liver, the major PPAR isoform is PPARα, which binds to PPAR 
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response elements (PPREs) within promoters of specific genes as an obligate 
heterodimer with the retinoid X receptor (RXR) (Harmon et al., 2011). This 
heterodimerization and initiation of transcription occurs in response to activation by 
endogenous ligands such as FAs and FA metabolites, or by synthetic ligands such as 
fibrates (Mandard et al., 2004). The canonical PPARα target is acyl-CoA oxidase (ACO), 
which stimulates peroxisomal oxidation of long chain FAs (Mandard et al., 2004). This 
stimulation of hepatic fatty acid oxidation is likely the key component in the ability of 
fibrates, synthetic ligands for PPARα, to effectively lower plasma TG levels. Fibrates are 
the current standard of care in the treatment of hypertriglyceridemia in dyslipidemic 
patients with insulin resistance (Reyes-Soffer et al., 2013). 
In addition to PPARα, the other PPAR isoform that can stimulate fat utilization is 
PPARδ (Wang et al., 2003). In fact, CPT1α is a known PPARδ target gene (Lee et al., 
2006a). The ability of PPARδ activation to regulate fatty acid oxidation and consequently 
prevent macrophage foam cell formation and hepatic steatosis is a significant 
component of the data in chapters 2 and 5 of this thesis. A more detailed discussion of 
PPARδ-regulated processes and functions will be presented in section 1.7. 
1.4.5 AMPK – THE PIVOTAL REGULATOR OF FAT OXIDATION AND LIPOGENESIS 
The adenosine monophosphate-activated protein kinase (AMPK) is an 
evolutionarily conserved serine/threonine kinase that controls cellular and whole body 
energy metabolism (O'Neill et al., 2013). The heterotrimeric protein consists of an α-
catalytic subunit, as well as β- and γ-regulatory subunits both of which are required for 
the catalytic activity of the α-subunit (O'Neill et al., 2013). Hepatocytes isolated from 
mice lacking the β1-subunit display significantly reduced AMPK activitiy (Dzamko et al., 
2010). As an energy-sensing protein kinase, AMPK operates as a fulcrum between 
anabolic and catabolic processes in response to changes in cellular AMP and ATP 
levels (Figure 1.9). During periods of low energy such as fasting, increases in cellular 
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Figure 1.9: Regulation of FA synthesis and oxidation by AMPK activation. 
AMPK operates as a fulcrum between anabolic and catabolic processes in response to 
changes in adenylate charge. During periods of low energy, increased cellular AMP 
binds to the γ-subunit of AMPK, inducing a conformational change in the heterotrimer 
that unmasks α-catalytic subunit to upstream kinases. The two major AMPK-activating 
kinases are liver kinase B1 (LKB1) and calcium/calmodulin-dependent protein kinase 
kinase (CaMKK), both of which phosphorylate AMPK on Thr172 within the α-catalytic 
subunit. LKB is an AMP-sensitive kinase. Activated AMPK stimulates the 
phosphorylation of SREBP-1c which inhibits SREBP-1c processing and reduces 
expression of genes required for fatty acid synthesis. Concomitantly, AMPK 
phosphorylates ACC, which inhibits ACC function thereby inhibiting the production of 
malonyl CoA. This limits substrate availability for fatty acid synthesis. Reduced malonyl-
CoA also results in the derepression of CPT1α, thus increasing fatty acid oxidation.  
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ADP and AMP results in the binding of either of these nucleotides to the γ-subunit of 
AMPK, inducing a conformational change in the heterotrimer that unmasks the activation 
loop of the α-catalytic subunit to upstream kinases (O'Neill et al., 2013). The two major 
AMPK-activating kinases are liver kinase B1 (LKB1) and calcium/calmodulin-dependent 
protein kinase kinase (CaMKK), both of which phosphorylate AMPK on Thr172 within the 
α-catalytic subunit. In addition, ADP and AMP suppress AMPK inactivation by preventing 
the dephosphorylation of phospho-Thr172 by protein phosphatases PP2A and PP2C 
(Oakhill et al., 2011, Sanders et al., 2007). Activated AMPK inhibits anabolic processes 
(such as lipogenesis) and stimulates catabolic processes (such as fatty acid oxidation) to 
simultaneously conserve and produce energy. Once cellular energy has been restored, 
or feeding has occurred thus providing energy excess due to the stimulation glycolysis 
and fatty acid oxidation by dietary glucose and TG, respectively, AMP levels are 
depleted and ATP levels are increased. Accordingly, PP2A and PP2C reduce AMPK 
activity, catabolic processes cease and anabolic processes ensue (O'Neill et al., 2013). 
Amongst the myriad of AMPK targets is ACC, which is thought to be the major 
contributor to the pivotal regulation of lipogenesis and oxidation (O'Neill et al., 2013). 
ACC exists in two isoforms, ACC1 and ACC2, which are phosphorylated by AMPK on 
Ser79 and Ser221, respectively (O'Neill et al., 2013). Phosphorylation of these ACC 
sites by AMPK results in the inactivation of ACC thus reducing malonyl-CoA production. 
In turn, substrate availability for FAS is limited, thereby downregulating lipogenesis to 
conserve energy. Additionally, low malonyl-CoA alleviates allosteric inhibition of CPT1α 
and therefore stimulates fat oxidation. Given the ability of activated AMPK to favorably 
regulate metabolic processes and so collectively reduce cellular fat deposition, 
pharmacological modulators of AMPK represent a promising therapeutic strategy to 
regulate of lipid imbalances observed in cardiometabolic disease (Pinkosky et al., 2013). 
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1.5 INSULIN SIGNALING 
 Insulin is a peptide hormone that is produced, processed and secreted by the β-
cells of the pancreas in response to feeding, and is central to regulating the metabolism 
of carbohydrate, protein and lipids. Insulin responsive tissues such as muscle, adipose 
and liver among others, express plasma membrane bound insulin receptors which 
transduce the insulin signal. Binding of insulin to the extracellular ligand-binding domain 
rapidly stimulates the intrinsic activity of the receptor tyrosine kinase, resulting in 
autophosphorylation of tyrosine residues in the intracellular subunit domains (Kido et al., 
2001). This autophosphorylation event causes the recruitment of insulin receptor 
substrate (IRS) proteins to the cytoplasmic tail of the insulin receptor that serve as 
docking proteins between the membrane-bound receptor and its intracellular effectors. 
One major downstream target of the insulin signal is phosphoinositide 3 (PI3)-kinase, 
which signals the phosphorylation and activation of protein kinase B/Akt (Kido et al., 
2001). Under normal physiology, the downstream consequences of acute insulin-
stimulated Akt activation include suppression of hepatic glucose production and 
promotion of de novo lipogenesis. 
1.5.1 INSULIN-REGULATED HEPATIC GLUCOSE METABOLISM 
 Dietary glucose stimulates the release of insulin from the pancreas, which 
induces a feedback loop to suppress hepatic gluconeogenesis to maintain normal (low) 
blood glucose levels (Brown and Goldstein, 2008). Molecularly, insulin inhibits hepatic 
glucose production by stimulating the phosphorylation of forkhead box O1 (FoxO1) 
through the action of Akt (Figure 1.10). Phosphorylated FoxO1 is excluded from the 
nucleus, which effectively downregulates the transcription of genes involved in 
gluconeogenesis, most prominently glucose 6-phosphatase (G6PC) and 
phosphoenolpyruvate carboxykinase (PEPCK) (Matsumoto et al., 2006). Mice 
overexpressing constitutively active hepatic FoxO1 exhibit hyperglycemia and 
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Figure 1.10: Insulin signaling.  
Insulin signalling via the insulin receptor results in enhanced IRS/PI3K signalling, leading 
to Akt phosphorylation. In turn Akt phosphorylates its downstream effector substrates 
mTORC1 and FoxO1. Akt-induced phosphorylation of mTORC1 renders the protein 
active, resulting in increased SREBP-1c-mediated fatty acid synthesis. In contrast, Akt-
mediated phosphorylation of FoxO1 results in the inhibition of FoxO1 translocation into 
the nucleus. This suppresses PEPCK expression and consequently inhibits 
gluconeogenesis. 
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hyperinsulinemia, whereas RNAi knockdown of FoxO1 reverses these metabolic 
abnormalities (Kamagate et al., 2008). 
1.5.2 INSULIN-REGULATED HEPATIC LIPID METABOLISM 
Another major effect of insulin signaling in the liver is stimulation of de novo 
lipogenesis by activation of SREBP-1c. Mice lacking hepatic insulin receptors have 
severely diminished expression of the SREBPs and their targets (Biddinger et al., 2008), 
suggesting that hepatic insulin signaling is required for the stimulation of lipogenesis in 
the fed state. The molecular basis for insulin-stimulated SREBP activity occurs through 
dual actions of Akt in the insulin signaling cascade. As outlined in section 1.4.1, Akt can 
directly target INSIG2a for degredation via mechanisms that are not completely 
understood, thereby allowing for SREBP processing and translocation into the nucleus 
(Yecies et al., 2011). On the other hand, activated Akt stimulates the phosphorylation of 
the mammalian target of rapamycin complex (mTORC) 1 (Figure 1.10), which is known 
to enhance the transcription of SREBP-1c and its targets (Li et al., 2010, Yecies et al., 
2011). Despite the insulin-mediated increase in hepatic de novo lipogenesis, insulin 
signaling also acutely suppresses hepatic VLDL secretion. The Akt-mediated 
phosphorylation and nuclear exclusion of FoxO1 reduces MTP expression (Kamagate et 
al., 2008), thus inhibiting cotranslational lipidation of apoB100. Additionally, insulin 
activates the MAPKerk pathway, which also regulates MTP expression and reduces lipid 
availability for VLDL secretion (Allister et al., 2005). 
1.5.3 INSULIN RESISTANCE 
 The metabolic syndrome is defined as a cluster of abnormalities including 
increased waist circumference, hypertension, low plasma HDL, high fasting blood 
glucose and high plasma TG, which collectively puts individuals at risk for the 
development of premature cardiovascular disease (Eckel et al., 2010). Insulin resistance 
is considered central to the pathophysiology of the metabolic syndrome and is clinically 
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defined as the inability of insulin to maintain glucose homeostasis (Haas and Biddinger, 
2009). In response to elevated blood glucose levels during fasting in the insulin resistant 
state, the pancreas responds by increasing insulin secretion to compensate for the lack 
of sensitivity in peripheral tissues, thus maintaining glycemic control (Eckel et al., 2010). 
Eventually the pancreas cannot provide sufficient insulin, blood glucose increases, and 
the diabetic state ensues. Therefore, insulin resistance has been causally linked to the 
development of type 2 diabetes (Eckel et al., 2010). 
Although the clinical definition of insulin resistance is useful, it fails to address 
other processes that are a result of insulin resistance. Insulin resistance is most 
prominently manifest in three organs: adipose, muscle and liver (Li et al., 2010). In the 
adipose tissue, failure of insulin to suppress TG lipolysis increases FA release and 
contributes to elevated plasma FFAs as well as the hepatic pool of FA available for TG 
re-synthesis and VLDL assembly and secretion. In muscle, the inability of insulin to 
stimulate glucose transporter (GLUT) 4 translocation to the plasma membrane, reduces 
insulin-mediated glucose uptake and contributes to fasting hyperglycemia. In the liver, 
however, an interesting paradox occurs where the lipogenic SREBP-1c branch of insulin 
signaling remains sensitive, whereas the gluconeogenic FoxO1 branch becomes 
resistant. 
1.5.3.1 INSULIN RESISTANCE IN THE LIVER 
 As alluded to above, hepatic insulin resistance cannot simply be defined as the 
failure of insulin to propagate signal transduction through the insulin receptor. Impaired 
insulin receptor signaling has been observed in a variety of settings (Nyomba et al., 
1990, Nyomba et al., 1991, Ozcan et al., 2004), and likely contributes to insulin 
resistance at certain stages of disease progression. However, in mice with hepatic 
insulin receptor ablation (termed pure insulin resistance), hyperinsulinemia and 
hyperglycemia still develop, yet in the complete absence of hepatic steatosis and 
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hypertriglyceridemia due to reduced SREBP-1c activity (Biddinger et al., 2008). Hence, 
the diabetic triad of hyperinsulinemia, hyperglycemia and hypertriglyceridemia breaks 
down in pure insulin resistance. This resulted in the hypothesis that normal insulin 
signaling must occur in the liver to at least some particular point (Brown and Goldstein, 
2008). After this hypothesized point, the insulin signal should bifurcate to generate 
insulin resistant and insulin sensitive branches of the pathway (termed selective insulin 
resistance) (Figure 1.11). This dual action of insulin is a major contributor to the 
hypertriglyceridemia and hyperglycemia observed in the insulin resistant state. 
Inhibition of PI-3K and Akt kinase activity in primary rat hepatocytes revealed that 
these were common mediators of the gluconeogenic and lipogenic branches of the 
insulin signal (Li et al., 2010). However, mTORC1 inhibition abolished insulin-induced 
SREBP-1c expression, but had no effect on insulin-mediated suppression of PEPCK (Li 
et al., 2010), demonstrating that the bifurcation point of the insulin signal is Akt. Hence, 
fasting hyperinsulinemia during insulin resistance chronically drives de novo lipogenesis, 
but fails to suppress gluconeogenesis due to the inability of Akt to phosphorylate and 
inactive FoxO1. Furthermore, active FoxO1 results in constitutive activation of MTP 
expression, and together with increased lipogenesis contributes to increased apoB100 
secretion (Biddinger et al., 2008, Kamagate et al., 2008). 
The bifurcation of the insulin signaling cascade begs the questions of how and 
why Akt phosphorylates and activates mTORC1 but fails to phosphorylate and inactivate 
FoxO1. Recently, it has been demonstrated that a particular cytosolic calcium sensing 
kinase, calcium-calmodulin dependent kinase II gamma (CaMKIIγ), stimulates the 
phosphorylation of FoxO1 on non-Akt sites, thereby promoting FoxO1 entry into the 
nucleus to stimulate hepatic glucose production (Ozcan et al., 2012). Importantly, activity 
of CaMKIIγ was significantly increased in obese ob/ob mice as well as wild type mice fed 
a high-fat diet for 20-weeks. Adenoviral knockdown of CaMKIIγ in either of these settings 
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Figure 1.11: Selective versus pure insulin resistance.  
Selective hepatic insulin resistance – Under hyperinsulinemic/insulin resistant 
conditions, the elevated plasma insulin results in chronic phosphorylation of the cascade 
to Akt. Paradoxically, the ability of Akt to phosphorylate mTORC1 remains sensitive, 
whereas Akt-mediated phosphorylation of FoxO1 becomes resistant. In turn, mTORC1-
driven SREBP-1c-mediated lipogenesis is significantly increased, whereas FoxO1-
processes remain activated rather than inhibited as in normal insulin signalling. 
Consequently, PEPCK-mediated gluconeogenesis ensues. The combined physiological 
effects of selective hepatic insulin resistance are: hyperinsulinemia, hypertriglyceridemia 
and hyperglycemia (the so-called diabetic triad) as well as hepatic TG accumulation. 
 
Pure hepatic insulin resistance – With liver-specific deletion of the insulin receptor, the 
diabetic triad breaks down. Although these animals develop hyperinsulinemia, the liver 
cannot respond to the plasma insulin. As a result, mTORC1 remains inactive, whereas 
the lack of impediment on FoxO1 renders it chronically active. The physiological 
consequences in this scenario are: hyperinsulinemia and hyperglycemia, with normal 
plasma and hepatic TG. 
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Adapted from Brown and Goldstein, 2008. Cell Metab, 7, 95-96. 
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diminished hepatic gluconeogenic gene expression, decreased fasting glycemia and 
improved insulin sensitivity (Ozcan et al., 2012). Given that ER-stress is known to 
accompany insulin resistance in the liver (Ozcan et al., 2004), and that ER-stress can 
dramatically increase cytosolic calcium levels (Fu et al., 2012), it is plausible that the 
CaMKIIγ-specific phosphorylation of FoxO1 is significantly induced during hepatic insulin 
resistance and prevents insulin-mediated phosphorylation and suppression of FoxO1 
activity. However, this hypothesis has yet to be explored. 
1.5.3.2 INSULIN RESISTANCE IN THE VASCULATURE 
 In addition to promoting atherogenic risk factors, namely dyslipidemia, insulin 
resistance may also drive atherosclerosis directly at the level of the artery wall (Tabas et 
al., 2010). Bone marrow transplantation from insulin receptor knockout mice (Insr-/-) into 
Ldlr-/- recipients substantially increased atherosclerotic lesion formation, specifically due 
to ER-stress induced apoptosis and necrotic core formation (Han et al., 2006). 
Furthermore, crossing Akt1-/- mice onto the apoE-/- background yields profound coronary 
atherosclerosis, attributable to increased inflammation in the vessel wall (Fernandez-
Hernando et al., 2007). In macrophages deficient for the insulin receptor, FC-induced 
ER-stress and apoptosis involves increased nuclear FoxO1 translocation and activity 
(Senokuchi et al., 2008). Consistent with this, FoxO1 is known to stimulate the 
transcription of at least one proatherogenic inflammatory cytokine in macrophages (Su et 
al., 2009), and FoxO1 ablation in vascular endothelial cells attenuates atherosclerosis 
development (Tsuchiya et al., 2012). All of these studies use proof-of-concept genetic 
ablation of insulin signaling strategies and consequently fail to address whether a 
selective insulin resistant phenotype may be occurring in the vessel wall during diet-
induced atherogenesis.  
A recent study demonstrated that macrophages isolated from Insr-/- or ob/ob mice 
displayed a significant reduction in expression and activity of the sarcoplasmic 
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endoplasmic reticulum calcium ATPase, which led to reduced flux of cytoslic calcium 
back into the ER and as a result, increased ER-stress-induced apoptosis (Liang et al., 
2012). This study suggests that a similar mechanism of insulin resistance may occur in 
the liver as well as in the vasculature. Thus, therapeutic agents that correct selective 
hepatic insulin resistance may also alleviate vascular insulin resistance, and reduce 
atherosclerosis through either of these mechanisms. 
1.6 TYPE 2 DIABETES 
 As insulin resistance persists, the pancreas responds by continuously increasing 
insulin secretion in an attempt to maintain glycemic control. However, maintenance of 
blood glucose homeostasis does not occur indefinitely, as pancreatic β-cells cannot 
undergo hyperplasia ad infinitum to keep up with the insulin resistant state of the 
periphery (Prudente et al., 2009). Consequently, the full type 2 diabetic state ensues, 
putting patients at up to four-fold higher risk of developing CVD than non-diabetic 
subjects (Fox et al., 2007, Fox et al., 2004). The proatherogenicity of type 2 diabetes has 
been thought to be multi-factorial, as hyperlipidemia, hyperglycemia, hyperinsulinemia 
and increased oxidative stress and inflammation combine to accelerate atherogenesis 
(Ginsberg, 2000).  
Despite considerable data demonstrating a positive correlation between diabetes 
and development of cardiovascular disease, delineating the relative contribution of each 
process outlined above to cardiovascular risk has proven difficult. Elevated plasma TG 
remains an independent risk factor for CVD development (Musunuru, 2010), and 
residual CVD risk left behind by statin monotherapy is at least 50% (Mazzone et al., 
2008). The ACCORD Lipid trial tested whether LDL-C lowering statin therapy in 
combination with TG-lowering fibrate therapy further reduced CVD risk. There was no 
significant reduction observed in patients receiving combination therapy compared to 
those receiving statin alone (Ginsberg et al., 2010). With respect to hyperglycemia, 
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intensive long-term glucose lowering has not proven successful in reducing 
cardiovascular events (Gerstein et al., 2011). Finally, the conjecture that 
hyperinsulinemia is atherogenic is also controversial, as this would imply that insulin is a 
proatherogenic molecule. If this were the case, then insulin therapy would be a poor 
choice for patients with insulin resistance or type 2 diabetes (Ginsberg, 2000). However, 
results from the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated a 
nearly statistically significant (P=0.052) effect of insulin and sulfonylurea treatment in 
reducing cardiovascular events (Group, 1998), and insulin glargine treatment for 6 years 
had a neutral effect on cardiovascular outcomes (Gerstein et al., 2012). Although 
assessment of long-term CVD prevention with insulin secretogogues such as GLP-1 
analogues and DPP4 inhibitors has not been completed, the data accumulated thus far 
suggests that CVD risk is not worsened and might be reduced, due at least in part to 
TG-lowering (Anagnostis et al., 2011, DeFronzo et al., 2008). Interestingly, the GLP-1 
analogue exenatide reverses FC-induced ER-stress and apoptosis in macrophages 
(Liang et al., 2012). Collectively, these studies suggest that patients with type 2 diabetes 
should be treated to the current standard of care for hyperglycemia and hyperlipidemia, 
until new clinical trials further our understanding of how to manage CVD risk in patients 
with type 2 diabetes.  
1.7 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS 
 The peroxisome proliferator-activated receptor (PPAR) δ has emerged as an 
important regulator of lipid homeostasis and inflammatory signaling. Recent in vitro, in 
vivo and human clinical studies have highlighted a role for PPARδ activation in 
prevention and treatment of insulin resistance and atherosclerosis. 
1.7.1 PPAR OVERVIEW 
The PPARs are a class of ligand-dependant transcription factors within the 
nuclear receptor superfamily. The three isoforms (PPARα, PPARγ and PPARδ) are 
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encoded by three separate genes, which exhibit overlapping but largely distinct patterns 
of tissue distribution and function (Chawla et al., 1994, Kliewer et al., 1994). PPARs 
follow the basic modular structure common to most nuclear receptors (Harmon et al., 
2011). Six exons encode four distinct domains which regulate PPAR function (Fournier 
et al., 2007). Exon 1 encodes the N-terminal activating function (AF)-1 domain which is a 
ligand-independent modulation domain amenable to post-translational modifications 
(Fournier et al., 2007). Exons 2 and 3 encode the zinc-finger DNA binding domain of 
PPARs, which bind to the PPAR response element (PPRE) direct repeat sequence 
AGGTCAnAGGTCA within promoter regions of PPAR-target genes (Fournier et al., 
2007). The hinge region, which is thought to participate in the nuclear translocation 
signal, is encoded by exon 4 (Fournier et al., 2007). The carboxy-terminal AF-2 domain, 
encoded by exons 5 and 6, contains the ligand binding domain and co-factor 
dimerization domains (Fournier et al., 2007). Additionally, the AF-2 domain includes the 
RXR-heterodimerization interface (Fournier et al., 2007). 
In an unliganded state, the PPAR-RXR heterodimer is bound to the PPRE by co-
repressors such as the nuclear co-repressor (NCoR) or the silencing mediator of retinoid 
and thyroid hormone receptor (SMRT), which are part of the histone deacetylase 
(HDAC) complex. Deacetylated histones keep chromatin tightly wound, thereby 
repressing gene expression. Consequently, in the absence of ligand, PPARs exert active 
repression of their target genes (Harmon et al., 2011). However, the binding of ligand 
induces a PPAR conformational change that results in the dissociation of co-repressor 
complexes from the PPAR-RXR heterodimer. This conformational change in PPARs 
results in a so-called “PPAR LxxLL charge clamp” in the AF-2 domain, which stimulates 
the recruitment of LxxLL-containing co-activator complexes, such as the nuclear co-
activator (NCoA) and the steroid receptor co-activator (SRC). NCoA and SRC are part of 
the histone acetyl transferase (HAT) complex (Harmon et al., 2011), which modifies 
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chromatin structure thereby allowing for gene transcription to ensue (Fournier et al., 
2007). Hence, ligand-dependent activation of PPARs results in active gene transcription.  
In addition to active repression and ligand-dependent activation, regulation of 
PPAR target genes can occur as a result of post-translational modification of the AF-1 
domain. One such example is the phosphorylation of the AF-1 domain of PPARγ by 
cyclin-dependent kinase (CDK) 5 (Choi et al., 2010). Consequently, PPARγ target genes 
are further actively repressed as a result of stronger association of the receptor with co-
repressor complexes which exert greater HDAC activity (Choi et al., 2010). Ligand-
binding in the AF-2 domain of PPARγ inhibits CDK5-mediated phosphorylation of 
PPARγ, which is one mechanism by which thiazoledinediones exert their anti-diabetic 
action (Choi et al., 2010). Additionally, inhibition of CDK5 results in the de-repression of 
PPARγ target genes as a result of this ligand-independent modificiation of the AF-1 
domain (Choi et al., 2011). Although this discovery has led to the search for novel 
approaches of modulating PPAR activity by manipulating the co-regulator complexes 
associated with PPARs, this field is still in its infancy and requires further study. 
PPARs most prominently differ in their ligand binding pockets as well as the 
tissues in which they are expressed. However, these receptors have a large compliment 
of target genes, which can create difficulties in establishing PPAR-specific effects 
(Harmon et al., 2011). Nevertheless, PPARα is predominantly expressed in hepatocytes, 
where activation of this isoform stimulates the catabolism of fatty acids while 
suppressing inflammatory responses (Mandard et al., 2004). Fibrates are synthetic 
ligands for PPARα which are currently used as therapeutic agents in the treatment of 
hypertriglyceridemia. PPARγ is expressed primarily in adipocytes where it functions as 
an essential regulator of adipose tissue inflammation, fat storage and differentiation 
(Barak et al., 1999, Rosen et al., 1999, Tontonoz et al., 1994). In addition, PPARγ 
activation increases expression of adiponectin, an adipokine that enhances insulin 
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sensitivity (Yamauchi et al., 2001). PPARγ is the target of thiazolidinediones, used 
clinically in the treatment of type 2 diabetes. In contrast to the more restricted tissue 
distribution of PPARα and PPARγ, PPARδ is ubiquitously expressed with particularly 
high abundance in muscle tissue and macrophages (Vosper et al., 2001, Wang et al., 
2004). Although PPARδ activation has yet to achieve clinical application, recent 
advancements have reduced the gap between preclinical studies and clinical use. 
1.7.2 PPARδ IN MACROPHAGES 
 Macrophage exposure to VLDL or VLDL-derived fatty acids readily stimulates 
foam cell formation (Whitman et al., 1999), the inflammatory response and ER-stress 
induced apoptosis, independent of lipopolysaccharide (Anderson et al., 2012, 
Saraswathi and Hasty, 2006). Induction of the inflammatory response was independent 
of toll-like receptors 4 or 2 (Anderson et al., 2012). Paradoxically, VLDL-derived fatty 
acids also activate macrophage PPARδ resulting in up-regulation of genes involved in 
fatty acid catabolism, including CPT1α (Chawla et al., 2003, Lee et al., 2006a). Thus, 
from an evolutionary standpoint, PPARδ serves as a fatty acid sensor in cells of the 
vasculature to prevent arterial lipid accumulation under normolipidemic conditions. 
However, in the context of hypertriglyceridemia, if PPARδ-regulated lipid homeostasis 
induced by fatty acids were sufficient to clear the incoming atherogenic substrate, 
atherosclerosis would not ensue. The requirement for potent synthetic agonists of 
PPARδ to reduce VLDL-induced macrophage lipid deposition has not been examined. 
 PPARδ also regulates the macrophage inflammatory response, in part, through 
the repressor protein B-cell lymphoma 6 (BCL-6) (Lee et al., 2003). In the absence of 
ligand, PPARδ is bound to BCL-6, thereby repressing its function. Consequently, 
proinflammatory cytokine expression is elevated. Ligand activation induces a 
conformational change in PPARδ resulting in dissociation of BCL-6 from the PPARδ 
corepressor complex and subsequent transrepression of proinflammatory mediators 
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(Figure 1.12). This phenomenon has also been documented in PPARδ knockout cells 
and cells expressing dominant negative PPARδ, suggesting that defective PPARδ, the 
absence of PPARδ, or ligand-activation of PPARδ render similar anti-inflammatory 
effects, due to the lack of BCL-6 sequestration (Figure 1.12) (Barish et al., 2008, Lee et 
al., 2003, Takata et al., 2008). Thus, in addition to protection from lipid overload, 
activation of PPARδ by fatty acids also serves to protect macrophages from lipotoxic 
proinflammatory responses under normolipidemic conditions. However, as discussed in 
sections 1.2.5 and 1.5.3.2, VLDL and VLDL-derived fatty acids mediate proinflammatory 
cytokine expression through MAPK activation (Anderson et al., 2012, Saraswathi and 
Hasty, 2006), and insulin resistant macrophages display enhanced proinflammatory 
cytokine expression due to dysregulated Akt/forkhead box protein O1 (FoxO1) signaling 
(Su et al., 2009). The impact of PPARδ activation on VLDL-induced macrophage 
inflammatory responses remains to be established.  
 Clinically relevant plaques are prone to rupture and exhibit lipid rich necrotic 
cores as a result of inflammation and ER-stress-induced apoptosis (Moore and Tabas, 
2011). Defective macrophage apoptosis is central to necrotic core formation and is 
therefore a major component of the progression of complex lesions to clinically relevant 
lesions (Tabas, 2010). Phagocytosis of apoptotic cells results in the engulfment of large 
amounts of lipids, including FAs, into the macrophage (Erwig and Henson, 2008), which 
in turn activates PPARδ expression (Mukundan et al., 2009). Bone marrow derived 
macrophages (BMDMs) from Pparδ-/- mice displayed significantly reduced phagocytosis 
of apoptotic cells (Mukundan et al., 2009), concomitant with a significant reduction in the 
expression of opsonins, molecules that regulate enhanced recognition and phagocytosis 
of apoptotic cells (Erwig and Henson, 2008, Lauber et al., 2004). In wild-type BMDMs, 
the PPARδ agonist GW0742 stimulated the expression of opsosnins and enhanced 
clearance of apoptotic cells which was entirely PPARδ-dependent 
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Figure 1.12: Consequences of PPARδ activation and PPARδ deletion: 
PPARδ Activation - PPARδ binding sites within promoter regions of its target genes are 
known as PPAR response elements (PPREs). In an unliganded state, the PPARδ-
retinoid X receptor (RXR) obligate heterodimer is bound to corepressor complexes, 
which inhibits basal transcription of PPARδ target genes. Ligand activation results in a 
conformational change in the receptor leading to dissociation of the corepressor 
complexes and subsequent recruitment of coactivator complexes to the PPARδ-RXR 
heterodimer. As a result, PPARδ-responsive genes are transcriptionally activated. Part 
of the PPARδ corepressor complex is the BCL-6 protein, which acts as an inflammatory 
repressor protein in response to ligand activation of PPARδ. The ligand-induced 
conformational change in PPARδ results in the dissociation of BCL-6 from the PPARδ 
corepressor complex. Subsequently, BCL-6 corepressor complexes are recruited to 
promoter regions of inflammatory cytokine genes, leading to the inhibition of 
proinflammatory mediator expression. 
PPARδ Deletion – Genetic ablation of PPARδ mimics the liganded state of the receptor, 
as the presence PPARδ is required for the corepressor complex to maintain basal target 
gene expression suppressed. Moreover, PPARδ is required for BCL-6 sequestration. 
Hence, when PPARδ is eliminated, cytokine expression is suppressed by BCL-6, and 
PPARδ-target genes are derepressed. 
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(Mukundan et al., 2009). These studies uniquely demonstrate that PPARδ activation in 
macrophages orchestrates efficient clearance of dying cells by induction of opsonin 
expression and represents a therapeutically relevant mechanism. Collectively, studies in 
cultured macrophages suggest that PPARδ activation may serve as a guardian of the 
vascular insult, and thus impact atherogenesis.  
1.7.3 PPARδ ACTIVATION AND THE PROTECTION FROM DIET-INDUCED 
ATHEROSCLEROSIS 
The in vivo role of PPARδ on atherosclerosis has proven elusive, due, in part, to 
the unique transcriptional regulation of proinflammatory processes (when associated) 
and anti-inflammatory processes (when dissociated) by the PPARδ:BCL-6 complex. Lee 
et al. demonstrated that transplantation of Pparδ-/- bone marrow into Ldlr-/- recipient mice 
resulted in significant atheroprotection (Lee et al., 2003). As discussed above, these 
studies revealed that deletion of Pparδ mimicked the liganded state of the receptor, and 
suggested that ligand-activation may be atheroprotective. However, in subsequent 
studies involving prevention protocols, administration of synthetic PPARδ agonists 
produced conflicting reports. The first two reports PPARδ activation in vivo utilized the 
GW0742 compound, and only showed an effect at megadoses at which this ligand is no 
longer PPARδ-specific (Li et al., 2004) (Graham et al., 2005). A subsequent study 
showed that lower PPARδ-specific doses of GW0742 reduced lesions and aortic 
expression of inflammatory cytokines in the angiotensin II–induced mouse model of 
atherosclerosis (Takata et al., 2008). It is important to note that angiotensin II 
significantly increases PPARδ expression, resulting in increased BCL-6 sequestration 
and enhanced inflammation (Takata et al., 2008). The next generation PPARδ agonist, 
GW1516, at PPARδ-specific doses, prevented atherosclerosis in apoE-/- mice fed a high-
fat diet, concomitant with reduced aortic inflammatory cytokine expression (Barish et al., 
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2008). However, lesion complexity and morphometry were not examined. Nevertheless, 
the prevention protocols used to date have not examined the ability of PPARδ activation 
to attenuate or to induce regression pre-established lesions. Furthermore, insulin 
resistance within arterial macrophages is known to enhance lesion development. The 
impact of PPARδ activation on arterial wall insulin sensitivity remains to be determined.  
1.7.4 PPARδ ACTIVATION IN HEPATOCYTES 
Hyperinsulinemia results in amplified stimulation of mTORC1, which 
consequently drives the master transcriptional regulator of lipogenesis, sterol regulatory 
element binding protein (SREBP)-1c (Haas et al., 2012, Horton et al., 2002, Yecies et 
al., 2011). In turn, SREBP-1c activates the lipogenic transcriptional program, which 
includes genes such as fatty acid synthase (Fasn), acetyl-CoA carboxylase (Acc) and 
stearoyl-CoA desaturase (Scd) (Horton et al., 2002). In db/db mice GW1516 treatment 
increased hepatic expression of Fasn, Acc and Scd2 leading to a modest increase in 
hepatic triglyceride (Lee et al., 2006b). In Ldlr-/- mice, adenoviral PPARδ (adPPARδ) 
gene delivery stimulated the expression of Fasn, Acc1, Acc2, Srebf1c and Pgc1b, and 
increased liver triglyceride content (Liu et al., 2011). In contrast, HepG2 cells treated 
with GW0742 displayed a marked reduction in TG accumulation, due to reduced 
processing of nuclear SREBP-1, which resulted in attenuated expression of Fasn and 
Scd1 (Qin et al., 2008). GW0742 increased expression of insulin-induced gene (Insig)-1, 
an SREBP-1 endoplasmic reticulum (ER) retention protein which contains a PPAR 
response element within its promoter. These results were reproduced in livers of db/db 
mice injected with adPPARδ (Qin et al., 2008). The spectrum of results observed in 
these studies can be explained by different mouse models, diets, selection of drugs 
used, or gene delivery versus drug strategies of increasing PPARδ activity. However, 
that PPARδ activation increases hepatic steatosis is counterintuitive, given the 
overwhelming data demonstrating that PPARδ activation improves whole-body insulin 
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sensitivity and lipid homeostasis, and stimulates fatty acid oxidation in a variety of cell 
types and tissues (Lee et al., 2006b, Tanaka et al., 2003, Wang et al., 2003). Therefore, 
additional studies are required to reconcile the ability of PPARδ activation to regulate 
resistant hepatic steatosis linked to insulin resistance. 
Liver inflammation has been implicated as a major contributor to hepatic insulin 
resistance (Gregor and Hotamisligil, 2011, Hummasti and Hotamisligil, 2010). PPARδ 
activation in HepG2 cells attenuates interleukin (IL)-6-induced inflammation and insulin 
resistance. These effects were mediated via PPARδ inhibition of IL-6-induced signal 
transducer and activator of transcription (STAT)-3, resulting in restoration of normal 
insulin signaling (Serrano-Marco et al., 2011). Importantly, livers of Pparδ-/- mice 
displayed significantly elevated phospho-STAT-3, suggesting that PPARδ regulates 
STAT-3 in vivo, contributing to improved insulin resistance (Serrano-Marco et al., 2011). 
Kupffer cell-specific deletion of Pparδ in mice resulted in impaired hepatic Akt 
phosphorylation coupled with increased hepatic inflammation (Odegaard et al., 2008). 
Together, these studies demonstrate that activation of hepatic PPARδ attenuates 
inflammation and contributes to improved hepatic insulin sensitivity. Further 
experimentation is required to determine whether selective PPARδ agonists reduce 
hepatic inflammation in vivo.  
1.7.5 PPARδ AGONISTS IN HUMANS 
The available in vitro and in vivo data prompted the examination of selective 
PPARδ agonists in human clinical trials for the treatment of metabolic dysregulation, 
including dyslipidemia. In healthy volunteers, GW1516 (2.5 mg or 10 mg/day for 2 
weeks) reduced plasma TG concentrations, enhanced post-prandial TG clearance and 
increased plasma HDL-cholesterol (Sprecher et al., 2007). In moderately obese men, 
GW1516 (10 mg/day for 2 weeks) stimulated moderate weight loss, reduced plasma TG, 
NEFA, total cholesterol and LDL cholesterol. Hepatic fat content was reduced in the 
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GW1516-treated cohort. Fasting plasma insulin and fasting blood glucose levels were 
decreased and insulin sensitivity improved as calculated by the homeostasis model 
assessment of insulin resistance (HOMA-IR). No adverse effects were observed 
(Riserus et al., 2008). Recently, a large multi-dose study of GW1516 (2.5, 5.0 and 10 
mg/day for 12 weeks) in subjects with low HDL-C revealed significant increases in HDL-
C and apo A-I with concomitant reductions in plasma FFA, apoB, VLDL, IDL and large 
LDL particles, all of which demonstrate a transition toward a less atherogenic lipoprotein 
profile (Olson et al., 2012). In dyslipidemic men with central obesity, a recent 
randomized double-blind, crossover trial of 6-week intervention periods with placebo or 
GW1516 (2.5mg/day), lipoprotein kinetic studies provided mechanistic insight into the 
anti-dyslipidemic properties of GW1516 (Ooi et al., 2011). Decreased plasma TG, NEFA, 
apoB-100 and apoB-48 concentrations were observed. GW1516 decreased VLDL apoB 
concentrations due to an enhanced fractional catabolic rate, which was related to a 
significantly lower production rate of apo C-III. GW1516 increased plasma HDL-
cholesterol, concomitant with increased apo A-II production and reduced CETP activity 
(Ooi et al., 2011). 
Recent back-to-back randomized, double-blind, placebo-controlled, parallel 
group studies involving a novel PPARδ agonist (MBX-8025) administered as 
monotherapy or in combination with atorvastatin, examined the ability of PPARδ 
agonists to improve dyslipidemia in overweight patients (Bays et al., 2011, Choi et al., 
2012). In the first study, MBX-8025 alone or in combination with atorvastatin significantly 
reduced plasma concentrations of apoB100 and LDL-cholesterol. However, the 
combination did not significantly reduce either of these parameters beyond that of 
atorvastatin alone. In contrast to atorvastatin monotherapy, MBX-8025 alone or in 
combination with atorvastatin significantly reduced plasma TGs and NEFAs, and 
increased HDL-C (Bays et al., 2011). In addition, MBX-8025 reduced HOMA-IR, the 
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number of patients meeting diagnostic criteria for the metabolic syndrome, VLDL particle 
number, the preponderance of small and very small LDL particles and increased LDL 
peak diameter (Bays et al., 2011, Choi et al., 2012). MBX-8025 was well tolerated, with 
no major adverse effects (Bays et al., 2011, Choi et al., 2012). Collectively, these human 
trials demonstrate that PPARδ agonists exert favourable effects on CVD risk factors that 
are not improved by statin monotherapy. Whether PPARδ agonists reduce the residual 
CVD risk beyond statin treatment requires longer-term outcome and safety studies. 
1.8 MODELS TO BE USED 
1.8.1 CELL CULTURE 
THP-1 cells are a monocytic cell line initially derived from the blood of a one-
year-old boy with acute monocytic leukemia (Tsuchiya et al., 1980). Treatment of THP-1 
monocytes with phorbol esters such as phorbol 12,13-dibutyrate, results in their 
differentiation into macrophage-like cells, which exhibit many characteristics of native, 
mature macrophages (Auwerx, 1991). Although the extent to which differentiated THP-1 
cells mimic vascular wall macrophages is not fully understood, these cells have been 
used extensively as a model to gain insight into macrophage foam cell formation and 
function (Qin, 2012). Treatment of THP-1 cells with a phorbol ester results in the 
upregulation of scavenger receptors (Johnson et al., 2003), which makes THP-1 
macrophages a reasonable model to recapitulate macrophage behavior during 
atherogenesis. One caveat to these cells is that phorbol ester treatment results in the 
downregulation of LDLR expression (Johnson et al., 2003), which results in reduced 
uptake of native LDL compared to modified LDL. However, high doses of LDL (100-
200μg/mL) will stimulate CE uptake and foam cell formation (Banka et al., 1991), which 
still makes THP-1 macrophages a fundamentally good model to study foam cell 
formation in response to native LDL in the context of hypercholesterolemia. In the 
context of hypertriglyceridemia, THP-1 macrophages synthesize and secrete LPL (Qin, 
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2012), and can therefore readily take up VLDL-derived fatty acids resulting in foam cell 
formation. These cells were used extensively for the studies described in Chapters 2 and 
3. 
1.8.2 Ldlr-/- MICE 
Deletion of the Ldlr in C57Bl/6J disrupts normal murine lipoprotein metabolism, 
resulting in elevated plasma cholesterol, particularly in the LDL fraction as a result of 
defective LDL clearance (Ishibashi et al., 1993). Furthermore, these animals develop 
increased cholesterol in both VLDL and IDL when fed a high-fat diet (Getz and Reardon, 
2006). Ldlr-/- mice fed a high-fat, cholesterol containing (HFHC) diet for 12 weeks 
recapitulate many features of the metabolic syndrome such as dyslipidemia, 
hyperinsulinemia, insulin resistance and hepatic steatosis (Assini et al., 2013). 
Furthermore, these animals develop atherosclerotic lesions that are relatively advanced, 
exhibiting significant lipid accumulation, increased macrophage and smooth muscle cell 
infiltration and enhanced collagen deposition (Assini et al., 2013). Ldlr-/- mice were 
extensively used for the studies described in Chapters 4 and 5. 
1.8.3 ANIMAL DIETS 
1.8.3.1 CHOW DIET 
Laboratory chow was used as a control diet which provided a reference for 
metabolic indices altered by feeding the HFHC diet. The chow diet contains complex 
carbohydrates and 14% calories as fat (4% by weight). The caloric value of the chow 
diet is 3.0 kcal/g (Table 1-2). The chow diet was fed ad libitum to mice in studies 
described in Chapters 4 and 5. 
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1.8.3.2 WESTERN DIET WITH ADDED CHOLESTEROL (HFHC DIET) 
The western diet commonly used to induce metabolic abnormalities and 
atherosclerosis is composed of 42% calories as fat (21.2% by weight). Of the total fat, 
saturated fatty acids comprise 58% by weight, monounsaturated fatty acids 36% and 
polyunsaturated fatty acids 5%. This diet contains 0.05% cholesterol (by weight), derived 
from milkfat and lard (Harlan Teklad, TD96125). The addition of 0.15% cholesterol (for a 
total of 0.2%) modifies the western diet to the HFHC diet (Harlan Teklad, TD09268). 
Diets with the same or similar amounts of dietary cholesterol are known to increase 
macrophage inflammation and exacerbate the development of dyslipidemia, insulin 
resistance, hepatic steatosis and atherosclerosis (Subramanian et al., 2011, 
Subramanian et al., 2008). The carbohydrate component is 42.8% of calories (48.7% by 
weight) and is derived from sucrose, while the protein source is casein (15.2% of 
calories, 17.3% by weight). This diet does not contain any cholate. The caloric value of 
the HFHC diet is 4.5 kcal/g (Table 1-2). The HFHC diet was fed ad libitum to mice in 
studies described in Chapters 4 and 5.  
1.9 SCOPE OF THESIS AND HYPOTHESES 
 Dyslipidemia and insulin resistance are major risk factors for the development of 
premature atherosclerosis. Specifically, elevated plasma TG-rich VLDL can readily 
induce macrophage foam cell formation, and insulin resistance is becoming increasingly 
accepted to accelerate foam cell formation. Therapeutic strategies that improve insulin 
sensitivity, the atherogenic lipid profile of the insulin resistant state and have direct 
effects on cells of the vessel wall to reduce macrophage foam cell formation and 
atherosclerosis, remain sparce. Therefore, identification and characterization of the 
novel therapeutic strategies that correct the metabolic consequences of insulin 
resistance are becoming increasingly important. 
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 The studies in this thesis were undertaken to understand the physiological and 
molecular mechanisms involved in the attenuation of macrophage foam cell formation, 
the inflammatory response, atherosclerosis and metabolic dysregulation by activation of 
PPARδ. We first examine the ability of synthetic PPARδ ligands (GW0742 and 
GW501516) to specifically activate PPARδ and attenuate VLDL-induced macrophage 
foam cell formation. We investigated both the lipid lowering and anti-inflammatory 
capabilities of PPARδ-specific activation in this setting, and determined the mechanism 
by which the GW compounds lower macrophage TG accumulation and prevent VLDL-
induced proinflammatory cytokine expression. We next examined the ability of these 
compounds to attenuate CE-rich lipoprotein-induced foam cell formation. To determine if 
our in vitro results translated in vivo, we subsequently determined whether intervention 
to a high-fat high-cholesterol diet with GW501516 was able to either prevent 
progression, or induce regression of pre-established atherosclerotic lesions. Additionally, 
we studied whether GW501516 was capable of correcting pre-established metabolic 
dysregulation, including hepatic steatosis, and sought to define the mechanisms 
involved. Therefore, Chapters 2 to 5 of this thesis address the following hypotheses: 
1. PPARδ-specific activation in macrophages attenuates TG accumulation and 
the inflammatory response, induced by VLDL (Chapter 2). 
2. PPARδ-specific activation in macrophages attenuates CE accumulation and 
the inflammatory response, induced by native and modified forms of LDL 
(Chapter 3). 
3. PPARδ-specific activation in vivo attenuates progression of diet-induced 
atherosclerosis, aortic inflammation and aortic insulin resistance in Ldlr-/- mice 
(Chapter 4). 
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4. Hepatic PPARδ-specific activation attenuates steatosis via increased fatty acid 
oxidation, reduced de novo lipogenesis and improves insulin sensitivity in Ldlr-/- 
mice (Chapter 5). 
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Chapter 2* 
Activation of PPARδ inhibits human macrophage foam cell formation and the 
inflammatory response induced by very low-density lipoprotein 
 
2.1 INTRODUCTION 
Excessive lipid accumulation within macrophages of the arterial intima drives the 
synthesis and secretion of proinflammatory mediators, potentiating atherogenesis 
(Hansson, 2005). Canonically, elevated plasma low density lipoprotein (LDL) is 
considered a major lipoprotein contributing to accelerated atherogenesis. However, 
epidemiological evidence strongly suggests that hypertriglyceridemia also increases the 
risk of premature atherosclerosis, especially in the context of metabolic syndrome and 
type 2 diabetes (Nordestgaard et al., 2007, Reaven, 2005). Plasma triacylglycerol (TG)-
carrying very low density lipoprotein (VLDL) has been localized within atherosclerotic 
lesions from human patients and animal models (Proctor and Mamo, 1998, Rapp et al., 
1994), providing rationale for examining the mechanisms by which these lipoproteins 
induce the development of macrophage foam cells. VLDL readily induces macrophage 
lipid accumulation (Evans et al., 1993, Whitman et al., 1999, Whitman et al., 1998), 
which in turn stimulates the synthesis of cytokines such as IL-1β and MIP-1α 
(Saraswathi and Hasty, 2006, Stollenwerk et al., 2005a, Stollenwerk et al., 2005b). The 
mechanisms regulating these lipid-induced macrophage inflammatory responses have 
not been fully characterized.  
In mouse macrophages, VLDL-induced expression of Mip-1α requires fatty acid 
liberation by lipoprotein lipase (LPL) and is dependent on the activation of ERK1/2 
(Saraswathi and Hasty, 2006). Furthermore, VLDL potentiates LPS-stimulated 
macrophage IL-1β secretion via activation of the transcription factor AP-1 (Stollenwerk et 
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al., 2005a). which is known to be regulated by MAP kinases ERK1/2 and p38 (Eferl and 
Wagner, 2003). The involvement of p38, which is thought to act cooperatively with 
ERK1/2 in AP-1 associated inflammatory responses (Eferl and Wagner, 2003), has not 
been established (Saraswathi and Hasty, 2006). In addition, macrophage insulin 
resistance may potentiate the inflammatory response. Macrophage-specific deletion of 
the insulin receptor in Ldlr-/- mice significantly increased atherosclerosis (Han et al., 
2006), an effect attributed to impaired macrophage Akt/FoxO1 signaling (Han et al., 
2006). Insulin-resistant macrophages with cholesterol-induced ER-stress display 
impaired Akt phosphorylation, increased nuclear FoxO1 activity and enhanced apoptosis 
(Senokuchi et al., 2008). Furthermore, Il-1β is a FoxO1 target gene in macrophages with 
insulin resistance (Su et al., 2009). Collectively, these studies highlight the importance of 
examining the role of AKT/FoxO1 signaling in the VLDL-induced inflammatory response. 
The peroxisome proliferator-activated receptors (PPARs) are important 
regulators of metabolic and inflammatory signaling (Lee et al., 2003b). The three known 
isoforms, namely PPARα, PPARγ and PPARδ, each exhibit distinct tissue distribution 
and PPAR-specific regulation of gene transcription (Lee et al., 2003b). In contrast to 
PPARα and PPARγ, expression of PPARδ is ubiquitous, with high levels in 
macrophages (Vosper et al., 2001), where its biological role is unclear. Macrophage 
PPARδ is activated by VLDL-derived fatty acids (Chawla et al., 2003, Lee et al., 2006), 
and conflicting reports have demonstrated that synthetic ligands promote either lipid 
accumulation (Vosper et al., 2001), or fatty acid catabolism (Chawla et al., 2003, Lee et 
al., 2006). Consequently, the net effect of PPARδ activation on VLDL-induced TG 
accumulation is unknown. The anti-inflammatory properties of PPARδ activation have 
been linked to the liberation of BCL-6 from unliganded PPARδ (Lee et al., 2003a), which 
inhibits expression of AP-1-inducible cytokines by localizing to AP-1 response elements 
and recruiting co-repressors to these promoter regions (Vasanwala et al., 2002). 
96 
Additionally, in adipocytes and cardiomyocytes, PPARδ agonists inhibit LPS-induced 
NFκB regulated cytokine expression (Ding et al., 2006, Rodriguez-Calvo et al., 2008). 
The mechanism(s) underlying VLDL-induced cytokine expression in macrophages, in the 
absence of LPS, and the impact of PPARδ activation have not been elucidated.  
In the present study, we report that synthetic ligand activation of PPARδ 
attenuates VLDL-stimulated TG accumulation by activating a transcriptional program 
resulting in attenuation of LPL activity, increased fatty acid uptake and enhanced β-
oxidation. VLDL stimulates the expression of proinflammatory cytokines IL-1β, MIP-1α, 
and ICAM-1 via both ERK1/2- and AKT/FoxO1-dependent signaling mechanisms. 
Furthermore, macrophage treatment with synthetic PPARδ ligands inhibits 
proinflammatory cytokine expression, by inhibiting VLDL-stimulated ERK1/2 activation 
and reversing VLDL-mediated inhibition of AKT/FoxO1 phosphorylation. 
2.2 MATERIALS AND METHODS 
2.2.1 LIPOPROTEINS 
Subjects were recruited from the Lipid Clinic at the London Health Sciences 
Center University Campus (London, Ontario, Canada). The University of Western 
Ontario Health Science Standing Committee on Human Research approved the studies 
(IRB reference #15685). VLDL (Sf 20 to 400) was isolated from plasma of type IV 
hyperlipoproteinemic patients by differential ultracentrifugation using a Beckman 70.1 Ti 
rotor (16hr, 40,000 rpm, 12°C) as previously described (Whitman et al., 1998). 
2.2.2 CELL CULTURE 
The human THP-1 macrophage-like cell line was obtained from American Type 
Culture Collection (ATCC, Manassas, VA). For experiments, cells were cultured at 
4.0x106 cells/35-mm plate (Falcon Scientific, BD Biosciences) in RPMI 1640 
supplemented with 10% fetal bovine serum (Sigma), β-mercaptoethanol (5x10-5 mol/L), 
100 units/mL penicillin, and 100 µg/ml streptomycin and differentiated with 300 nmol/L 
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phorbol 12,13-dibutyrate (PDB, Sigma) for 1 week prior to use in experiments as 
described (Argmann et al., 2005, Beyea et al., 2007). PPARδ agonists GW0742 (Sigma) 
and GW501516 (Alexis Biochemicals, Plymouth, PA) were dissolved in dimethyl 
sulfoxide (DMSO, Sigma) and incubated with cells at the indicated concentrations. THP-
1 macrophages were preincubated (24 hr) in the presence or absence of PPARδ 
agonists. Subsequently, cells were incubated with PPARδ agonists in the presence or 
absence of lipoproteins or various inhibitors as indicated. HepG2 cells were obtained 
from ATCC and grown as described previously (Evans et al., 1992). For experiments, 
HepG2 cells were plated in either 100-mm or six-well (35-mm) culture plates (Falcon, 
Mississauga, ON) and maintained in minimal essential medium (MEM) containing 10% 
fetal bovine serum (FBS), but switched to MEM containing 5% human lipoprotein-
deficient serum (LPDS) for experimental incubations.  
2.2.3 LUCIFERASE REPORTER ASSAYS 
Luciferase reporter assays were performed as previously described (Mulvihill et 
al.). Briefly, HepG2 cells were transfected with 0.01µg/mL human PPARα,γ or δ.SG5 
expression vectors and reporter gene plasmids, 0.5µg/mL of pTK-PPRE(x3)-Luc and 
0.05µg/mL of the TK promoter-Renilla luciferase construct, (tk.pRL) (provided by Dr. 
John Capone, McMaster University, Hamilton ON). Cells were incubated for 24 hr with 
DMSO or the appropriate PPAR agonists: PPARα (10nmol/L, GW7647, Sigma); PPARγ 
(3µmol/L, rosiglitazone, Alexis Biochemicals, Cedarlane Laboratories, Burlington, ON), 
or PPARδ (GW0742 and GW501516) at a range of concentrations. Cell lysates were 
prepared and the Luciferase activity (relative light units (RLU)) was measured and 
normalized to Renilla activity, as previously described (Allister et al., 2005, Argmann et 
al., 2005). 
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2.2.4 CELLULAR LIPID MASS 
THP-1 macrophages were preincubated in the presence of PPARδ agonists or 
equal volume of DMSO (not to exceed 0.5% of total medium) for 24 hr in RPMI 1640 
supplemented with 10% fetal bovine serum (FBS) and 300nmol/L PDB. Cells were 
incubated for a further 16 hr with fresh media containing 5% LPDS and compounds in 
the absence or presence of HTG-VLDL (50 μg of lipoprotein total cholesterol (TC)/mL 
medium). Cellular CE, TC, FC, TG, FFA (NEFA) and protein mass were determined 
using enzymatic colorimetric assays for NEFA, TC and FC (Wako Diagnostics, 
Richmond, VA) as well as TG (Boehringer Mannheim, Laval, QC) as previously 
described (Rowe et al., 2003). Cellular CE was determined as the difference between 
TC and FC (Rowe et al., 2003). Cells were lysed in 1mL of 0.1N NaOH, and aliquots 
were used to determine protein concentrations (Beyea et al., 2012). 
2.2.5 ENZYME-LINKED IMMUNOSORBENT ASSAY 
THP-1 macrophages were preincubated in the presence of PPARδ agonists or 
equal volume of DMSO (not to exceed 0.5% of total medium) for 24 hr in RPMI 1640 
supplemented with 10% fetal bovine serum (FBS) and 300nmol/L PDB. Cells were 
incubated for a further 16 hr with fresh media containing 5% LPDS and compounds in 
the absence or presence of hypertriglyceridemic (HTG)-VLDL (50 μg of lipoprotein total 
cholesterol (TC)/mL medium). Media was collected and analyzed for IL-1β secretion via 
enzyme-linked immunosorbent assay (ELISA) using the BD OptEIA human IL-1β ELISA 
kit II (BD Biosciences, Mississauga, ON) as per manufacturer’s protocol. 
2.2.6 QUANTITATIVE REAL-TIME PCR GENE ABUNDANCE ANALYSIS 
THP-1 cells were incubated for 24 hr in RPMI 1640 with 5% LPDS, 300nmol/L 
PDB, in the presence or absence of PPARδ agonists, and subsequently total RNA was 
isolated using TriZol reagent (Invitrogen, Burlington, ON) according to manufacturer’s 
instructions . In experiments examining VLDL-induced inflammatory cytokine expression, 
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cells were preincubated for 24 hr in RPMI 1640 with 10% FBS, 300nmol/L PDB, in the 
presence or absence of PPARδ agonists. Cells were then incubated with fresh 5%-
LPDS media and compounds with or without the CPT-1α inhibitor etomoxir (Sigma, 
50µmol/L for 0.5 hr, followed by a further 16 hr in the absence or presence of HTG-VLDL 
(50μg-TC/mL) prior to TriZol RNA extraction. Abundance of total RNA (2µg) was reverse 
transcribed using the Applied Biosystems High Capacity cDNA reverse transcription kit 
according to the manufacturer’s protocol. Subsequently, cDNA (10ng) was analyzed in 
triplicate by quantitative real time RT-PCR (qRT-PCR) on an ABI Prism (model 7900HT) 
Sequence Detection System (Applied Biosystems, Foster City, CA) according to the 
manufacturer’s instructions and as previously described (Beyea et al., 2007). Primer-
probe sets for each gene were obtained from Applied Biosystems (Carlsbad, CA). 
Abundance of target genes was normalized to GAPDH abundance. 
2.2.7 LPL ACTIVITY, TG SYNTHESIS, FA β-oxidation, AND FA UPTAKE 
LPL activity of THP-1 cells (cell surface and medium) was determined following a 
24 hr incubation in RPMI 1640 with 5% human LPDS and 300nmol/L PDB in the 
presence or absence of selected concentrations of PPARδ agonists, as the release of 
free fatty acids from intralipid (an exogenous lipid source) as previously described 
(Whitman et al., 1999). The synthesis of triacylglycerol was measured in THP-1 cells 
following a preincubation in 5% LPDS-containing medium for 19 hr in the presence or 
absence of selected concentrations of PPARδ agonists. For a subsequent 5 hr 
incubation, 0.08nCi/mL [1-14C]oleic acid (Amersham Biosciences) complexed with fatty 
acid-free bovine serum albumin in a molar ratio of 5.36:1 (Sigma) was added as 
described previously (Evans et al., 1993). Cellular lipid extracts were separated by thin 
layer chromatography (Evans et al., 1993). Fatty acid β-oxidation experiments were 
performed as described previously (Mulvihill et al.). Briefly, THP-1 cells were 
preincubated in the presence or absence of PPARδ agonists in 10% FBS-containing 
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medium for 24 hr, followed by the addition of 2.0µCi/mL [3H]-palmitate in 100µmol/L 
palmitate per well for 0.5 hr. The media was removed and 10% trichloroacetic acid was 
added. Unreacted FAs were extracted from the supernatant with n-hexane and the 
remaining counts determined by scintillation counting. Data was determined as nmol 
palmitate oxidized/min/mg cell protein and was corrected for differences in fatty acid 
uptake in the presence of PPARδ agonists. Fatty acid uptake experiments were 
performed as described (Lee et al., 2006). Briefly, THP-1 cells were preincubated in the 
presence or absence of PPARδ agonists in 5% LPDS-containing medium for 24 hr, 
followed by the addition of either [1-14C]oleic acid or [3H]-palmitate (both prepared as 
described above) for 1min. Ice cold stop solution (200µmol/L phloretin in phosphate 
buffered saline) was added directly to the culture medium. Cells were washed five times 
with ice cold stop solution. Cells were lysed in 1mL of 0.1N NaOH, and aliquots were 
used to determine protein concentrations and the amount of unprocessed radiolabelled 
fatty acid. 
2.2.8 IMMUNOBLOT ANALYSIS AND DENSITOMETRY 
Total cell lysates were fractionated into cytosolic and nuclear fractions as 
previously described (Azzout-Marniche et al., 2000). Proteins were separated by SDS-
PAGE, transferred to polyvinylidene difluoride membranes and immunoblotted as 
described previously (Rowe et al., 2003). Cellular cytosolic fractions were probed using 
antibodies against human phospho (p)-FoxO1, pERK1/2, p-p38, pAKT, FoxO1, ERK1/2, 
p38, AKT, β-actin (Cell Signaling, Danvers, MA) and nuclear fractions were probed using 
antibodies against human total-FoxO1 and Lamin A/C (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA). Quantification analysis of the developed films was performed using an 
imaging densitometer (Bio-Rad Quantity One Software). Phospho-proteins from 
cytosolic fractions were normalized to their respective total proteins or β-Actin, whereas 
nuclear fractions were normalized to lamin A/C. Additionally, cytosolic and nuclear 
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fractions were immunoblotted for Lamin A/C and β-Actin, respectively, in order to 
demonstrate complete separation of these fractions. 
2.2.9 STATISTICAL ANALYSIS 
Data are expressed as means +/- standard error of the mean (SEM). The 
Shapiro-Wilk normality test was used to test for parametric distributions in each data set. 
P values for observed differences between treatment and control groups were calculated 
by one-way ANOVA followed by Bonferroni post hoc test or paired student’s t-test where 
indicated. P values for observed pair-wise comparisons were calculated by one-way 
ANOVA followed by Tukey’s post hoc test. Significance thresholds were P values less 
than 0.05. Statistical analyses were performed with SigmaPlot 11.0 software (Systat, Inc, 
San Jose, CA). 
2.3 RESULTS 
2.3.1 PPARδ-SPECIFIC ACTIVATION ATTENUATES VLDL-INDUCED 
MACROPHAGE TRIACYLGLYCEROL ACCUMULATION 
THP-1 cells treated with VLDL demonstrated a dose-dependent increase in TG 
mass achieving a marked 5-fold increase with VLDL at 50 µg/mL (Figure 2.1A-B). Pre-
treatment with PPARδ agonists for 24 hours modestly but significantly reduced VLDL-
induced TG mass by 25-30% (Figure 2.1A-B). VLDL significantly induced intracellular 
FFA mass, which was unchanged by pre-treatment with PPARδ agonists (Figure 2.1C). 
Cellular cholesteryl ester or free cholesterol concentrations were unaffected by VLDL or 
PPARδ agonists (Figure 2.1D), indicating that whole particle VLDL uptake was modest. 
A known PPARδ-specific target gene, adipocyte differentiation-related protein (ADRP) 
(Chawla et al., 2003), was significantly increased by both agonists (Figure 2.1E), 
indicating PPARδ activation. 
High doses of PPAR agonists can activate PPAR isoforms non-selectively 
(Berger et al., 1999, Willson et al., 2000). Therefore, we determined the PPARδ-
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Figure 2.1 PPARδ-specific activation attenuates VLDL-induced triacylglycerol 
mass accumulation.  
THP-1 cells were pre-incubated with PPARδ agonists GW0742 and GW501516 for 24hr, 
followed by a 16hr incubation with or without VLDL (50μg-TC/mL). A,B TG mass (n=5-
7). C, Free fatty acid (FFA) mass (n=3-4). D, Cholesteryl ester (CE) and free cholesterol 
(FC) mass (n=6). E, ADRP mRNA in THP-1 cells following preincubation with PPARδ 
agonists for 24hr, and following a 16hr incubation, with or without VLDL (n=4). Data is 
presented as mean +/- SEM. Different letters indicate significant differences; ANOVA 
with post-hoc Tukey’s test (P<0.05). * indicates significant difference versus DMSO 
control; ANOVA with post hoc Bonferroni’s test (P<0.05) 
. 
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specificity of the concentrations of agonists employed. PPARδ-deletion results in 
derepression of PPARδ target genes (Lee et al., 2006), and transrepression of 
inflammatory cytokine expression, creating an experimental confounder for the present 
studies (Lee et al., 2003a). We therefore assessed agonist-specificity by co-transfecting 
HepG2 cells with luciferase reporter constructs driven by PPAR response elements and 
each PPAR isoform (α, γ, δ). We determined dose-responses for each receptor in cells 
treated with PPARδ agonists (GW0742 and GW501516), and used agonists for PPARα 
(GW7647) and PPARγ (rosiglitazone) as positive controls. GW0742 at 25nmol/L and 
GW501516 at 100nmol/L were concentrations at which these ligands maximally 
activated PPARδ, without activation of either PPARα or PPARγ (Figure 2.2A-D). 
Furthermore, canonical PPARα and PPARγ target genes (ACOX and FABP4, 
respectively) were unaffected by either 25nmol/L GW0742 or 100nmol/L GW501516 
(Figure 2.2E-F). Although unlikely, these agonists may have effects on non-PPAR 
targets. However, with respect to PPARs, these data demonstrate selectivity of the 
agonist concentrations used for PPARδ. 
2.3.2 PPARδ AGONISTS REGULATE LPL ACTIVITY, FATTY ACID UPTAKE AND 
FATTY ACID β-OXIDATION 
We examined whether PPARδ activation attenuated VLDL-induced TG mass by 
regulating lipoprotein hydrolysis, fatty acid uptake or fatty acid esterification. In contrast 
to rosiglitazone, LPL mRNA was unchanged in response to PPARδ agonists, further 
demonstrating PPARδ-specificity (Figure 2.3A and Figure 2.2G). The PPARδ-target 
gene, angiopoietin-like 4 (ANGPTL4) encodes a protein known to potently inhibit LPL 
activity (Sukonina et al., 2006). ANGPTL4 mRNA expression was markedly enhanced by 
both PPARδ agonists in the presence or absence of VLDL, which was associated with a 
50% inhibition of LPL activity (Figure 2.3B,C). The PPARδ ligands significantly increased
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Figure 2.2 GW0742 and GW501516 are PPARδ-specific agonists.  
Human hepatoma (HepG2) cells were co-transfected with plasmids encoding a PPRE-
luciferase construct, a Renilla luciferase construct (transfection control) and vectors 
encoding each individual PPAR isoform as indicated. Cells were incubated with (A) 
PPARα agonist GW7647, (B) PPARγ agonist rosiglitazone or PPARδ agonists (C) 
GW0742 or (D) GW501516 for 24hr. Cell lysates were isolated and luciferase relative 
light units (RLU) were measured (n=2-4). In separate experiments, THP-1 cells were 
incubated with PPAR agonists for 24hr. Total RNA was isolated and (E) ACOX, (F) 
FABP4 and (G) LPL mRNA abundance was measured by qRT-PCR  (n=3-6). Data is 
presented as mean +/- SEM. * indicates significant difference versus DMSO control; 
ANOVA with post hoc Bonferroni test (P<0.05). 
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Figure 2.3 PPARδ activation regulates triglyceride metabolism.  
A, LPL mRNA in THP-1 cells following preincubation with PPARδ agonists for 24hr. 
mRNA abundance of (B) ANGPTL4, (D) CD36 and (G) CPT-1α in THP-1 cells following 
preincubation with PPARδ agonists for 24hr, and following a 16hr incubation, with or 
without VLDL (n=4). C, LPL activity (n=4). Cell surface-bound LPL activity = Total activity 
(heparin) minus secreted activity (without heparin). E,F Fatty acid uptake (n=3). H, β-
oxidation (n=3). Data is presented as mean +/- SEM. Different letters indicate significant 
differences; ANOVA with post-hoc Tukey’s test (P<0.05). *indicates significant difference 
versus DMSO control. In C, # indicates significant difference versus cell bound DMSO 
control; ANOVA with post hoc Bonferroni’s test (P<0.05).  
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expression of the PPAR-target gene CD36 (Welch et al., 2003) irrespective of lipid load, 
which was correlated with a 25% increase in palmitate uptake, but not oleate uptake 
(Figure 2.3D-F). DGAT1 mRNA, DGAT2 mRNA, and TG synthesis were unaffected by 
PPARδ activation (Figure 2.4). PPARδ ligands significantly upregulated CPT-1α mRNA, 
with or without VLDL, which was associated with a 40% increase in fatty acid oxidation 
(Figure 2.3G,H). Collectively, these results indicate that although PPARδ activation 
modestly increases palmitate uptake, the attenuation of LPL-mediated VLDL TG-
hydrolysis and the enhancement of fatty acid β-oxidation results in a net reduction of 
macrophage triglyceride content. 
2.3.3 PPARδ AGONISTS INHIBIT VLDL- AND FREE FATTY ACID-INDUCED 
CYTOKINE EXPRESSION 
Exposure of mouse macrophages to VLDL stimulates Mip-1α expression, an AP-
1 mediated inflammatory response (Saraswathi and Hasty, 2006). Here, human VLDL 
significantly induced macrophage expression of IL-1β, MIP-1α, and ICAM-1 mRNA. Pre-
treatment with PPARδ ligands significantly inhibited the VLDL-induced expression of all 
three cytokines (Figure 2.5A-C), without affecting basal cytokine expression (Figure 2.6). 
Furthermore, media levels of VLDL-induced IL-1β were significantly decreased by both 
PPARδ agonists (Figure 2.7A). Canonical NFκB-target genes TNFα and IL-6 were 
unaffected by VLDL treatment (Figure 2.7B). Moreover, parthenolide, an inhibitor of 
NFκB signaling, had no effect on VLDL-stimulated expression of IL-1β, MIP-1α and 
ICAM-1, however parthenolide completely inhibited cytokine stimulation by LPS, a 
known NFκB activator (Figure 2.7C). Collectively, these data suggest that VLDL-induced 
macrophage inflammatory responses do not require NFκB activation 
. 
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Figure 2.4 Effect of PPARδ activation on FFA re-esterification mechanisms.  
THP-1 cells were incubated with PPARδ-specific agonists for 24hr. Total RNA was 
isolated and (A) DGAT1 and (B) DGAT2 mRNA was measured by qRT-PCR (n=4). C, 
Following a 19hr incubation with PPARδ agonists at indicated concentrations, THP-1 
cells were incubated for a further 5hr with PPARδ agonists and 1-[14C]oleic acid to 
measure oleate incorporation into cellular triacylglycerol (n=3). Data is presented as 
mean +/- SEM.  
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Figure 2.5 PPARδ agonists attenuate VLDL-stimulated expression of AP-1 
associated inflammatory cytokines.  
THP-1 cells were pre-incubated with PPARδ agonists for 24hr, followed by a 16hr 
incubation with or without VLDL. mRNA abundance for (A) IL-1β, (B) MIP-1α and (C) 
ICAM-1 was measured (n=4). D, THP-1 cells were incubated with PPARδ agonists for 
24hr, followed by an incubation with Etomoxir (ETO 50μmol/L) for 0.5hr and a 
subsequent incubation with or without VLDL for 16hr. mRNA for IL-1β, MIP-1α and 
ICAM-1 mRNA was measured (n=3). Data is presented as mean +/- SEM. Different 
letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05).  
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Figure 2.6 PPARδ activation does not affect basal cytokine expression in THP-1 
human macrophages  
THP-1 cells were incubated with PPARδ-specific agonists at the indicated 
concentrations for 24hr. Total RNA was isolated and IL-1β, MIP-1α and ICAM-1 mRNA 
was measured by qRT-PCR (n=4). Data is presented as mean +/- SEM (n=4).  
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Figure 2.7 The effect of PPARδ agonists on media IL-1β protein; the effect of VLDL 
on TNFα or IL-6 expression and the VLDL-induced inflammatory response in the 
presence of an inhibitor of NFκB. THP-1 cells were pre-incubated with PPARδ 
agonists for 24hr, followed by a 16hr incubation with or without VLDL (50μg-TC/mL). A, 
Media was collected and analyzed for IL-1β protein levels by enzyme-linked 
immunosorbent assay. In separate experiments, THP-1 cells were incubated with or 
without VLDL (50μg-TC/mL) for 16hr. Total RNA was isolated and (B) TNFα and IL-6 
mRNA were measured by qRT-PCR (n=4). C, THP-1 cells were incubated with IκB 
kinase inhibitor (Parthenolide 10μmol/L) for 0.5hr followed by 16hr incubation with or 
without VLDL or LPS at the indicated concentrations. Total RNA was isolated and IL-1β, 
MIP-1α and ICAM-1 mRNA was measured by qRT-PCR (n=3-4). Data is presented as 
mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc 
Tukey’s test (P<0.05).  
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2.3.4 INHIBITION OF VLDL-INDUCED INFLAMMATION BY PPARδ ACTIVATION IS 
INDEPENDENT OF REDUCED CELLULAR TRIGLYCERIDE  
We examined if inhibition of VLDL-induced inflammation by PPARδ agonists was 
a consequence of reduced TG accumulation. Complete inhibition of LPL with 
tetrahydrolipstatin (THL), blocked cellular TG and cytokine expression. However, 
inhibition of TG accumulation with low-dose THL, to the same extent as that achieved by 
PPARδ agonists (~25%), decreased ICAM-1 expression by 30% but did not affect MIP-
1α or IL-1β (Figure 2.8). PPARδ activation normalized VLDL-induced cytokine 
expression, even when β-oxidation was inhibited by etomoxir (Figure 2.5D), a CPT-1α 
inhibitor (Galic et al., 2011). This data suggests that activated PPARδ-induced β-
oxidation only partially accounts for reduced cytokine expression by PPARδ activation.  
Our results are consistent with the concept that VLDL-derived FAs are the 
primary mediators of the inflammatory response (Anderson et al., 2012, Saraswathi and 
Hasty, 2006). Paradoxically, FAs also activate PPARδ (Chawla et al., 2003). To 
reconcile this, macrophages were treated with oleic acid, which resulted in a marked 
induction of TG mass and expression of IL-1β and MIP-1α (Figure 2.9A,B). These effects 
were significantly attenuated by pre-incubation of cells with GW501516 (Figure 2.9A,B), 
suggesting that the known ability of FAs to activate PPARδ (Chawla et al., 2003), is 
insufficient to prevent macrophage TG accumulation and cytokine expression. 
2.3.5 VLDL-STIMULATED EXPRESSION OF INFLAMMATORY CYTOKINES IS 
DEPENDENT ON MAPK ACTIVATION AND REPRESSION OF AKT/FoxO1 
SIGNALING 
VLDL-induced Mip1α expression in mouse macrophages involves activation of 
ERK1/2 (Saraswathi and Hasty, 2006). In THP-1 cells, ERK1/2 phosphorylation 
increased significantly within 0.5hr of VLDL exposure, which returned to baseline by 1hr 
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Figure 2.8 Prevention of VLDL-induced TG accumulation and cytokine expression 
are independent effects of PPARδ activation.  
THP-1 cells were incubated with lipolysis inhibitor (THL) at the indicated concentrations 
for 0.5hr followed by 16hr incubation with or without VLDL (50μg-TC/mL). A, TG mass 
(n=2). B, TG mass (n=4). THP-1 cells were incubated with THL at the indicated 
concentrations for 0.5hr followed by 16hr incubation with or without VLDL (50μg-TC/mL) 
or LPS (0.1ng/mL). Total RNA was isolated and (C) IL-1β, MIP-1α and ICAM-1 mRNA 
was measured by qRT-PCR (n=3). Data is presented as mean +/- SEM. Different letters 
indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05).  
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Figure 2.9 Free fatty acids are the primary effectors of the VLDL-induced 
inflammatory response in human macrophages. THP-1 cells were pre-incubated with 
PPARδ agonist GW501516 for 24hr, followed by a 16hr incubation with or without oleic 
acid (OA, 200μmol/L). A, TG accumulation (n=4). B, Total RNA was isolated and IL-1β 
and MIP-1α mRNA was measured by qRT-PCR (n=4). C, In a separate set of 
experiments, THP-1 cells were pre-incubated with the PPARδ agonist at the indicated 
concentration for 24hr, followed by a 0.5hr incubation with or without 200μmol/L OA. 
Cytosolic fractions were isolated and immunoblotted for ERK1/2. Equal loading was 
confirmed by total ERK. Representative immunoblots for phosphorylated and total 
ERK1/2 with quantitation shown (n=4). Data is presented as mean +/- SEM. Different 
letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05).  
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(Figure 2.10A and Figure 2.9C). Similarly, VLDL stimulated p38 phosphorylation, 
reaching peak phosphorylation by 0.5hr, and remained elevated for ~3hr (Figure 2.10B). 
The MEK1/2 inhibitor, U0126, abrogated VLDL-stimulated expression of all cytokines 
(Figure 2.10C). In contrast, the p38 inhibitor SB203580 stimulated cytokine expression 
under basal conditions, and further increased cytokine expression in VLDL-treated cells 
(Figure 2.10D). Inhibition of p38 resulted in a 5-fold induction in ERK1/2 phosphorylation 
(Figure 2.11A) suggesting that the MAPKerk signal stimulates cytokine expression, 
whereas MAPKp38 represses the actions of MAPKerk. 
The temporal disconnect between VLDL-induced MAPKerk activation/de-
activation (1hr) and elevated cytokine expression (16hr), suggests that other 
macrophage inflammatory signaling pathways are stimulated by VLDL. Given that IL-1β 
is a target of nuclear FoxO1 in macrophages in the context of fatty acid-induced insulin 
resistance (Su et al., 2009), we examined the role of AKT/FoxO1 in VLDL-induced 
inflammation. Exposure of THP-1 cells to VLDL resulted in a time-dependent reduction 
of phospho-AKT levels for up to 6hr (Figure 2.12A). Reduced phospho-AKT was 
correlated with attenuated phospho-FoxO1 and increased nuclear-FoxO1 by 3hr (Figure 
2.12B, C), demonstrating that VLDL inhibits AKT/FoxO1-signaling. As proof-of-concept, 
treatment of macrophages with AKTinhibitor IV mimicked VLDL-treatment, resulting in 
reduced phospho-AKT, reduced phospho-FoxO1 over 6hr (Figure 2.11B) and significant 
elevations in the expression of IL-1β as well as MIP-1α and ICAM-1 over 16hr (Figure 
2.11C). 
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Figure 2.10 MAPK signaling in THP-1 human macrophages in response to VLDL.  
THP-1 cells were incubated for indicated times with or without VLDL. Representative 
immunoblots of phosphorylated (A) ERK1/2 and (B) p38 from cytosolic fractions (n=4). 
C, THP-1 cells were incubated with MEK1/2 inhibitor (U0126 10μmol/L) or its inactive 
form (U0124 10μmol/L) for 0.5hr followed by 16hr incubation with or without VLDL. IL-
1β, MIP-1α and ICAM-1 mRNA was measured by qRT-PCR. D, THP-1 cells were 
incubated with p38 inhibitor (SB203580 10µmol/L) or its inactive isoform (SB202474 
10µmol/L) for 0.5hr followed by a 16hr incubation with or without VLDL. mRNA 
determinations as in (C). Values are mean +/- SEM (n=4). A,B * indicates significant 
difference versus respective DMSO control; ANOVA with post hoc Bonferroni’s test 
(P<0.05). Representative bands are from the same immunoblot, cut from different 
regions. C,D Different letters are significantly different; ANOVA with post-hoc Tukey’s 
test (P<0.05).  
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Figure 2.11 Effects of inhibitors on cell signalling cascades. THP-1 cells were 
incubated with or without p38 inhibitor SB203580 (10μmol/L) for 0.5hr. Cytosolic 
fractions were isolated and immunoblotted for (A) pERK1/2 and p-p38. Equal loading 
was confirmed by total ERK and total p38, respectively (n=3). In a separate experiment, 
THP-1 cells were incubated for indicated times with or without AKT inhibitor (AKTi) IV 
(10μmol/L). Levels of (B) pAKT and pFoxO1 were determined by immunoblotting of 
cytosolic fractions. Quantitation was determined relative to total AKT and β-Actin, 
respectively (n=3). C, THP-1 cells incubated for 16hr with or without AKT activity inhibitor 
(AKT
i
 IV 10µmol/L). mRNA for IL-1β, MIP-1α and ICAM-1 mRNA was measured by qRT-
PCR. Data is presented as mean +/- SEM (n=4). * indicates significant difference versus 
control; t-test (P<0.05). For A-B, relative intensities represent the mean ratio of 
phospho:total protein relative to the respective DMSO control of 3 independent 
experiments. 
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Figure 2.12 VLDL induces human macrophage inflammation via AKT/FoxO1 
signaling.  
THP-1 cells were incubated for indicated times with or without VLDL. Representative 
immunoblots of (A) phosphorylated-AKT and (B) phosphorylated-FoxO1from cytosolic 
fractions. (C) nFoxO1 from nuclear fractions. Equal loading was confirmed by total AKT, 
β-Actin, and Lamin A/C respectively (n=4). The immunoblots for Lamin A/C in (B) and for 
β-Actin in (C) show no detectable bands demonstrating complete separation of cytosolic 
and nuclear fractions, respectively. Data is presented as mean +/- SEM (n=4). * 
indicates significant difference versus control; t-test (P<0.05). Representative bands are 
from the same immunoblot, cut from different regions.  
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2.3.6 VLDL-STIMULATED ACTIVATION OF MAPK SIGNALING AND REPRESSION 
OF AKT/FoxO1 SIGNALING ARE CORRECTED BY PPARδ ACTIVATION  
To determine the mechanism whereby PPARδ activation attenuates VLDL-
induced cytokine expression, we examined the effect of PPARδ agonists on 
macrophage MAPK and AKT/FoxO1 signaling. GW0742 and GW501516 significantly 
attenuated both VLDL-stimulated ERK1/2 and p38 activation (Figure 2.13A, B). 
Furthermore, both PPARδ agonists increased phospho-Akt and phospho-FoxO1 in 
control cells (Figure 2.13C), and reversed the reductions of phospho-Akt and phospho-
FoxO1 in VLDL-treated cells (Figure 2.13D, E). Importantly, GW0742 and GW501516 
prevented the VLDL-induced increase in nuclear FoxO1 (Figure 2.13F). Inhibition of β-
oxidation by etomoxir had no effect on the ability of PPARδ activation to normalize 
VLDL-induced MAPK signaling (Figure 2.14A,B) or restore normal AKT/FoxO1 signaling 
(Figure 2.14C,D). Collectively, these data demonstrate that PPARδ activation inhibits 
VLDL-induced inflammatory cytokine expression by inhibiting MAPK signaling and 
restoring signaling through AKT/FoxO1. Furthermore, the modulation of both signaling 
pathways by PPARδ activation was independent of PPARδ agonist-induced β-oxidation. 
131 
 
 
 
 
 
 
 
Figure 2.13 PPARδ activation normalizes VLDL-stimulated inflammatory signaling.  
THP-1 cells were pre-incubated with PPARδ agonists for 24hr, followed by a 0.5hr 
incubation with or without VLDL. Representative immunoblots of phosphorylated (A) 
pERK1/2 and (B) p-p38 from cytosolic fractions (n=5-7). THP-1 cells were incubated for 
6hr with or without PPARδ agonists. Levels of (A) pAKT and pFoxO1 were determined 
by immunoblotting cytosolic fractions. Equal loading was confirmed by total AKT and β-
Actin, respectively (n=2). Relative intensities represent ratio of phospho:total protein 
relative to the respective DMSO control of the representative immunoblot. D-F, THP-1 
cells were pre-incubated with PPARδ agonists for 24hr, followed by 6hr incubation with 
or without VLDL. Representative immunoblots of phosphorylated (C) pAKT and (D) 
pFoxO1 from cytosolic fractions and (E) nFoxO1 from nuclear fractions. Equal loading 
was confirmed by total AKT, β-Actin, and Lamin A/C respectively (n=5-7). Different 
letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05).   
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Figure 2.14 Inhibition of β-oxidation had no effect on the ability of PPARδ 
activation to correct VLDL-induced inflammatory signalling. THP-1 cells were pre-
incubated with PPARδ agonists for 24hr, followed by a 0.5hr incubation with the CPT-1α 
inhibitor etomoxir (ETO). For a subsequent 0.5hr, cells were incubated with or without 
VLDL. Representative immunoblots of phosphorylated (A) pERK1/2 and (B) p-p38 from 
cytosolic fractions (n=3). C,D, THP-1 cells were pre-incubated with PPARδ agonists for 
24hr, followed by a 0.5hr incubation with ETO. For a subsequent 6hr, cells were 
incubated with or without VLDL. Representative immunoblots of phosphorylated (C) 
pAKT and (D) pFoxO1 from cytosolic fractions (n=3). Data is presented as mean +/- 
SEM. Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test 
(P<0.05).  
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2.4 DISCUSSION 
Patients with insulin resistant syndromes such as type 2 diabetes and metabolic 
syndrome have significant elevations of plasma VLDL, which confers increased risk for 
atherosclerosis (Facchini et al., 2001, Reaven, 2005). Type 2 diabetes, metabolic 
syndrome and atherosclerosis are interwoven by the commonality of chronic low-grade 
inflammation (Dandona et al., 2004, Hotamisligil, 2006). However, the molecular 
processes that link elevated plasma VLDL, atherosclerosis and inflammation require 
further elucidation. In the present study, we demonstrate that human native VLDL 
induces both macrophage TG accumulation and expression of proinflammatory 
cytokines, in the absence of exogenous LPS. Furthermore, we demonstrate that PPARδ 
activation attenuates both of these pathogenic macrophage foam cell processes, and 
define the mechanisms involved. Although VLDL-derived fatty acids are the stimulus for 
cytokine expression, the ability of PPARδ agonists to dampen the inflammatory 
response is independent of agonist-induced LPL inhibition, stimulation of β-oxidation or 
reduction in cellular TG. 
PPARδ is expressed in abundance in macrophages (Vosper et al., 2001), but its 
biological role in lipid homeostasis has been controversial (Chawla et al., 2003, Lee et 
al., 2006, Vosper et al., 2001). In this study, we demonstrate that VLDL-induced TG 
accumulation is significantly decreased by PPARδ activation. Hydrolysis of VLDL-TG by 
macrophage LPL is required for cellular FA uptake and TG resynthesis (Evans et al., 
1993). PPARδ agonists increased ANGPTL4 expression, which was coupled to a 
reduction in LPL activity thereby limiting liberated FAs for macrophage uptake. These 
findings are consistent with recent studies demonstrating that ANGPTL4 is a PPARδ 
target gene, which is expressed in macrophages and irreversibly inactivates LPL by 
converting active LPL-dimers into inactive LPL-monomers (Adhikary et al., , Sukonina et 
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al., 2006). PPARδ activation increased expression of the FA transporter CD36, which 
resulted in a modest increase in FA uptake, albeit from a smaller FA pool. However, we 
confirm that PPARδ agonists upregulate CPT-1α expression (Lee et al., 2006), which 
enhances FA oxidation. Furthermore, we show for the first time, that PPARδ activation 
results in a net depletion of VLDL-induced TG accumulation. These results are 
consistent with the concept that one role for PPARδ activation in macrophages is to 
prevent lipotoxicity by limiting VLDL hydrolysis and enhancing FA catabolism (Chawla et 
al., 2003, Lee et al., 2006), and contradict the notion that PPARδ activation promotes 
lipid accumulation (Vosper et al., 2001). Furthermore, although VLDL-derived FAs 
activate PPARδ (Chawla et al., 2003), potent synthetic agonists of PPARδ are required 
in order to attenuate VLDL-stimulated macrophage foam cell formation, as well as inhibit 
the inflammatory response.  
VLDL markedly stimulates expression of AP-1-inducible inflammatory cytokines, 
which occurs in the absence of NFκB signaling or exogenous LPS. VLDL has been 
demonstrated to induce Mip-1α in murine macrophages via ERK1/2 activation 
(Saraswathi and Hasty, 2006). We extend this response to human THP-1 macrophages 
and to include the induction of IL-1β and ICAM-1. In THP-1 macrophages, both ERK1/2 
and p38 are activated in response to VLDL, and p38 phosphorylation remains elevated 
well beyond that of ERK1/2. Inhibition of p38 stimulated ERK1/2 phosphorylation and 
enhanced cytokine expression. Moreover, the combination of VLDL treatment and p38 
inhibition results in additive stimulation of cytokine expression over either treatment 
alone, suggesting that relieving the p38-induced impediment on ERK1/2 signaling 
enhances cytokine expression. Although in some cells, p38 activation has no effect or 
amplifies ERK1/2 signaling, we and others have reported that in hepatoma cells, insulin-
induced phosphorylation of p38 also acts as a negative regulator of insulin-stimulated 
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ERK1/2 activation (Allister et al., 2005, Keeton et al., 2002). The present study supports 
this paradigm, and demonstrates for the first time, that VLDL-stimulation of macrophage 
cytokine expression through MAPKerk involves p38 acting as a negative regulator of 
ERK1/2 signaling.  
VLDL-treated macrophages displayed attenuated AKT and FoxO1 
phosphorylation which coincided with increased nuclear FoxO1 and increased cytokine 
expression. Although the mechanism by which VLDL attenuates AKT signaling leading 
to activation of FoxO1 has not been defined, it is known that FoxO1 is a direct 
transcriptional activator of Il-1β in mouse macrophages (Su et al., 2009). Several reports 
indicate that lipid-induced macrophage insulin resistance is associated with impaired 
AKT/FoxO1 signaling, increased FoxO1 activity, and thus plays a critical role in 
macrophage inflammation and ER-stress-induced apoptosis (Han et al., 2006, 
Senokuchi et al., 2008, Su et al., 2009). Some studies have suggested that free fatty 
acids induce macrophage inflammation through activation of toll-like receptor (TLR) 
signaling (Nguyen et al., 2007, Shi et al., 2006). However, more recent reports have 
provided contrary evidence (Anderson et al., 2012, Erridge and Samani, 2009). The 
present study is consistent with the concept that VLDL-stimulated macrophage 
inflammatory cytokine expression results from macrophage insulin resistance, rather 
than elicitation of a TLR-NFκB response. This is evidenced by: (i) impaired AKT/FoxO1 
signaling and enhanced MAPK signaling by VLDL treatment, (ii) canonical NFκB target 
genes TNFα and IL-6 being unaffected by VLDL treatment, and (iii) the inability of 
parthenolide, (an inhibitor of NFκB signaling) to block VLDL-stimulated expression of IL-
1β, MIP-1α and ICAM-1.  
It is tempting to hypothesize that VLDL-induced inflammatory responses are 
initially derived from rapid ERK1/2 activation followed by later and sustained AKT 
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signaling. The ERK1/2 signal is rapidly down-regulated by activated p38, whereas the 
AKT signal is possibly mitigated by a self-limiting feedback loop (Fan et al., 2010). 
Furthermore, with time, it is possible that incoming FAs increase the saturated lipid 
content of the ER membrane, thereby inducing an ER-stress response (Borradaile et al., 
2006), and subsequent amplification of nuclear FoxO1 (Ozcan et al., 2004). The exact 
relationship among time-dependent signaling events governing VLDL-stimulated 
inflammatory responses requires further study.  
VLDL-induced expression of inflammatory cytokines was completely normalized 
by both PPARδ agonists, despite a lack of effect on intracellular FFA levels, and even 
under conditions of inhibited β-oxidation. This suggests that stimulation of β-oxidation by 
PPARδ activation is insufficient to explain the anti-inflammatory effects. Additionally, 
VLDL-stimulated phosphorylation of both ERK1/2 and p38 were normalized by PPARδ 
activation, suggesting regulation of a common upstream MAPK factor. This concept is 
consistent with a previous report that GW0742 inhibited angiotensin II-induced 
phosphorylation of ERK1/2 and p38 in mouse macrophages, via upregulation of RGS4 
and RGS5 (Takata et al., 2008). Whether this mechanism applies to the present study 
remains to be determined.  
Macrophages exposed to VLDL in the presence of PPARδ agonists restored 
levels of phospho-AKT, phospho-FoxO1 and nuclear FoxO1 to those observed in 
untreated cells, an effect independent of PPARδ agonist-induced enhanced β-oxidation. 
Although modulation of AKT activity by PPARδ activation has been observed in 
keratinocytes and endothelial cells (Di-Poi et al., 2002, Han et al., 2008), the 
mechanisms underlying this phenomenon remain unclear. Di-Poi et al. demonstrated 
that PPARδ ligand L-165041 induced expression of integrin-like kinase (ILK) and 3-
phosphoinositide-dependent kinase-1 (PDK1), which led to phosphorylation of AKT and 
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FoxO1 (Di-Poi et al., 2002). In contrast, Han et al. reported that GW501516-treated 
endothelial progenitor cells displayed marked elevations in phospho-AKT, without 
increased ILK expression (Han et al., 2008). In our experiments in macrophages, 
PPARδ agonists increased phospho-AKT and phospho-FoxO1, without effecting ILK or 
PDK1 expression (Figure 2.15). This suggests that the anti-inflammatory effect of 
PPARδ activation is, in part, due to direct stimulation of AKT/FoxO1 phosphorylation, 
thereby preventing VLDL from dysregulating this signaling cascade.  
 In summary, VLDL-induced macrophage lipid accumulation and proinflammatory 
cytokine synthesis are attenuated by PPARδ activation, effects which involve ERK1/2- 
and AKT-dependent signaling mechanisms. These combined reductions of lipid 
accumulation and inflammatory cytokine expression by PPARδ ligands reveal a novel 
mechanism for preventing the deleterious consequences of macrophage foam cell 
formation.
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Figure 2.15 Effects of PPARδ agonists on expression of ILK and PDK1. 
THP-1 cells were incubated with PPARδ-specific agonists at the indicated 
concentrations for 24hr. Total RNA was isolated and ILK and PDK1 mRNA was 
measured by qRT-PCR (n=4). Data is presented as mean +/- SEM.  
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Chapter 3 
Activation of PPARδ inhibits human macrophage foam cell formation induced by 
native and modified low-density lipoprotein 
 
3.1 INTRODUCTION 
During atherogenesis, excessive macrophage uptake of lipoproteins drives lipid 
accumulation and the synthesis and secretion of proinflammatory mediators within the 
arterial wall, events that potentiate lesion progression (Libby et al., 2011). An important 
risk factor for the development of atherosclerosis is the elevation of plasma lipoproteins, 
primarily due to their ability to permeate the vessel wall and initiate macrophage foam 
cell formation as well as maladaptive immune responses (Libby et al., 2011, Moore and 
Tabas, 2011). Specifically, increased plasma cholesteryl ester (CE)-rich low-density 
lipoprotein (LDL) is a major foam cell-inducing lipoprotein, and in turn, a significant 
contributor to accelerated atherogenesis (Libby et al., 2011, Moore and Tabas, 2011). 
High plasma LDL is also positively correlated with inflammation linked to atherogenesis 
in both humans and mice (Blake and Ridker, 2003, Getz and Reardon, 2006). Therefore, 
pharmacological inhibition of LDL-induced macrophage foam cell formation and the 
linked inflammatory response(s) represent an attractive therapeutic strategy.  
Cholesterol homeostasis in macrophages is a dynamic process regulated by 
uptake, storage and efflux. The predominant LDL uptake pathway in macrophages of the 
arterial intima is via it’s modified form through the scavenger receptors cluster of 
differentiation (CD) 36 and scavenger receptor A I/II (SRAI/II) (Moore and Freeman, 
2006). Subendothelial retention of LDL leads to the formation of oxLDL (Steinberg, 2009, 
Steinberg and Witztum, 2010), a high-affinity scavenger receptor ligand (Moore and 
Freeman, 2006). Binding of oxLDL to either of these scavenger receptors readily 
induces macrophage cholesterol accumulation (Argmann et al., 2003). Once 
internalized, lipoprotein derived CEs are hydrolyzed in the late endosomes to free 
cholesterol and fatty acids (Maxfield and Tabas, 2005), which are subsequently re-
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esterified in the endoplasmic reticulum (ER) by acyl-CoA:cholesterol acyltransferase 
(ACAT) (Brown et al., 1980, Ikonen, 2008). In macrophages, ACAT1 is the only 
expressed isoform that generates CE for storage in cytoplasmic lipid droplets (Ikonen, 
2008). Collectively, under these circumstances, it is important that cholesterol efflux 
maintains the rate of cholesterol uptake, to prevent accumulation of cholesterol-laden 
foam cells within the arterial intima (Libby et al., 2011). 
In response to massive cholesterol accumulation, macrophage foam cells also 
synthesize and secrete proinflammatory mediators that potentiate lesion progression 
(Tabas, 2010). Although the mechanisms by which cholesterol induces inflammatory 
responses are not fully understood, one proposed stimulus has been the induction of the 
endoplasmic reticulum (ER)-stress pathway (Tabas, 2010). As a consequence of 
excessive lipoprotein-derived cholesterol uptake, free cholesterol (FC) builds up in the 
ER, causing ER-stress (Tabas, 2010). Subsequently, the C/EBP homologous protein 
(CHOP) is induced, which in turn stimulates Nfκb signaling to upregulate the expression 
of tumor necrosis factor (TNF) α and interleukin (IL)-6 (Li et al., 2005). Therefore, 
excessive lipoprotein-derived cholesterol delivered to macrophages must be 
appropriately partitioned, either to storage in cytoplasmic lipid droplets or to cholesterol 
efflux pathways, in order to prevent the deleterious proinflammatory consequences of 
FC accrual in the ER (Rong et al., 2013, Tabas, 2010).  
In addition to the ER-stress pathway, a growing body of evidence suggests that 
cell-surface receptor signaling also plays a role in the stimulation of macrophage 
inflammatory responses. Specifically, a series of studies support the concept that oxLDL 
stimulates proinflammatory cytokine expression through CD36 in concert with the pattern 
recognition toll-like receptors (TLR) (Moore and Tabas, 2011). The assembly of CD36-
TLR complexes leads to the activation of nuclear factor kappa B (Nfκb) signal 
transduction to simulate expression of proinflammatory effector molecules, such as Tnf 
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and interleukin Il6 (Stewart et al., 2010). Addition of lipopolysaccharide (LPS) to cultured 
macrophages significantly enhances oxLDL-induced inflammation (Wiesner et al., 2010). 
In macrophages isolated from CD36 deficient patients, oxLDL fails to stimulate cytokine 
expression (Janabi et al., 2000). In mice, genetic ablation of either CD36 or various 
TLRs is linked to protection from diet-induced atherosclerosis and aortic inflammation 
(Curtiss et al., 2012, Febbraio et al., 2000, Michelsen et al., 2004, Mullick et al., 2005).  
Despite the overwhelming positive evidence for oxLDL-induced inflammatory 
responses, a series of studies have provided contrary evidence (Chung et al., 2000, 
Kannan et al., 2012, Qiu et al., 2007). LPS-induced expression of the proinflammatory 
cytokine IL-12 was significantly reduced in macrophages treated with oxLDL (Chung et 
al., 2000). A subsequent study showed that macrophages treated with oxLDL exhibited 
lower expression of a panel of proinflammatory cytokines that included TNFα and IL-6 
(Qiu et al., 2007). Most recently, oxLDL-treatment of monocytes failed to increase TNFα 
and IL-6 expression, and protected these cells from LPS-induced proinflammatory 
responses (Kannan et al., 2012). Collectively, these studies suggest that our 
understanding of macrophage inflammatory responses in the context of lipoprotein 
uptake, is not well defined.  
The peroxisome proliferator-activated receptors (PPARs) are important 
regulators of metabolic and inflammatory signaling (Harmon et al., 2011, Lee et al., 
2003). There are three known isoforms (PPARα, γ and δ) which exhibit distinct patterns 
of tissue distribution and function (Harmon et al., 2011, Lee et al., 2003). In contrast to 
the predominant expression of PPARα and PPARγ in a cell- or tissue-specific manner 
(Harmon et al., 2011), expression of PPARδ is ubiquitous. However, the expression of 
PPARδ is high in macrophages (Vosper et al., 2001) where its role in cholesterol 
homeostasis remains unclear. Conflicting reports have demonstrated that synthetic 
PPARδ agonists either stimulate cholesterol efflux and reverse cholesterol transport or 
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promote lipid accumulation (Oliver et al., 2001, Vosper et al., 2001, Wallace et al., 2005). 
One study suggested that the PPARδ agonist GW0742 had no effect on cholesterol 
accumulation in mouse peritoneal macrophages isolated from mice fed a high-fat, high 
cholesterol diet supplemented with the compound (Li et al., 2004). Consequently, the net 
effect of PPARδ activation on oxLDL-induced macrophage cholesterol accumulation has 
been difficult to define. With regard to inflammation, in adipocytes and cardiomyocytes, 
PPARδ agonists inhibit LPS-induced Nfκb-mediated inflammatory responses (Ding et al., 
2006, Rodriguez-Calvo et al., 2008). However, the impact of PPARδ activation on the 
mechanisms underlying oxLDL-induced inflammatory responses, in the absence of LPS, 
has not been examined. 
 In the present study, we report that synthetic ligand activation of PPARδ in 
macrophages attenuates LDL- and oxLDL-induced CE accumulation as well as oxLDL-
induced FC accumulation. This was at least in part due to promoting ABCA1-mediated 
cholesterol efflux to apoAI. OxLDL-treated macrophages displayed reduced expression 
of TNFα and IL-6 compared to untreated cells, which was not further affected by PPARδ 
activation. The oxLDL-mediated anti-inflammatory response was associated with 
increased expression of genes known to be regulated by the liver X receptor (LXR) as 
well as by PPARγ and PPARδ.  
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3.2 MATERIALS AND METHODS 
3.2.1 LIPOPROTEINS 
LDL and high-density lipoprotein3 (HDL3) were isolated from plasma of human 
subjects recruited from the Lipid Clinic at the London Health Sciences Centre, University 
Campus (London, Ontario, Canada). This study was approved by the University of 
Western Ontario Institutional Review Board (IRB reference #15685). Lipoproteins were 
separated by differential ultracentrifugation using a Beckman 70.1 Ti rotor (16hr, 40,000 
rpm, 12°C) as previously described (Whitman et al., 1997). LDL was oxidized (oxLDL) 
via the copper sulfate method and the extent of modification was confirmed by 
alterations in electrophoretic mobility (Whitman et al., 1997). 
3.2.2 CELL CULTURE 
Human THP-1 macrophages were obtained from American Type Culture 
Collection (Manassas, VA) and cultured as described previously (Beyea et al., 2007). 
PPARδ agonists GW0742 (Sigma) and GW501516 (Alexis Biochemicals, Plymouth, PA) 
were dissolved in dimethyl sulfoxide (DMSO, Sigma) and incubated with cells at the 
indicated concentrations. These concentrations have been determined to specifically 
activate PPARδ, in the absence of PPARα or PPARγ activation (Chapter 2). THP-1 
macrophages were preincubated (24 hr) the presence or absence of PPARδ agonists. 
Subsequently, cells were incubated with PPARδ agonists in the presence or absence of 
lipoproteins as indicated. The ACAT inhibitors Dup-128 (DuPont Merck Pharmaceutical 
Co.) and CI-1011 (Parke-Davis Pharmaceutical Research) were dissolved in DMSO and 
applied to THP-1 macrophages 0.5 hr prior to lipoprotein additions. Experimental 
concentrations of DMSO did not exceed 0.5% of total medium.  
3.2.3 CELLULAR LIPID MASS 
THP-1 macrophages were preincubated in the presence of PPARδ agonists or 
equal volume of DMSO (not to exceed 0.5% of total medium) for 24 hr in RPMI 1640 
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supplemented with 10% fetal bovine serum (FBS) and 300nmol/L PDB. Cells were 
incubated for a further 16 hr with fresh media containing 5% LPDS and compounds in 
the absence or presence of native or oxidatively modified LDL (150 μg of lipoprotein total 
cholesterol (TC)/mL medium). Cellular TC, FC, TG, and protein mass were determined 
using enzymatic colorimetric assays for TC and FC (Wako Diagnostics, Richmond, VA) 
as well as TG (Boehringer Mannheim, Laval, QC) as previously described (Rowe et al., 
2003). Cellular CE was determined as the difference between TC and FC (Rowe et al., 
2003). 
3.2.4 CHOLESTEROL ESTERIFICATION 
The esterification of cholesterol was measured in THP-1 cells following a 
preincubation in 5% LPDS-containing medium for 19 hr in the presence or absence of 
the indicated concentrations of PPARδ agonists. For a subsequent 5 hr incubation, 
0.08nCi/mL [1-14C]oleic acid (Amersham Biosciences) complexed with fatty acid-free 
bovine serum albumin in a molar ratio of 5.36:1 (Sigma) was added with or without LDL 
or oxLDL as described previously (Beyea et al., 2012). Cellular lipid extracts were 
separated by thin layer chromatography. Cells were lysed in 1mL of 0.1N NaOH, and 
aliquots were used to determine protein concentrations (Beyea et al., 2012). 
3.2.5 CHOLESTEROL EFFLUX 
THP-1 macrophages were incubated with acLDL (5 µg-TC/mL) in medium 
containing 0.2% FAF:BSA and [1α,2α (n)-3H]cholesterol (1 µCi/mL, Amersham 
Biosciences) for 24 hr. Monolayers were then washed with phosphate buffered saline 
(PBS) and incubated in fresh medium with GW0742 or GW1516 at the indicated 
concentrations for 24 hr. Subsequently, macrophages were incubated with fresh 
compound and medium with 0.2% FAF:BSA alone, apoAI (10 µg/mL, Sigma) or HDL3 
(100μg-TC/mL) for a further 16 hr. Cholesterol efflux was expressed as the percentage 
of [3H] counts in the media versus total [3H] cholesterol counts (media plus cell) and 
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normalized to cell protein determined from 0.1N NaOH lysates as described (Argmann et 
al., 2003). 
3.2.6 QUANTITATIVE REAL-TIME PCR mRNA ABUNDANCE ANALYSIS 
THP-1 cells were incubated for 24 hr in RPMI 1640 with 5% LPDS, 300nmol/L 
PDB, in the presence or absence of PPARδ agonists, and subsequently total RNA was 
isolated using TriZol reagent (Invitrogen, Burlington, ON) according to the 
manufacturer’s instructions. In experiments examining oxLDL-induced inflammatory 
cytokine expression, cells were preincubated for 24 hr in RPMI 1640 with 10% FBS, 
300nmol/L PDB, in the presence or absence of PPARδ agonists. Cells were then 
incubated with fresh 5%-LPDS media and compounds for a further 16 hr in the absence 
or presence of oxLDL (150μg-TC/mL) prior to TriZol RNA extraction. Abundance of total 
RNA (2µg) was reverse transcribed using the Applied Biosystems High Capacity cDNA 
reverse transcription kit according to the manufacturer’s protocol. Subsequently, cDNA 
(10ng) was analyzed in triplicate by quantitative real time RT-PCR (qRT-PCR) on an ABI 
Prism (model 7900HT) Sequence Detection System (Applied Biosystems, Foster City, 
CA) according to the manufacturer’s instructions and as previously described (Chapter 
2). Primer-probe sets for each gene (ABCA1, ABCG1, ACAT1, ACOX, ADFP, DHCR24, 
FABP4, FAS, IL-6, MYLIP, SREBP-1c, and TNFα) were obtained from Applied 
Biosystems (Carlsbad, CA). Abundance of target genes, calculated using the standard 
curve method, was normalized to GAPDH abundance. 
3.2.7 IMMUNOBLOT ANALYSIS AND DENSITOMETRY 
Total cell lysates were prepared as previously described (Chapter 2). Proteins 
were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes and 
immunoblotted as described (Rowe et al., 2003). Cellular cytosolic fractions were probed 
using antibodies against human ABCA1, ABCG1 (Novus Biologicals, Littleton, CO) and 
β-actin (Cell Signaling, Danvers, MA). Quantification analysis of the developed films was 
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performed using an imaging densitometer (Bio-Rad Quantity One Software). ABCA1 and 
ABCG1 from cytosolic fractions were normalized to β-Actin. 
3.2.8 STATISTICAL ANALYSES 
Data are expressed as means +/- standard error of the mean (SEM). The 
Shapiro-Wilk normality test was used to test for parametric distributions in each data set. 
P values for observed differences between treatment and control groups were calculated 
by one-way ANOVA followed by Bonferroni post hoc test. P values for observed pair-
wise comparisons were calculated by one-way ANOVA followed by Tukey’s post hoc 
test. Significance thresholds were P values less than 0.05. Statistical analyses were 
performed with SigmaPlot 11.0 software (Systat, Inc, San Jose, CA). 
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3.3 RESULTS  
3.3.1 PPARδ-SPECIFIC ACTIVATION ATTENUATES NATIVE AND OXIDIZED LDL-
INDUCED MACROPHAGE CHOLESTERYL ESTER ACCUMULATION 
THP-1 cells treated with native LDL (150 µg-TC/mL) displayed a modest but 
significant 1.6-fold increase in CE accumulation (Figure 3.1A). Pre-treatment with 
PPARδ agonists at concentrations known to be PPARδ-specific (Chapter 2) for 24 hours 
almost completely normalized LDL-induced CE mass (Figure 3.1A). Cellular free 
cholesterol (FC) concentrations were unaffected by LDL or PPARδ agonist treatment, 
whereas triglyceride (TG) mass trended towards a reduction in the presence of the 
PPARδ ligands (Figure 3.1B). In contrast to the modest induction of foam cell formation 
by native LDL, oxLDL (150 µg-TC/mL)-treated macrophages exhibited a marked 5-fold 
increase in CE mass, which was significantly attenuated (~40%) by 24 hour pre-
treatment with PPARδ agonists (Figure 3.1C). The 1.8-fold increase in FC accumulation 
induced by oxLDL was reduced (~50%) in the presence of the PPARδ ligands (Figure 
3.1D). Collectively, these results demonstrate that PPARδ activation attenuates CE-rich 
lipoprotein induced macrophage foam cell formation. 
3.3.2 PPARδ AGONISTS ENHANCE CHOLESTEROL UPTAKE GENES AND ABCA1-
MEDIATED CHOLESTEROL EFFLUX TO APOAI, HAVE NO EFFECT ON ABCG1-
MEDIATED EFFLUX to HDL3 AND INHIBIT CHOLESTEROL ESTERIFICATION 
We hypothesized that the observed attenuation of CE mass mediated by the 
PPARδ agonists may be due to reduced lipoprotein uptake. However, PPARδ activation 
enhanced both LDLR (Figure 3.2A) and CD36 mRNA abundance (Chapter 2, Figure 
2.3D), which would be predicted to enhance native and oxidized LDL uptake, 
respectively. We next examined cholesterol esterification, and found that ACAT1 
expression was unchanged in response to the PPARδ ligands (Figure 3.2B). However, 
both PPARδ agonists attenuated basal and lipoprotein-induced  
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Figure 3.1: PPARδ activation attenuates LDL-induced cholesteryl ester mass 
accumulation.  
THP-1 cells were pre-incubated with PPARδ agonists at the indicated concentrations for 
24h, followed by a 16h incubation with or without LDL. A, Total and free cholesterol 
mass were measured via a colorimetric assay. Cholesteryl ester (CE) is calculated as 
the difference between total and free cholesterol. Values are expressed as CE mass +/- 
SEM of duplicate determinations (n=6). B, Free cholesterol and triacylglycerol mass 
were measured via a colorimetric assay. Values are expressed as CE mass +/- SEM 
and FC mass +/- SEM of duplicate determinations (n=6). C, oxLDL-induced CE mass. D, 
oxLDL-induced FC and TG mass. Different letters are significantly different from one 
another. ANOVA with post hoc Tukey’s test (P<0.05).  
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Figure 3.2: Effect of PPARδ activation on uptake and FFA re-esterification into 
cholesteryl ester.  
THP-1 cells were incubated with PPARδ-specific agonists at the indicated 
concentrations for 24h. mRNA was harvested and (A) LDLR and (B) ACAT1 abundance 
was measured by qRT-PCR. Values are expressed as a fold change of DMSO control 
cells normalized to GAPDH +/- SEM of duplicate determinations (n=2-4). In separate 
experiments, following a 19h incubation with PPARδ agonists at indicated 
concentrations, THP-1 cells were incubated for a further 5h with PPARδ agonists and 
(C) 1-[14C]oleic acid, (D) with or without LDL and (E) with or without oxLDL to measure 
oleate incorporation into cellular cholesteryl ester. Values are expressed as a fold 
change of DMSO control cells +/- SEM of duplicate determinations (n=3-4). Different 
letters are significantly different from one another. ANOVA with post hoc Tukey’s test 
(P<0.05).  
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cholesterol esterification, as evidenced by reduced incorporation of 14C-oleic acid into 
CE (Figure 3.2C-E).  
Regarding cholesterol efflux, abundance of ABCA1 mRNA and protein was 
significantly increased in THP-1 cells treated with either PPARδ agonist (Figure 3.3A, B). 
Moreover, cells treated with GW0742 (25nmol/L) displayed a marked 2-fold increase in 
ABCG1 mRNA, and significantly increased ABCG1 protein, effects which were not 
observed with GW501516 (Figure 3.3C, D). Increased ABCA1 mRNA and protein was 
associated with a significant 1.8-fold increase in cholesterol efflux to apoAI (Figure 
3.3E). Although there was a trend towards increased cholesterol efflux to HDL3, this did 
not achieve statistical significance (Figure 3.3C). Collectively these results suggest that 
PPARδ activation stimulates ABCA1- but not ABCG1-mediated cholesterol efflux, which 
likely contributes to a net reduction in macrophage CE content. 
3.3.3 PPARδ ACTIVATION DOES NOT FURTHER AFFECT THE OXLDL-MEDIATED 
REDUCTION IN PROINFLAMMATORY CYTOKINE EXPRESSION 
Exposure of macrophages to oxLDL has been shown to stimulate Nfκb-mediated 
proinflammatory responses (Janabi et al., 2000, Stewart et al., 2010), and macrophages 
loaded with FC are thought to stimulate expression the canonical Nfκb-target genes, 
TNFα and IL-6 (Li et al., 2005). Here, oxLDL-treated macrophages exhibited reduced 
expression of TNFα (-50%) and IL-6 (-30%) (Figure 3.4A, B). Pre-treatment with the 
PPARδ agonists had no further effect on expression of these cytokines (Figure 3.4A, B). 
We reasoned that the observed 1.8-fold increase in macrophage FC content in response 
to oxLDL (Figure 3.1D) was perhaps insufficient to stimulate ER-stress and induce an 
inflammatory response (Li et al., 2005). Treatment of macrophages with ACAT inhibitors 
Dup-128 or CI-1011 in the presence of oxLDL resulted in a further 1.3- and 1.5-fold 
increase in macrophage FC content, respectively (Figure 3.4C). CE mass 
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Figure 3.3: PPARδ activation enhances ABCA1 and ABCG1 mRNA and 
protein,leading to increased cholesterol efflux.  
THP-1 cells were incubated with PPARδ agonists for 24h. Total RNA was analyzed for 
(A) ABCA1 and (C) ABCG1 mRNA by qRT-PCR. Values are expressed as a fold change 
of DMSO control cells normalized to GAPDH +/- SEM of duplicate samples. ANOVA with 
post hoc Bonferroni correction, *P<0.05 versus control (n=4). B,E, ABCA1 and ABCG1 
protein; representative immunoblots of 4 independent experiments shown. D, 
Cholesterol efflux from macrophages was measured following incubation with 
[3H]cholesterol and acetylated LDL (5μg of total cholesterol/mL, 24h) in 0.2% (w/v) fatty 
acid-free bovine serum albumin medium followed by 24h with vehicle or PPARδ agonists 
at the indicated concentrations, and a final 16h incubation with vehicle or PPARδ 
agonists in the presence of FAF:BSA alone or apoAI (10μg/mL) or HDL3 (100μg/mL). 
Cholesterol efflux is expressed as the percentage of [3H]cholesterol in the medium 
relative to total [3H]cholesterol (medium plus cell) normalized to total cell protein and 
plotted as a ratio of apoAI with vehicle alone (mean +/- SEM, n=4). ANOVA with post 
hoc Tukey’s test, different letters are statistically different (P< 0.05). 
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Figure 3.4: PPARδ agonists and ACAT inhibitors do not further affect the oxLDL-
mediated reduction in proinflammatory cytokine expression.  
THP-1 cells were pre-incubated with PPARδ agonists at the indicated concentrations for 
24h, followed by a 16h incubation with or without oxLDL (150µg-TC/mL) for 16h. Total 
RNA was analyzed for the proinflammatory cytokines (A) TNFα and (B) IL-6 by qRT-
PCR and normalized to GAPDH. In a separate set of experiments, THP-1 cells were pre-
incubated with or without ACAT inhibitors at the indicated concentration for 0.5h, 
followed by a 16h incubation with or without oxLDL (150µg-TC/mL) for 16h. C, Free 
cholesterol mass. D, Cholesteryl Ester mass. TNFα (E) and IL-6 (F) mRNA abundance 
normalized to GAPDH. Data is presented as mean +/- SEM of duplicate samples (n=2).
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was significantly reduced by the presence of the ACAT inhibitors (Figure 3.4D). Despite 
the further induction of cellular FC by ACAT inhibition, the suppression of TNFα or IL-6 
expression by oxLDL was unaffected (Figure 3.4E, F). These data suggest that oxLDL 
treatment or FC accumulation in macrophages does not stimulate the inflammatory 
response. 
3.3.4 OXLDL-TREATED MACROPHAGES DISPLAY INCREASED EXPRESSION OF 
LXR, PPARγ AND PPARδ TARGET GENES 
It has recently been reported that peritoneal macrophages isolated from high-fat, 
high cholesterol fed Ldlr-/- mice display significant enrichment of cholesterol, coupled to 
substantially reduced dehydrocholesterol reductase (DHCR) 24 expression (Spann et 
al., 2012). The DHCR24 transcript encodes the enzyme responsible for catalyzing the 
conversion of lanosterol to 24,25-dihydrolanosterol in the Kandutsch-Russel cholesterol 
biosynthetic pathway, as well as the conversion of desmosterol to cholesterol in the 
Bloch pathway (Spann et al., 2012). Accordingly, a significant accumulation of the potent 
LXR-ligand desmosterol was observed in cholesterol-rich peritoneal macrophages. As 
LXR activation is known to negatively regulate the inflammatory response, increased 
desmosterol was associated with a marked reduction in the expression of 
proinflammatory genes (Spann et al., 2012). We hypothesized that this phenomenon 
might reconcile the data observed in Figure 3.4 of the current study. THP-1 cells 
exposed to increasing concentrations of oxLDL exhibited a dose-dependent decrease in 
TNFα and IL-6 expression (Figure 3.5A, B). Reduced cytokine expression was 
associated with a significant decrease in DHCR24 mRNA abundance (Figure 3.5C). 
Moreover, expression of the LXR-target genes ABCA1, ABCG1 and MYLIP was 
substantially enhanced in oxLDL-treated macrophages (Figure 3.5D-F). Macrophages 
abundant in oxysterols, like desmosterol, are known to exhibit reduced processing of 
SREBP-1c, resulting in reduced expression of SREBP-1c target genes (Beyea et al., 
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2007). Here, SREBP-1c and FAS expression were significantly reduced in oxLDL-
treated THP-1 macrophages (Figure 3.5G, H). Taken together these data support the 
notion that cholesterol-loaded macrophages down-regulate DHCR24 expression and 
activity, which results in an anti-inflammatory response mediated partially through LXR 
activation.  
Given that PPARs are known to regulate anti-inflammatory responses (Harmon 
et al., 2011), and that oxLDL-treatment of macrophages can activate PPARγ 
transcriptional activity (Nagy et al., 1998), we examined whether there was any evidence 
of PPAR activation in oxLDL-loaded THP-1 cells. OxLDL had no effect on the PPARα-
specific target gene ACOX (Figure 3.5I). In contrast, macrophage oxLDL-treatment 
significantly increased expression of the PPARγ- and PPARδ-specific target genes 
FABP4 and ADFP, respectively (Figure 3.5J, K). These results suggest that PPARγ and 
PPARδ activation may contribute to part of the oxLDL-mediated anti-inflammatory 
response.
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Figure 3.5: oxLDL dose-dependently reduces proinflammatory cytokine 
expression which is associated with a dose-dependent increase in LXR, PPARγ 
and PPARδ target genes  
THP-1 cells were incubated with oxLDL (25-150µg-TC/mL) for 16h. Total RNA was 
analyzed for the proinflammatory cytokines (A) TNFα and (B) IL-6, for the cholesterol 
biosynthesis regulatory gene (C) DHCR24, the LXR-target genes (D) ABCA1, (E) 
ABCG1 and (F) MYLIP, the SREBP-1c target genes (G) SREBP-1c and (H) FAS and the 
PPARα-, γ-, and δ-specific target genes (I) ACOX (J) FABP4 and (K) ADFP, 
respectively, by qRT-PCR and normalized to GAPDH. Data is presented as mean +/- 
SEM of duplicate samples. Asterisk (*) indicates P<0.05 versus control; ANOVA with 
post hoc Bonferroni test. 
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3.4 DISCUSSION 
High circulating LDL significantly increases the risk for the development of 
atherosclerotic cardiovascular disease (Libby et al., 2011). A strong positive correlation 
exists between high plasma LDL, inflammation and atherosclerosis (Blake and Ridker, 
2003, Getz and Reardon, 2006, Libby et al., 2011). However, the molecular processes of 
atherosclerosis-associated inflammation as a consequence of high plasma LDL require 
further elucidation. Here, we demonstrate that oxLDL induces both CE and FC 
accumulation in THP-1 human macrophages, which are significantly attenuated by 
PPARδ activation. Additionally, we show that in response to oxLDL, proinflammatory 
cytokine expression is decreased, rather than activated, and is not further affected by 
synthetic PPARδ agonists or ACAT inhibitors. The anti-inflammatory response observed 
in oxLDL-treated macrophages was associated with decreased DHCR24 expression, 
and increased expression of LXR-, PPARγ- and PPARδ-target genes. 
PPARδ is expressed in abundance in macrophages (Vosper et al., 2001), but its 
biological role in cholesterol homeostasis has been controversial (Li et al., 2004, Oliver 
et al., 2001, Vosper et al., 2001, Wallace et al., 2005). In this study, we demonstrate that 
oxLDL-induced CE and FC accumulation are significantly decreased by PPARδ 
activation. We confirm that PPARδ activation increases ABCA1 mRNA and protein, 
which enhances cholesterol efflux to apoAI (Ogata et al., 2009, Oliver et al., 2001). 
Furthermore, our results imply that the PPARδ agonist-induced increase in macrophage 
ABCA1 expression is greater than that induced by downregulation of DHCR24 in 
response to oxLDL alone. With regard to ABCG1 activation, the effects of PPARδ have 
not been reported. Although GW0742 enhanced ABCG1 mRNA and protein, 
functionally, this did not enhance cholesterol efflux to HDL3. Nevertheless, both PPARδ 
agonists used in this study reduced LDL- and oxLDL-induced CE and FC accumulation. 
Deletion of Abca1 but not Abcg1 in mice, results in increased atherosclerotic plaque 
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development (Yvan-Charvet et al., 2007). Furthermore, Abcg1-/- mice crossed to an 
apolipoprotein E knockout background are protected from diet-induced atherosclerosis 
(Tarling et al., 2010). These studies suggest that ABCA1, rather than ABCG1, is a 
critical efflux transporter for the regulation of cholesterol homeostasis in hematopoietic 
cells of the arterial intima. The findings reported here, at least with respect to 
macrophages, support this concept. 
Given that oxLDL-uptake is mediated, in part, by CD36, and that PPARδ 
activation is known to increase CD36 expression (Chapter 2, Figure 2.3D) it would be 
predicted the PPARδ ligands would promote oxLDL uptake. Our laboratory has 
previously demonstrated that macrophages treated with PPARγ activators, which also 
activate CD36 expression, increased oxLDL uptake, yet increased ABCA1-mediated 
cholesterol efflux, resulting in a net depletion of CE and FC (Argmann et al., 2003). The 
data reported here suggest that PPARδ activation may promote a similar mechanism of 
macrophage cholesterol homeostasis in response to oxLDL. Furthermore, the results in 
the current study contradict the notion that PPARδ activation has either no effect, or a 
stimulatory effect, on cholesterol accumulation (Li et al., 2004, Vosper et al., 2001).  
Cholesterol esterification under basal and lipoprotein-stimulated conditions was 
attenuated by PPARδ activation. The apparent reduction in ACAT activity is likely a 
secondary effect of the PPARδ agonist’s ability to increase cholesterol efflux, thereby 
preventing cholesterol from reaching the ACAT-accessible pool. Pharmacological and 
genetic manipulations that increase cholesterol efflux pathways are known to reduce 
cholesterol esterification by virtue of shuttling cholesterol away from the ER esterification 
pool, and towards the plasma membrane for efflux (Beyea et al., 2012, Yamauchi et al., 
2004). Although further studies would be required to determine the specific effects of 
PPARδ agonists on cholesterol trafficking in macrophages, our results support the 
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paradigm that increasing cholesterol efflux leads to a secondary reduction in cholesterol 
esterification (Francis and Perry, 1999, Wang et al., 2001).  
Several studies have suggested that oxLDL stimulates macrophage inflammatory 
responses through elicitation of TLR-Nfκb signaling (Curtiss et al., 2012, Febbraio et al., 
2000, Janabi et al., 2000, Michelsen et al., 2004, Mullick et al., 2005, Stewart et al., 
2010). Additionally, ACAT inhibition leading to FC-loading of macrophages is thought to 
activate the ER-stress-Nκb cascade, resulting in the stimulation of TNFα and IL-6 
expression (Li et al., 2005). However, recent reports have provided contrary evidence to 
both of these paradigms (Anderson et al., 2012, Kannan et al., 2012, Qiu et al., 2007). 
oxLDL not only reduces monocyte and macrophage basal expression of TNFα and IL-6, 
but it also inhibits LPS-stimulated expression of both these cytokines (Kannan et al., 
2012, Qiu et al., 2007). Furthermore, lipotoxicity-induced inflammation can occur in the 
absence of ER-stress (Anderson et al., 2012). The findings reported here are in support 
of these latter studies. In our hands, oxLDL-treated macrophages displayed attenuated 
expression of TNFα and IL-6, which was unaffected by treatment with the PPARδ 
agonists. Furthermore, inhibition of ACAT activity to significantly increase FC 
accumulation, did not induce a pro-inflammatory phenotype in oxLDL-treated 
macrophages. Collectively, the present study is consistent with the concept that 
macrophages loaded with cholesterol are anti-inflammatory (Spann et al., 2012, Suzuki 
et al., 2012), rather than proinflammatory, and that PPARδ agonists are incapable of 
further suppression. 
Cholesterol-loaded mouse peritoneal macrophages display significant 
accumulation of desmosterol, a known potent activator of LXR (Spann et al., 2012). It is 
well characterized that activation of LXR is anti-inflammatory, as liganded LXR recruits 
corepressor complexes to promoter regions of proinflammatory genes (Im and Osborne, 
2011). This recruitment event results in protein-protein interactions between Nfκb and 
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the LXR-bound corepressors, which prevents Nfκb from stimulating transcription of 
proinflammatory cytokines (Im and Osborne, 2011). PPARγ activation exerts anti-
inflammatory effects through a similar mechanism (Straus and Glass, 2007). Whether 
oxLDL-treatment increases corepressor occupancy of the TNFα and IL-6 promoters in 
THP-1 macrophages remains to be determined. Nevertheless, our studies support the 
concept that desmosterol accumulation within macrophages is associated with 
suppression of pro-inflammatory gene expression (Spann et al., 2012).  
Given that oxLDL stimulated the expression of the PPARδ-specific target gene 
ADFP, it is tempting to hypothesize that PPARδ ligands accumulate in response to 
cholesterol loading. Fatty acids are known to activate PPARδ (Chawla et al., 2003). In 
cholesterol-loaded or desmosterol-treated mouse peritoneal macrophages, Spann et al. 
observed increases in cellular oleic acid in the picomolar range (Spann et al., 2012). In 
the micromolar range, oleic acid induces macrophage inflammatory responses (Chapter 
2). However, picomolar concentrations of oleic acid may be sufficient to activate PPARδ 
but insufficient to stimulate the inflammatory response. The possibility that PPARδ 
activation plays a role in the oxLDL-mediated anti-inflammatory response of 
macrophages requires further study.  
In summary, oxLDL-induced foam cell formation is attenuated by PPARδ 
activation, supporting the use of synthetic PPARδ agonists as a macrophage-targeted 
therapeutic strategy in the treatment of atherosclerosis. Furthermore, our studies 
suggest that macrophages of the arterial intima are not proinflammatory in response to 
cholesterol loading, per se. Rather we support the shift in paradigm that under conditions 
of high plasma LDL, immune cells of the arterial intima, such as dendritic cells (Becker et 
al., 2012), are the inflammatory effectors that secrete extrinsic factors to promote 
proinflammatory macrophage activation (Spann et al., 2012).  
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*a version of this chapter has been submitted 
 
Chapter 4* 
PPARδ agonist GW1516 attenuates diet-induced aortic inflammation, insulin 
resistance and atherosclerosis in Ldlr-/- mice 
 
4.1 INTRODUCTION 
The principal cause of mortality in type 2 diabetic patients is atherosclerosis 
(Grundy et al., 2002, Libby et al., 2009), a chronic inflammatory disease that is the 
primary precursor underlying most cardiovascular events (Tabas et al., 2007). Although 
the molecular and pathophysiological links between type 2 diabetes and atherosclerosis 
are not fully understood, a crucial factor is likely insulin resistance (DeFronzo, 2010, 
Rewers et al., 2004). This is in part due to promotion of multiple independent risk factors 
associated with cardiovascular disease including obesity, hypertension and dyslipidemia 
(DeFronzo, 2010, Ginsberg, 2000). Atherogenic dyslipidemia associated with insulin 
resistance is characterized by increased plasma concentrations of triglyceride (TG)-rich 
very low-density lipoprotein (VLDL) and cholesteryl ester (CE)-rich LDL, both of which 
can permeate a compromised endothelium and initiate atherogenesis (Ginsberg, 2000, 
Tabas et al., 2010). Therapeutic strategies to reduce plasma LDL have proven effective 
in reducing cardiovascular events (Kearney et al., 2008). However, a significant unmet 
medical need persists in cardioprotective therapy, making VLDL-lowering strategies an 
attractive therapeutic target.  
Subendothelial retention of atherogenic lipoproteins leads to a series of 
maladaptive immune responses, culminating in the development of macrophage foam 
cells (Tabas et al., 2010, Tabas et al., 2007). Macrophages of the arterial intima also 
play a critical role in the evolution of fatty streaks towards progression of complex 
lesions. In particular, M1 macrophages secrete inflammatory effector cytokines such as 
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interleukin (IL)-1β and tumor necrosis factor alpha (TNFα), driven predominantly by 
MAPK and NF-κB signaling (Moore and Tabas, 2011, Stollenwerk et al., 2005). 
However, insulin signaling, namely the Akt/forkhead box O1 (FoxO1) pathway, may also 
play an important role in atherogenic inflammation (Tabas et al., 2010). In vitro, Il-1β is a 
FoxO1 target gene in macrophages with fatty acid-induced insulin resistance (Su et al., 
2009). Although not consistent across all experimental models, a growing body of 
evidence suggests that in vivo, arterial insulin resistance directly promotes 
atherosclerosis (Tabas et al., 2010). In fat-fed apolipoprotein E knockout mice (apoE-/-) 
mice, insulin receptor (IR) deletion (Insr-/-) in myeloid cells decreased lesion size 
(Baumgartl et al., 2006). In contrast, global loss of the major insulin signaling mediator 
Akt1 in apoE-/- mice resulted in accelerated coronary artery disease and aortic 
atherosclerosis, concomitant with significant aortic inflammation (Fernandez-Hernando 
et al., 2007). Hematopoetic deletion of the insulin receptor in LDL receptor knockout 
(Ldlr-/-) mice significantly increased atherosclerosis, an effect attributed to impaired 
macrophage Akt signaling (Han et al., 2006). Furthermore, increased areas of apoptotic 
macrophages and necrotic core have been visualized in atherosclerotic lesions from 
patients with type 2 diabetes (Burke et al., 2004). Collectively, these studies highlight 
that arterial insulin resistance and inflammation may amplify atherogenesis.  
Peroxisome proliferator-activated receptors (PPARs) are a class of ligand-
dependant transcription factors involved in regulation of metabolic and inflammatory 
signaling (Wahli and Michalik, 2012). Three isoforms exist (α,γ,δ) which exhibit 
overlapping but distinct patterns of tissue distribution and function (Evans et al., 2004). 
Although PPARδ has been considered the most enigmatic of the PPARs, this receptor 
has emerged as an important regulator of cellular lipid homeostasis and the 
inflammatory response (Barish et al., 2006). In cultured macrophages, PPARδ inhibits 
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both macrophage lipid accumulation and pro-inflammatory cytokine expression in 
response to human VLDL (Chapter 2). Furthermore, TG accumulation was decreased 
via inhibition of extracellular lipolytic activity through angiopoietin-like (ANGPTL) 4-
mediated inhibition of lipoprotein lipase (LPL) and enhanced carnitine 
palmitoyltransferase (CPT) 1α-stimulated fatty acid β-oxidation, whereas attenuated 
cytokine expression was mediated through both inhibition of ERK1/2 and activation of 
Akt/FoxO1 signaling (Chapter 2). In vivo, Lee et al. demonstrated that macrophage 
deletion of Pparδ in Ldlr-/- mice paradoxically suppressed atherogenesis, attributed to the 
suppression of atherogenic inflammation by liberation of the inflammatory repressor 
protein BCL-6, as BCL-6 is normally sequestered by the PPARδ/RXR co-repressor 
complex (Lee et al., 2003). These studies elegantly highlighted that deletion of Pparδ 
mimicked the liganded state of the receptor, suggesting that ligand-activation may be 
atheroprotective. However, the studies that have examined the effects of synthetic 
PPARδ agonists using prevention protocols in mouse models of atherosclerosis have 
produced a spectrum of results (Barish et al., 2008, Graham et al., 2005, Li et al., 2004). 
In the first study, administration of the PPARδ agonist GW0742 to male Ldlr-/- mice on a 
high-fat, high cholesterol diet for 14 weeks had no effect on lesion size (Li et al., 2004). 
In a second study, 16 weeks of treatment with GW0742 reduced lesion development in 
female Ldlr-/- mice (Graham et al., 2005), however, the doses used yielded serum drug 
levels 2-fold higher than the reported EC50 values for murine PPARα and PPARγ (Barish 
et al., 2008), raising the possibility that the atheroprotective effects of GW0742 were not 
PPARδ-specific. In Ldlr-/- mice fed a high-fat diet, low doses of GW0742, prevented the 
development of angiotensin II-accelerated atherosclerosis (Takata et al., 2008). Barish 
et al. reported that a next generation PPARδ agonist (GW1516) at PPARδ-specific 
doses, prevented the development of atherosclerosis in apoE-/- mice fed a high-fat diet, 
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concomitant with reduced aortic inflammatory cytokine expression (Barish et al., 2008). 
Although on balance these studies indicate that PPARδ-specific agonists prevent the 
development of atherosclerosis and arterial inflammation, it is unknown whether PPARδ 
agonists are atheroprotective in an intervention model with pre-established insulin 
resistance. Furthermore, the impact of PPARδ activation on lesion pathology, as well as 
aortic inflammatory signaling cascades, insulin resistance and ER-stress has not been 
examined.  
In the present study we use C57BL/6J Ldlr-/- mice fed a high-fat, cholesterol 
containing (HFHC) diet, a model of diet-induced dyslipidemia and insulin resistance. We 
demonstrate that following an induction phase, intervention with the addition of the 
PPARδ-specific agonist GW1516 to the HFHC diet resulted in regression of metabolic 
dysregulation including reduced plasma lipids, glucose and insulin, and improved 
glucose and insulin tolerance. Intervention with GW1516 inhibited aortic MAPK and NF-
κB signaling, attenuated aortic inflammation, improved indices of aortic insulin signaling, 
reduced aortic ER-stress, and collectively attenuated the progression of pre-established 
atherosclerosis. 
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4.2 MATERIALS AND METHODS 
4.2.1 ANIMALS AND DIETS 
Male Ldlr-/- mice on the C57BL/6 background were obtained from the Jackson 
Laboratory and housed in pairs in standard cages at 23ºC. The animals were cared for in 
accordance with the Canadian Guide for the Care and Use of Laboratory Animals, and 
all experimental procedures were approved by the Animal Care Committee at the 
University of Western Ontario. Mice 10-12 weeks of age were fed ad libitum, a purified 
rodent chow diet (14% of calories from fat, Harlan Teklad TD8604, Madison WI) for 12 
weeks. Another group of mice were fed a high-fat cholesterol-containing western diet 
(HFHC - 42% of calories from fat, 0.2% cholesterol, Harlan Teklad TD09268) for 4 
weeks, followed by segregation of half of these mice to intervention to the HFHC with 
3mg/kg/day GW1516 (Enzo Life Sciences, Ann Arbor, MI) for an additional 8 weeks. In 
previously published reports, this dose administered by oral gavage rendered a plasma 
concentration of GW1516 that was more selective for PPARδ over PPARα or PPARγ by 
>1,000-fold (Barish et al., 2008, Barroso et al., 2011, Narkar et al., 2008). Animals were 
fasted for 4h prior to analyses or sacrifice. For fasting/re-feeding studies, animals were 
either fasted for 16h prior to sacrifice or fasted for 16h followed by 2h of acute re-feeding 
of experimental diets prior to sacrifice (Lu et al., 2012). Blood samples were obtained 
and the heart and aorta were excised as previously described (Covey et al., 2003, 
Mulvihill et al., 2009, Mulvihill et al., 2010). 
4.2.2 PLASMA LIPID, BLOOD GLUCOSE AND PLASMA INSULIN 
DETERMINATIONS  
Plasma TG, total cholesterol (TC), non-esterified fatty acids (NEFA), and blood 
glucose were determined as previously described (Mulvihill et al., 2009). Plasma insulin 
concentrations were determined by ELISA (Alpco Diagnostics, Salem, NH) on EDTA-
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plasma as per manufacturer’s instructions. Fast Performance Liquid Chromatography 
(FPLC) was performed on unfrozen EDTA-plasma using an AKTA purifier and Superose 
6 column (Mulvihill et al., 2009).  
4.2.3 GLUCOSE TOLERANCE AND INSULIN TOLERANCE 
A glucose tolerance test (GTT) was performed following i.p. injection with 15% 
glucose in 0.9% NaCl (1 g/kg of body weight). Blood for glucose measurements 
(Ascensia Elite glucometer, Bayer Healthcare, Toronto, Canada) was taken up to 120 
min post-injection. Insulin tolerance test (ITT) was conducted by i.p. injection with 0.6 
IU/kg Novolin ge Toronto (Novo Nordisk, Cooksville, ON). Blood for glucose 
measurements was obtained up to 60 min post-injection. Insulin sensitivity and glucose 
utilization were calculated based on the area under the curve (AUC). 
4.2.4 TISSUE HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
Histological and morphometric analyses were performed as described previously 
(Mulvihill et al., 2010). Briefly, at sacrifice, hearts were mounted in OCT and frozen. For 
quantitation of lesion area in the aortic sinus, oil red-O-stained sections were measured. 
Frozen serial sections (70-100 per heart, 10μm) of the aortic sinus, initiating at the origin 
of the aortic valves, were prepared using a Leica CM 3050S cryostat. Slides were 
stained with modified Verhoff’s and Masson’s trichrome at the Robarts Research 
Institute Molecular Pathology Core facility. Immunohistochemistry staining for 
macrophages by MOMA-2 (Accurate Chemical and Scientific Corporation #MCA519G, 
Westbury, NY) and smooth muscle α-actin (monoclonal anti-α-smooth muscle actin, 
Clone 1AH, Sigma) was performed. Briefly, slides were fixed in acetone and blocked in 
2% bovine serum albumin. After incubation with primary antibody, a goat biotinylated 
secondary antibody was used. Slides were then incubated in peroxidase blocking 
reagent, followed by incubation with the ABC reagent (ABC Elite Standard Kit, Vector 
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Laboratories, Burlington, ON). Slides were then exposed to the DAB substrate 
(Peroxidase substrate kit, Vector Laboratories) followed by counterstain in hematoxylin 
and mounting in xylene. Photomicrographs were obtained using an Olympus BX50 
microscope and a QImaging Retiga EXi FAST camera. In the aortic sinus, lesion area of 
four serial sections (100μm apart) were quantified using Axiovision computer software. 
Morphometric analysis of plaques in mice from each dietary group was also performed 
on serial sections. The relative area of the atherosclerotic plaque positive for MOMA-2, 
collagen or smooth muscle α-actin staining was determined as the area of positive 
staining divided by the area of the respective plaque. Quantitation was determined using 
Axiovision software. To ensure that a standard region was measured in each mouse, 
lesion analysis began at the origin of the aortic valves.  
4.2.5 IMMUNOBLOTTING AND DENSITOMETRY 
Total cell lysates were isolated from full-length aortae of mice as previously 
described (Beyea et al., 2007, Rowe et al., 2003). Proteins were separated by SDS-
PAGE, transferred to polyvinylidene difluoride membranes and immunoblotted (Rowe et 
al., 2003). Lysates were probed using antibodies against mouse phospho and total Akt, 
FoxO1, ERK1/2, p38, IKKα, and IκBα, as well as GRP78, CHOP, SHP-1 and β-actin 
(Cell Signaling, Danvers, MA). Protein levels were determined by densitometry as 
described (Beyea et al., 2007, Rowe et al., 2003).  
4.2.6 QUANTITATIVE REAL-TIME PCR GENE ABUNDANCE ANALYSIS 
Total RNA was isolated from full-length aortae of mice via standard TRIzol® 
reagent (Life Technologies, Burlington, ON) as per manufacturer’s instructions. Specific 
mRNA abundances (Ccl3, Il1b, Icam1, Tnf, Il6, Ccl2, Arg1, iNos, Ptpn6, Trib3, Adfp, 
Angptl4, Cpt1a, Acox, Lpl, Rgs4, Rgs5, and Gapdh) were measured via quantitative 
real-time PCR (qRT-PCR) using an ABI Prism (7900HT) Sequence Detection System 
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(Applied Biosystems, Foster City, CA) as previously described (Beyea et al., 2012, 
Mulvihill et al., 2009).  
4.2.7 STATISTICAL ANALYSES 
Data are expressed as means +/- SEM. One-way ANOVA followed by the 
Bonferroni test was used to determine significant differences between two groups. One-
way ANOVA followed by pair-wise comparisons by the Tukey’s test was used to 
determine differences between three or more groups. For fasting/re-feeding 
experiments, two-way ANOVA followed by pair-wise comparisons by the Tukey’s test 
was used to determine differences and interactions between diet groups and fasted/re-
fed state. Significance thresholds were P values less than 0.05 and indicated by different 
upper case or lower case letters as well as asterisks as indicated in the figure legends.  
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4.3 RESULTS  
4.3.1 GW1516 IMPROVES HFHC-INDUCED METABOLIC DYSREGULATION IN 
LDLR-/- MICE 
Male C57BL/6 Ldlr-/- mice were administered a Western diet with 0.2% 
cholesterol (HFHC diet) for 4 weeks. The metabolic effects of intervention with the 
PPARδ agonist GW1516 were evaluated following an additional 8 weeks (Figure 4.1A). 
Addition of GW1516 to the HFHC diet significantly attenuated HFHC-induced weight 
gain without affecting caloric intake (Figure 4.2A,B). GW1516 decreased fasting plasma 
cholesterol, TG and NEFAs compared to 4-week baseline levels, whereas the 
dyslipidemia of animals remaining on the HFHC diet alone continued to progress (Figure 
4.1B). FPLC analyses demonstrated that reduced fasting plasma cholesterol in 
GW1516-treated mice, was due to a significant reduction in the VLDL-C fraction and a 
modest but not statistically significant reduction in LDL-C (Figure 4.1C). GW1516 
increased HDL-C by 35% (Figure 4.1C). Furthermore, the GW1516-mediated reduction 
in plasma TG levels was due to a substantial 63% reduction in VLDL-TG (Figure 4.1D). 
GW1516 intervention decreased epididymal fat mass by 11% compared to 4-week 
baseline, and by 35% compared to mice remaining on the HFHC diet alone (Figure 
4.2C) thus contributing to the attenuation in the rate of weight gain. 
GW1516-intervention maintained blood glucose and significantly decreased 
plasma insulin compared to levels in HFHC-fed mice at 4-weeks. Relative to mice 
remaining on the HFHC diet, GW1516 intervention completely prevented the significant 
increase in fasting blood glucose and markedly attenuated the induction of fasting 
hyperinsulinemia (Figure 4.3A,B). In addition, GW1516 intervention improved whole 
body insulin sensitivity, as evidenced by improved glucose and insulin tolerance tests 
(Figure 4.3 C,D). 
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Figure 4.1: GW1516 regresses diet-induced dyslipidemia.  
Ldlr-/- mice were fed standard chow, or a high-fat, high-cholesterol diet (HFHC) for 4 
weeks. For a subsequent 8 weeks, chow-fed mice remained on chow; the HFHC-fed 
mice either remained on HFHC alone or HFHC supplemented with GW501516 
(GW1516) (3mg/kg/day). A, Experimental timeline for all studies performed. B, Plasma 
cholesterol, triglyceride, and non-esterified fatty acid (NEFA) concentrations were 
measured at week 0, 4 and 12 (8-12/group). C and D, Plasma was subjected to FPLC 
analysis at week 12, and cholesterol and triglyceride were measured in the eluted 
fractions (n=3-5/group). Arrows indicate time of GW1516 intervention. Data is presented 
as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc 
Tukey’s test (P<0.05). * indicates significant difference versus HFHC at the end of the 
study; ANOVA with post hoc Bonferroni’s test (P<0.05). 
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Figure 4.2: GW1516-treatment attenuates rate of body weight gain and epididymal 
fat mass. Ldlr-/- mice were fed a standard lab chow, or a high-fat, high-cholesterol diet 
(HFHC) for 4 weeks. For a subsequent 8 weeks, chow-fed mice remained on chow; the 
HFHC-fed mice either remained on HFHC alone or HFHC supplemented with 
GW501516 (GW1516) (3mg/kg/day). A, Body weight. Arrow indicates time of GW1516 
intervention. B, Caloric intake expressed as kcal per gram body weight per day of study. 
C, Epididymal fat mass in grams. Data is presented as mean +/- SEM (n=8-12/group). 
Different letters indicate significant differences; ANOVA with post-hoc Tukey’s test 
(P<0.05). 
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Figure 4.3: GW1516 improves diet-induced dysregulation of metabolic indices.  
Ldlr-/- mice were fed standard chow, or a high-fat, high-cholesterol diet (HFHC) for 4 
weeks. For a subsequent 8 weeks, chow-fed mice remained on chow; the HFHC-fed 
mice either remained on HFHC alone or HFHC supplemented with GW501516 
(GW1516) (3mg/kg/day). A, Fasting blood glucose levels. B, Fasting plasma insulin 
concentrations. C, Intraperitoneal glucose tolerance test at 12 weeks. Inset graph, 
absolute area under the curve (glucose mmol/Lx120min). D, Intraperitoneal insulin 
tolerance test at 12 weeks. Inset graph, absolute AUC (glucose mmol/Lx60min). Data is 
presented as mean +/- SEM (n=8-12/group). Different letters indicate significant 
differences; P<0.05. 
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4.3.2 GW1516 ATTENUATES AORTIC SINUS ATHEROSCLEROSIS AND AORTIC 
INFLAMMATION IN HFHC-FED LDLR-/- MICE 
Examination of aortic sinus atherosclerosis revealed that oil red-O stained lesion 
area of HFHC-fed mice at 4 weeks progressed significantly (~6-fold) over the 
subsequent 8 weeks (Figure 4.4). In contrast, although lesion area continued to 
increase, the area was significantly attenuated in the GW1516-intervention cohort by 
~33% compared to animals remaining on the HFHC diet alone (Figure 4.4). Dietary 
GW1516 influenced lesion composition. As a percent of total area, lesions of HFHC-fed 
animals for either 4- or 12-weeks displayed infiltration of MOMA-2-positive 
macrophages, which was significantly attenuated by intervention with GW1516 (Figure 
4.4). No appreciable smooth muscle cell (SMC) infiltration or collagen deposition was 
observed in lesions of HFHC-fed mice at 4 weeks (Figure 4.4). However, smooth muscle 
α-actin occupied 40% of lesion area in HFHC-mice at 12 weeks, which was similar to 
that of GW1516-intervenion mice. On the other hand, 12 weeks of the HFHC diet 
resulted in collagen deposition comprising 25% of lesion area, which was further 
increased (to 35%) in GW1516 intervention mice, despite no further effect on percent 
lesion SMC content (Figure 4.4). Lipid analyses of full-length aortae from HFHC-fed 
mice at 12 weeks revealed that aortic TG and TC mass increased 1.4-fold and 1.6-fold, 
compared to HFHC-mice at 4 weeks (Figure 4.5A,B). GW1516 supplementation 
decreased aortic TG by 60% compared to the 12-week HFHC-fed cohort, and by 40% 
compared to the 4-week HFHC-fed mice. GW1516 supplementation decreased aortic 
TC by 27% compared to HFHC-mice at 12 weeks, but values remained elevated (30%) 
compared to HFHC-mice at 4 weeks. Collectively, these analyses indicate that 
intervention to the HFHC diet with GW1516, results in the attenuation of lesion 
progression and the development of smaller, more stable atherosclerotic lesions. 
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Figure 4.4: GW1516 attenuates HFHC-induced atherosclerosis.  
A, Representative examples are given for oil red-O and Hematoxylin, MOMA-2, SM α-
actin and Trichrome stained aortic sinus sections. B, Quantitation of Oil-red-O, MOMA-2, 
collagen and SM α-actin stained areas expressed as lesion area or % of lesion area 
(n=6-9/group). SM α-actin and collagen were undetectable in 4-week baseline aortic 
sinus sections. Data is presented as mean +/- SEM. Different letters indicate significant 
differences; ANOVA with post-hoc Tukey’s test (P<0.05). 
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Figure 4.5: GW1516 attenuates lipid accumulation, M1 macrophage markers and 
induces a shift towards M2 macrophage markers in full length aortae.  
A, Triglyceride (TG) and (B) cholesterol (TC) concentrations were determined in aortic 
extracts (n=5-7/group). C, mRNA abundance of the indicated proinflammatory M1 
cytokines and (D) the anti-inflammatory M2 cytokine Arg1 and the Arg1/iNos ratio, 
determined in full length aortae dissected free of fat and connective tissue (n=4-
6/group). Data is presented as mean +/- SEM. Different letters indicate significant 
differences; ANOVA with post-hoc Tukey’s test (P<0.05). 
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To further assess disease progression, we examined a panel of cytokines known to 
modulate atherogenesis. In the full length aorta, following 4 weeks of HFHC feeding, 
only Ccl3 and Icam1 expression were increased compared to chow-fed controls, 
indicative of monocyte recruitment without overt inflammation (Figure 4.5C). However, 
expression of pro-inflammatory M1 cytokines, Ccl3, II1b, Icam1, Tnf, II6, and Ccl2 were 
markedly induced (2-to 25-fold) in the aortae of mice fed the HFHC diet for 12 weeks. In 
contrast, although all cytokines were elevated in GW1516-treated mice compared to 
HFHC-fed mice at baseline (4 weeks), cytokine expression was significantly lower (-25 
to -85%, mean -60%) compared to HFHC-fed mice at 12 weeks (Figure 4.5C). Although 
lesion MOMA-2 stained macrophages decreased ~25% in GW1516-treated mice, the 
greater reduction in cytokine expression suggests that macrophages remaining in 
lesions of the intervention mice were less inflammatory. Furthermore, 12 week HFHC-
feeding significantly increased aortic expression of the M1 marker iNos and suppressed 
aortic expression of the anti-inflammatory M2 marker Arg1, resulting in a greatly 
exacerbated iNos/Arg1 ratio, compared to HFHC-fed mice at 4 weeks (Figure 4.5C,D). 
GW1516 intervention completely reversed this expression pattern. Together, these data 
suggest that although lesion macrophage content is lower (Figure 4.4), there is a shift 
from M1 to M2 cytokine expression in aortae from PPARδ-agonist treated mice. 
We examined the cell signaling cascades known to regulate the macrophage 
inflammatory response (Moore and Tabas, 2011, Stollenwerk et al., 2005). Significant 
activation of MAP kinases ERK1/2 and p38 was observed in full-length aortae of HFHC-
fed mice at 12 weeks, compared to chow-fed controls (Figure 4.6A). In addition, we 
observed a marked induction of NF-κB activation in HFHC-mice at 12 weeks, as 
demonstrated by increased phospho-IKK and phospho-IκBα (Figure 4.6B). In contrast, 
intervention with GW1516 abrogated HFHC-induced activation of both MAPK and NF-κB
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Figure 4.6: GW1516 corrects aberrant MAPK and NF-κB signaling in full-length 
aortae of HFHC-fed mice.  
A, Immunoblots of MAPK signaling markers including pERK1/2 and p-p38 and (B) NF-
κB signaling markers pIKK and IκBα in full length aortae dissected free of fat and 
connective tissue. Representative immunoblots of aortic lysates from two mice from 
each treatment group with quantitations of 4-6 mice/group are shown. Data is presented 
as mean +/- SEM. Different letters indicate significant differences; ANOVA with post-hoc 
Tukey’s test (P<0.05). Representative bands are from the same immunoblot, cut from 
different regions due to loading of multiple replicate lanes.  
 
201 
 
 
 
 
 
 
 
 
202 
 
 
(Figure 4.6A,B). These results suggest that PPARδ activation diminishes aortic 
inflammation, in part, by attenuating diet-induced inflammatory signaling. 
4.3.3 GW1516-INTERVENTION CORRECTS DIET-INDUCED AORTIC INSULIN 
SIGNALING AND ER-STRESS, AND EXERTS PPARδ-SPECIFIC VESSEL WALL 
EFFECTS 
Genetic manipulations resulting in impaired insulin signaling in hematopoetic 
cells exacerbate atherosclerosis, due in part to increased aortic inflammation and ER-
stress (Fernandez-Hernando et al., 2007, Han et al., 2006, Tabas et al., 2010). Given 
the pro-inflammatory phenotype of aortae isolated from insulin-resistant HFHC-fed mice, 
we hypothesized that this was mediated in part by impaired aortic insulin signaling. To 
test this, we examined aortic phospho-Akt and phospho-FoxO1 in fasted and acutely re-
fed mice at the end of the 8-week intervention phase. Compared to chow-fed mice, Akt 
and FoxO1 phosphorylation was higher in the aortae excised from fasted HFHC-fed 
mice, and not further increased in response to re-feeding (Figure 4.7A). In contrast, 
GW1516-intervention restored the fasting-to-feeding dynamic regulation of Akt and 
FoxO1 phosphorylation to chow-fed controls (Figure 4.7A). The Src homology 2 domain-
containing phosphatase (SHP)-1 is a protein tyrosine phosphatase (PTP) primarily 
expressed by hematopoetic cells, and is a known negative regulator of hepatic insulin 
signaling (Dubois et al., 2006). We observed that aortae excised from HFHC-fed mice at 
12 weeks were significantly enriched for the SHP-1 transcript (Ptpn6) and SHP-1 
protein, 5- and 30-fold, respectively, both of which were strongly attenuated by 
intervention with GW1516 (Figure 4.7B,C).  
Coupled to dysregulated aortic insulin signaling was a significant increase in ER-
stress markers GRP78 and CHOP (Figure 4.7D). The known CHOP-target gene and 
negative regulator of insulin signaling, Trib3 (Du et al., 2003), was elevated in aortae of
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Figure 4.7: GW1516 corrects aberrant insulin signaling, the UPR and ER-stress in 
aortae of HFHC-fed mice.  
Western blotting or qRT-PCR were performed on full length aortae dissected free of fat 
and connective tissue. A, Immunoblots of insulin signaling proteins phosphorylated (p) 
AKT and pFoxO1 in aortae excised from mice fasted for 16h (designated F) and fasted 
for 16h followed by a 2h re-feeding period (designated RF) (n=6-8/group). B, mRNA 
abundance of negative regulator of insulin signaling Ptpn6 (n=4-6/group).  C, 
Immunoblots of SHP-1 (the protein product of Ptpn6) (n=4-6/group). D, ER-stress 
markers GRP78 and CHOP (n=4-6/group). E, mRNA abundance of negative regulator of 
insulin signaling Trib3 (n=4-6/group). Data is presented as mean +/- SEM. 
Representative immunoblots with quantitations shown. For A, different upper case 
letters indicate statistical significance among fasted animals, different lower case letters 
indicate statistical significance among re-fed animals, and asterisk (*) indicates statistical 
significance between fasted and re-fed within the same diet (P<0.05); two-way ANOVA 
with post-hoc Tukey’s test (P<0.05). For B-E different letters indicate significant 
differences; one-way ANOVA with post-hoc Tukey’s test (P<0.05). Representative bands 
are from the same immunoblot, cut from different regions due to loading of multiple 
replicate lanes. 
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HFHC-fed 12 week mice (Figure 4.7E). GW1516 intervention attenuated GRP78, CHOP 
and Trib3 to levels observed in 12-week chow-fed controls (Figure 4.7D,E).  
To determine whether GW1516 exerted effects directly at the level of the aorta, 
we examined aortic expression of known PPARδ target genes. Expression of Adfp, 
Angptl4 and Cpt1a was significantly increased in aortae of GW1516-treated mice 
compared to HFHC-fed mice or chow-fed controls at 12 weeks (Figure 4.8A). Expression 
of the PPARα- and PPARγ-specific target genes (Acox and Lpl, respectively) were 
unaffected by GW1516-treatment (Figure 4.8B). Similar results were observed in liver 
(Chapter 5, Figure 5.1). These results suggest that GW1516 exerts a direct effect on the 
arterial wall, which likely contributes to the attenuation of inflammation, insulin 
resistance, ER-stress and diet-induced lesion progression. These results further indicate 
that with respect to PPARs, the aortic effects of GW1516 are PPARδ-specific. 
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Figure 4.8: GW1516 activates aortic PPARδ but not PPARα or PPARγ.  
A, mRNA abundance of PPARδ-target genes Adfp, Angtpl4 and Cpt1a and B, PPARα- 
and PPARγ-target genes Acox and Lpl, respectively in full length aortae dissected free 
of fat and connective tissue (n=4-6/group). Data is presented as mean +/- SEM. Different 
letters indicate significant differences; ANOVA with post-hoc Tukey’s test (P<0.05).  
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4.4 DISCUSSION 
Risk of atherosclerotic cardiovascular disease is elevated up to 4-fold in adults 
with type 2 diabetes (Fox et al., 2007, Fox et al., 2004). Despite this, therapeutic 
strategies to alleviate atherosclerosis associated with insulin resistant syndromes have 
remained sparse. Reports have speculated that PPARδ agonists may confer 
atheroprotection in settings of insulin resistance (Coll et al., 2010). The present study is 
the first to demonstrate that intervention with a synthetic PPARδ agonist in the context of 
diet-induced dyslipidemia and insulin resistance attenuates progression of early stage 
lesions to more complex lesions. Furthermore, we show that in HFHC-fed mice, the 
inflammatory response and insulin signaling within the aorta are impaired, which are 
completely reversed by PPARδ activation. 
Atherogenic dyslipidemia in the setting of insulin resistance is characterized by 
elevated plasma VLDL and LDL, concomitant with reduced plasma HDL (Ginsberg, 
2000, Grundy, 2004). Statins are the current standard of therapy and effectively lower 
plasma LDL concentrations, reducing the relative risk of cardiovascular disease by ~30% 
(Bays et al., 2011, Kearney et al., 2008). However, statins do not fully correct other 
features of atherosclerosis risk, namely elevated plasma VLDL, decreased HDL, insulin 
resistance, and body fat composition, resulting in a substantial unmet therapeutic need 
(Sattar et al., 2010). The present study demonstrates that intervention with a synthetic 
PPARδ agonist to a HFHC diet corrects previously established metabolic disturbances. 
Although plasma LDL was modestly reduced, our results suggest that PPARδ activation 
primarily targets plasma VLDL and HDL. This is consistent with recent human studies 
demonstrating that synthetic PPARδ agonists correct mixed dyslipidemia in patients with 
the metabolic syndrome (Bays et al., 2011, Ooi et al., 2011). The present study 
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contributes to the plausibility of PPARδ agonists as therapeutic agents for metabolic 
dysregulation associated with insulin resistance.  
We recently demonstrated in cultured macrophages that PPARδ activation 
attenuates VLDL-induced triglyceride accumulation and pro-inflammatory cytokine 
expression (Chapter 2). We extend these in vitro findings, demonstrating that 
intervention with GW1516-treatment induces regression of aortic TG content associated 
with significant induction of the PPARδ-target genes Angptl4 and Cpt1a. These results 
suggest that GW1516 may stimulate aortic fatty acid β-oxidation and inhibit aortic 
lipoprotein lipase activity, thus contributing to reduced atherogenesis. We provide 
evidence that inflammatory cells within the aortae of HFHC-fed animals were polarized 
to the classically activated pro-inflammatory M1 phenotype (Goerdt et al., 1999, Mills et 
al., 2000). Furthermore, intervention with GW1516 resulted in polarization towards the 
anti-inflammatory M2 state (Gordon, 2003), consistent with reports demonstrating that 
alternative M2 activation of adipose tissue macrophages and hepatic Kupffer cells is, in 
part, mediated by PPARδ (Kang et al., 2008, Odegaard et al., 2008). M2 macrophages 
are thought to contribute to tissue remodelling and repair (Gordon, 2003), and are 
increased in lesions undergoing regression (Feig et al., 2011). Although GW1516 did not 
induce regression of early lesions, the M2 phenotype was associated with significant 
slowing of lesion progression. Longer-term studies would be required to assess whether 
PPARδ agonists can induce regression of more complex lesions. Nevertheless, the 
present study demonstrates the ability of PPARδ activation to alleviate aortic lipid 
accumulation and inflammation, thus contributing to attenuated lesion development. 
That GW1516 increased lesion collagen deposition without altering lesion SMC 
content is possibly due to PPARδ activation having a direct effect on plaque SMCs, 
enhancing their capacity to synthesize and deposit extracellular matrix. This hypothesis 
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is consistent with a report that PPARδ activation in cultured vascular (v) SMCs inhibits 
IL-1β-induced matrix metalloproteinase (MMP)-2 and MMP-9 expression (Kim et al., 
2010). Although reduced lipid deposition in VSMCs restores their capacity to synthesize 
extracellular matrix (Beyea et al., 2012, Frontini et al., 2009), the ability of PPARδ 
agonists to improve VSMC function in response to a lipid load requires further study.  
The MAPK and NF-κB signaling pathways are critical regulators of inflammatory 
cytokine expression (Moore and Tabas, 2011, Stollenwerk et al., 2005). In the aortae of 
HFHC-fed animals, we observed marked activation of both of these cascades. 
Intervention with GW1516 almost completely normalized both MAPK and NF-κB 
activation. In cardiac myocytes, the PPARδ agonist GW0742 has been shown to 
attenuate lipopolysaccharide–induced NF-κB activation through increased IκB 
expression, thereby inhibiting nuclear translocation of NF-κB (Ding et al., 2006). We did 
not observe any appreciable changes in total aortic IκB protein. Thus, the mechanism by 
which PPARδ inhibits NF-κB activation in the context of aortic inflammation remains to 
be determined. With respect to MAPK activation, GW0742 inhibited angiotensin II-
induced phosphorylation of ERK1/2 and p38 in mouse macrophages, via upregulation of 
Rgs4 and Rgs5 (Takata et al., 2008). Consistent with this report, we observed a 
significant upregulation of both Rgs4 and Rgs5 in aortae of GW1516-treated animals 
compared to aortae from HFHC-fed mice (Figure 4.9). Taken together, these results 
suggest that PPARδ activation in the aorta attenuates inflammatory signaling, leading to 
the attenuation of aortic inflammatory cytokine expression. 
Impaired insulin signaling in the vasculature has recently emerged as a major 
contributor to lesion progression (Tabas et al., 2010). Ldlr-/- mice receiving Insr-/- bone 
marrow developed larger more complex lesions, attributed to enhanced ER-stress and 
apoptosis-induced necrotic core formation (Han et al., 2006). Insulin-resistant
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Figure 4.9: GW1516 stimulates aortic expression of regulators of G-protein 
coupled receptor signaling Rgs4 and Rgs5. Ldlr-/- mice were fed a standard lab 
chow, or a high-fat, high-cholesterol diet (HFHC) for 4 weeks. For a subsequent 8 
weeks, chow-fed mice remained on chow; the HFHC-fed mice either remained on HFHC 
alone or HFHC supplemented with GW501516 (GW1516) (3mg/kg/day). Mice were 
fasted for 4h prior to sacrifice. Analyses were performed on samples of full length aortae 
dissected free of fat and connective tissue. The indicated cytokines were measured by 
qRT-PCR. Target genes were normalized to Gapdh. Expression relative to chow 
depicted for each cytokine as mean +/- SEM (n=4-6/group). Different letters indicate 
significant differences; ANOVA with post-hoc Tukey’s test (P<0.05).  
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macrophages with cholesterol-induced ER-stress display impaired Akt phosphorylation, 
increased nuclear FoxO1 activity and enhanced apoptosis (Senokuchi et al., 2008). In 
addition to macrophages, aberrant insulin signaling in vascular endothelial cells can also 
play a role in atherogenesis, as deletion of three Foxo isoforms in these cells resulted in 
atheroprotection, attributed in part to an anti-inflammatory effect (Tsuchiya et al., 2012). 
Although these proof-of-concept gene-deletion models highlight the significance of 
vascular insulin signaling in atherogenesis, these studies do not identify whether insulin 
signaling becomes dysregulated during lesion development (Bornfeldt and Tabas, 2011). 
Here we demonstrate that mice with diet-induced atherosclerosis exhibit impaired aortic 
insulin signaling, as evidenced by the loss of dynamic fasting-to-feeding regulation of 
both Akt and FoxO1 phosphorylation, coupled to a marked induction of negative 
regulators of insulin signaling, SHP-1 and Trib3 (Du et al., 2003, Dubois et al., 2006). 
Our data suggests that the loss of insulin regulation of both Akt and FoxO1 results in 
FoxO1 target genes such as Il1b (Su et al., 2009), to be chronically transcribed, rather 
than dynamically regulated during states of fasting and re-feeding. We propose that this 
mechanism contributes to the accumulation of pro-inflammatory mediators in the vessel 
wall, inducing a state of chronic low-grade inflammation. Moreover, this impairment of 
aortic insulin signaling is correlated with significant elevations in ER-stress markers 
CHOP and GRP78. We further demonstrate that activation of PPARδ restores dynamic 
insulin signaling responses within the aorta and attenuates ER-stress. It is important to 
note that the presence of arterial insulin resistance did not impair the ability of GW1516 
to attenuate pre-established lesion progression. Thus, although difficult to quantify, it 
remains possible that improved insulin signaling within GW1516-treated aortae 
contributes to protection from lesion progression. 
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In this study, a major factor in the attenuation of lesion development by 
intervention with GW1516 is reduction of plasma lipids, particularly VLDL/IDL, thereby 
reducing the atherogenic stimulus. However, the data presented here clearly 
demonstrate that in the aorta, GW1516 stimulates PPARδ-specific target genes, which 
are known to improve macrophage lipid homeostasis and attenuate the inflammatory 
response. Although these effects likely contribute to the observed reduction in 
atherosclerosis, further studies are required to elucidate the extent to which improved 
metabolic parameters, as compared to direct vessel wall effects contribute to PPARδ-
mediated atheroprotection. Nevertheless, the current study provides strong evidence 
that intervention to a HFHC diet with a PPARδ agonist delays the HFHC diet-induced 
progression of early lesions. It will be important to determine if intervention by PPARδ 
activation improves the pathology of more advanced lesions and whether extended 
treatment is able to achieve regression. We conclude that PPARδ activation remains a 
viable therapeutic target for atherosclerosis prevention and treatment. 
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Chapter 5* 
PPARδ-specific activation in liver attenuates triglyceride accumulation via 
enhanced fatty acid oxidation, reduced fatty acid synthesis and improved insulin 
sensitivity 
 
5.1 INTRODUCTION 
The prevalence of the metabolic syndrome has reached an epidemic proportion 
which has significantly increased the incidence of type 2 diabetes and atherosclerotic 
cardiovascular disease (Eckel et al., 2010). It represents a constellation of metabolic 
abnormalities that include obesity, hypertension, glucose intolerance and a dyslipidemia 
characterized by low plasma high-density lipoprotein (HDL) and high plasma very low-
density lipoprotein (VLDL) (Eckel et al., 2010). Insulin resistance can explain most, if not 
all of the metabolic syndrome and is defined as the inability of the hormone to maintain 
blood glucose homeostasis (Eckel et al., 2010, Haas and Biddinger, 2009). During 
insulin resistance hepatic lipogenesis persists which promotes hepatic steatosis, 
dyslipidemia and consequently cardiovascular disease risk (DeFronzo, 2010). Despite 
the prevalence of insulin resistant conditions and their significant morbidity and mortality, 
few therapeutic strategies exist that effectively correct these metabolic disorders. 
Hepatic steatosis, defined as excessive lipid accumulation in the liver, is a major 
clinical manifestation of insulin resistance observed in greater than 40% of patients with 
type 2 diabetes (Farese et al., 2012, Williamson et al., 2011). Although a causal 
relationship between hepatic steatosis and insulin resistance has been difficult to define 
(Farese et al., 2012), inflammation and endoplasmic reticulum (ER)-stress have been 
implicated as contributing factors to dysregulated hepatic insulin signaling (Hummasti 
and Hotamisligil, 2010, Ozcan et al., 2004). As a consequence, hyperinsulinemia-
mediated lipogenesis ensues which contributes to ectopic lipid deposition (Brown and 
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Goldstein, 2008). At a molecular level, insulin binding to its cognate receptor leads to 
receptor-mediated tyrosine phosphorylation of IRS-1 and/or IRS-2, which in turn 
activates PI3-K to simulate the phosphorylation and activation of Akt (Kido et al., 2001). 
Normally, the downstream consequences of insulin-stimulated Akt activation include 
suppression of hepatic gluconeogenesis due to phosphorylation and inactivation of 
forkhead box (Fox) O1, and promotion of de novo lipogenesis due to phosphorylation 
and activation of the mammalian target of rapamycin complex (mTORC1) (Li et al., 
2010). However, in the insulin resistant liver, Akt loses its ability to effectively inactivate 
FoxO1, but paradoxically maintains its ability to activate mTORC1 (Li et al., 2010). 
Consequently, mTORC1-driven transcription of the master regulator of lipogenesis, 
sterol regulatory element binding protein (SREBP)-1c, remains chronically active. In 
addition, insulin increases the amount of proteolytically processed active SREBP-1c 
through mechanisms that remain poorly understood (Yecies et al., 2011). Coupled to 
hyperinsulinemia, these actions of insulin during hepatic insulin resistance lead to 
continuous activation of genes required for fatty acid synthesis, thus contributing to 
excessive hepatic lipid accumulation.  
In addition to unregulated lipogenesis, decreased fatty acid oxidation often 
contributes to exacerbation of lipid content in the insulin resistant liver (Assini et al., 
2013, Mulvihill et al., 2009, Mulvihill et al., 2011). The adenosine monophosphate-
activated protein kinase (AMPK) is an evolutionarily conserved serine/threonine kinase 
that controls cellular and whole body energy metabolism (Dzamko and Steinberg, 2009, 
Fullerton et al., 2013). Specifically, hepatic AMPK is a pivotal regulator of fat oxidation 
and lipogenesis, primarily via direct phosphorylation and inhibition of acetyl-CoA 
carboxylase (ACC) (Fullerton et al., 2013, Kemp et al., 2003). Biochemically, this 
reduces malonyl CoA levels in the liver which (1) depletes fatty acid synthase (FAS) of 
substrate in the lipogenic pathway and (2) results in the de-repression of CPT1α in the 
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fatty acid oxidation pathway (Carlson and Kim, 1973, Saggerson, 2008). Thus, activation 
of AMPK represents a potential mechanism for the attenuation of hepatic steatosis. 
Peroxisome proliferator-activated receptors (PPARα, γ and δ) are a class of 
ligand-dependent transcription factors involved in regulation of glucose and lipid 
homeostasis (Evans et al., 2004). In contrast to PPARα and PPARγ, synthetic agonists 
for PPARδ have yet to reach the clinical arena, despite a number of studies having 
highlighted a potential role for this receptor in the treatment of metabolic disease (Reilly 
and Lee, 2008). In mice, genetic manipulations of Pparδ as well as prevention 
experiments involving administration of PPARδ agonists have revealed that activation of 
this receptor attenuates dyslipidemia and hyperglycemia, improves whole-body insulin 
sensitivity and prevents diet-induced obesity (Lee et al., 2006, Tanaka et al., 2003, 
Wang et al., 2003).  
With respect to PPARδ and hepatic lipid metabolism in mice, there are seemingly 
conflicting and controversial reports. Supplementation of mice with the PPARδ agonist 
GW1516 attenuated diet-induced hepatic steatosis; however the 2-fold increase in 
hepatic Acox expression suggested a PPARα-dependent effect (Nagasawa et al., 2006). 
Tanaka et al. reported that increased expression of genes involved in hepatic fat 
oxidation resulted in reduced hepatic TG in high-fat fed mice treated with GW1516 
(Tanaka et al., 2003). In db/db mice injected with adenoviral PPARδ (adPPARδ), liver 
TG content was reduced as a result of decreased SREBP-1c-mediated lipogenesis (Qin 
et al., 2008). Despite reports suggesting reduced hepatic steatosis, studies also 
demonstrated that PPARδ activation exerts either no effect (Barroso et al., 2011), or 
induction of liver TG accumulation (Lee et al., 2006, Liu et al., 2011). In db/db mice, 
GW1516-treatment resulted in accrual of hepatic TG as a result of direct transcriptional 
activation of ACCβ, and in turn, enhanced fatty acid synthesis (Lee et al., 2006). 
adPPARδ gene delivery to Ldlr-/- increased hepatic de novo lipogenesis and hepatic TG 
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(Liu et al., 2011). Of significance, none of these studies actually measured hepatic fatty 
acid oxidation. 
That PPARδ activation increases hepatic steatosis is counterintuitive since 
PPARδ agonists are known to improve whole-body insulin sensitivity and lipid 
homeostasis, and stimulate Cpt1a-mediated fatty acid oxidation in a variety of cell types 
and tissues (Lee et al., 2006, Tanaka et al., 2003, Wang et al., 2003). Furthermore, in 
muscle, GW1516 stimulated fatty acid oxidation, in part, through increased AMPK 
activity (Kramer et al., 2007, Kramer et al., 2005). Additionally, in a model of hepatic 
steatosis, GW1516 prevented the diet induced inactivation of hepatic AMPK (Barroso et 
al., 2011). This suggests that AMPK activation by PPARδ agonists has the ability to 
regulate hepatic β-oxidation and/or fatty acid synthesis. 
The objective of this study was to determine whether intervention to a high-fat, 
cholesterol containing diet (HFHC) with a selective PPARδ agonist can reverse hepatic 
steatosis. We demonstrate that GW1516 inhibited hepatic lipid deposition, a result of 
attenuated lipogenesis and increased fatty acid oxidation. Decreased fatty acid synthesis 
was due to GW1516-mediated correction of selective hepatic insulin resistance. We 
discovered that AMPK activation was required for the PPARδ-mediated attenuation of de 
novo lipogenesis, but was not required for PPARδ-mediated induction of fatty acid 
oxidation. The reduced liver TG content was coupled to attenuated hepatic inflammation 
and ER-stress. 
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5.2 MATERIALS AND METHODS 
5.2.1 ANIMALS AND DIETS 
Male Ldlr-/- mice on the C57BL/6 background were obtained from the Jackson 
Laboratory and housed in pairs in standard cages at 23ºC. The animals were cared for in 
accordance with the Canadian Guide for the Care and Use of Laboratory Animals, and 
all experimental procedures were approved by the Animal Care Committee at the 
University of Western Ontario. Mice 10-12 weeks of age (n=16) were fed ad libitum, a 
purified rodent chow diet (14% of calories from fat, Harlan Teklad TD8604, Madison WI) 
for 12 weeks. Another group of mice (10-12 weeks of age, n=48) were fed a high-fat 
cholesterol-containing western diet (HFHC - 42% of calories from fat, 0.2% cholesterol, 
Harlan Teklad TD09268) for 4 weeks. For the subsequent 8 weeks, half of these mice 
(n=24) remained on the HFHC diet, whereas the other half (n=24) were fed the HFHC 
diet supplemented with 3mg/kg/day GW1516 (Enzo Life Sciences, Ann Arbor, MI). In 
previously published reports, this dose administered by oral gavage produced plasma 
concentrations of GW1516 (106nmol/L) that was >1,000-fold more selective for PPARδ, 
compared to PPARα or PPARγ (Barish et al., 2008, Barroso et al., 2011, Narkar et al., 
2008). Animals were fasted for 4h prior to analyses or sacrifice. For fasting/re-feeding 
studies, animals were either fasted for 16h prior to sacrifice or fasted for 16h followed by 
a 2h acute re-feeding period of the experimental diets prior to sacrifice (Lu et al., 2012). 
Blood samples were obtained as previously described (Mulvihill et al., 2009, Mulvihill et 
al., 2010).  
5.2.2 ACTIVATION OF AMPK IN VIVO  
Activation of AMPK in vivo was assessed following intraperitoneal injection of 
GW1516 or A-769662. Analysis of respiratory exchange ratio (RER) was performed 
using the Oxymax Columbus Instruments Comprehensive Lab Animal Monitoring 
System (CLAMS) (Columbus Instruments, Columbus, OH); mice were acclimatized to 
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the system for 24hr prior to data collection. Animals were fasted overnight (15:00-07:00) 
to synchronize RER to ~0.7, followed by a period of free access to food (experimental 
diets) and water at 07:00 for 2hrs to re-synchronize RER to ~1. At 09:00, chow was 
removed and mice were injected with vehicle (5% dimethyl sulfoxide in phosphate-
buffered saline), 3mg/kg GW1516 or 30mg/kg A-769662 (SelleckBio, Houston, TX), a 
synthetic activator of AMPK (Cool et al., 2006). Metabolic measurements were collected 
until 15:30. Carbohydrate (4.58*VCO2-3.23*VO2) and fat (1.70*VO2 - 1.69*VCO2) 
utilization were calculated as previously described (Hawley et al., 2012). Analyses of in 
vivo phosphorylation of AMPK and ACC were performed in liver samples isolated at 
sacrifice by freeze-clamp method 90min after injection of the respective treatment and 
stored at -80°C until analysis as described (Hawley et al., 2012). 
5.2.3 ENERGY EXPENDITURE 
In the induction/intervention studies, analyses of energy expenditure (EE) and 
(RER) was performed using the Oxymax Columbus Instruments CLAMS; mice were 
acclimatized to the system for 24hr prior to a 24hr data collection period.  
5.2.4 PRIMARY MOUSE HEPATOCYTE ISOLATION, LIPOGENESIS AND FATTY 
ACID OXIDATION 
Primary mouse hepatocytes were isolated from WT or AMPKβ1-/- C57Bl/6J mice 
by the collagenase perfusion method as described (Dzamko et al., 2010). Experiments 
were performed the day following hepatocyte isolation. For mRNA expression analyses 
hepatocytes were incubated with either vehicle, GW1516 or A-769662 (at the indicated 
concentrations) for 6hrs prior to lysis in TRIzol® reagent. For lipogenesis and fatty acid 
oxidation experiments, cells were washed with PBS and incubated in serum-free 
Medium 199 for 3hrs. Lipogenesis was assessed by incubating cells with serum-free 
Medium 199 containing [1-14C]acetate (0.5 μCi/ml) (Amersham Biosciences) and 0.5 
mM unlabeled sodium acetate. After a 4hr incubation, cells were washed twice with PBS 
227 
 
and harvested by scraping cells into PBS. Lipids were extracted using the Bligh and 
Dyer method as described (Steinberg et al., 2006, Watt et al., 2006). For fatty acid 
oxidation, cells were incubated for 4hrs with serum-free Medium 199 containing [1-
14C]palmitic acid (0.5 μCi/ml) (Amersham Biosciences) and 0.5 mM unlabeled palmitate. 
Fatty acid oxidation was determined by measuring labelled CO2 and acid-soluble 
metabolites as described (Chen et al., 2005). 
5.2.5 PLASMA, BLOOD AND TISSUE ANALYSES 
Plasma insulin concentrations were determined by ELISA (Alpco Diagnostics, 
Salem, NH) in EDTA-plasma as per manufacturer’s instructions as described previously 
(Mulvihill et al., 2011). Blood glucose was determined using an Ascensia Elite 
glucometer (Bayer Healthcare, Toronto, Canada) (Mulvihill et al., 2011). Liver lipids were 
extracted from 100mg of tissue using the method of Folch et al. and quantitated as 
described previously (Assini et al., 2013, Folch et al., 1957). Fatty acid synthesis was 
measured following intraperitoneal injection of [1-14C]acetic acid as described (Mulvihill 
et al., 2009). Hepatic fatty acid oxidation was determined in tissue homogenates of fresh 
liver by conversion of [3H]palmitate to 3H2O (Mulvihill et al., 2009).  
5.2.6 IMMUNOBLOTTING AND DENSITOMETRY 
Total cell lysates were isolated from livers or primary mouse hepatocytes of mice 
as previously described (Beyea et al., 2007, Rowe et al., 2003). Proteins were separated 
by SDS-PAGE, transferred to polyvinylidene difluoride membranes and immunoblotted 
(Rowe et al., 2003). Lysates were probed using antibodies against mouse phospho and 
total Akt, FoxO1, mTORC1, AMPK and ACC as well as GRP78, CHOP and β-actin (Cell 
Signaling, Danvers, MA). Quantitation of protein was determined by densitometry as 
described (Beyea et al., 2007, Rowe et al., 2003).  
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5.2.7 QUANTITATIVE REAL-TIME PCR GENE ABUNDANCE ANALYSIS 
Total RNA was isolated from livers or primary mouse hepatocytes via TRIzol® 
reagent (Life Technologies, Burlington, ON) as per manufacturer’s instructions. Specific 
mRNA abundances (Pgc1a, Ppara, Acox, Cpt1a, Adfp, Srebpf1c, Fasn, Pck1, Tnf, 
Icam1, Il1b, Ccl2, Ccl3, iNos, Arg1 and Gapdh) were measured via quantitative real-time 
PCR (qRT-PCR) using an ABI Prism (7900HT) Sequence Detection System (Applied 
Biosystems, Foster City, CA) as previously described (Beyea et al., 2012, Mulvihill et al., 
2009). mRNA abundances were calculated using the standard curve method  
5.2.8 STATISTICAL ANALYSES 
Data are expressed as means +/- SEM. One-way ANOVA followed by the 
Bonferroni test was used to determine significant differences between two groups. One-
way ANOVA followed by pair-wise comparisons by the Tukey’s test was used to 
determine differences between three or more groups. For fasting/re-feeding experiments 
and experiments involving WT or AMPKβ1-/- primary mouse hepatocytes, two-way 
ANOVA followed by pair-wise comparisons by the Tukey’s test was used to determine 
statistically significant differences and interactions. Significance thresholds were P 
values less than 0.05 and marked by different upper case or lower case letters as well 
as asterisks as indicated in the figure legends.  
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5.3 RESULTS 
5.3.1 GW1516-TREATMENT ATTENUATES HEPATIC TG ACCUMULATION, IN 
PART, BY STIMULATING FATTY ACCY β-OXIDATION  
To examine the role of PPARδ activation in hepatic lipid metabolism, male 
C57BL/6 Ldlr-/- mice were administered a HFHC diet for 4 weeks to induce hepatic 
steatosis. Subsequently, mice were fed the HFHC diet supplemented with either vehicle 
or GW1516 (3mg/kg/day) for an additional 8 weeks. In mice fed the HFHC diet, 
prominent hepatic steatosis developed at the end of the 4-weeks, as evidenced by 
significantly increased TC, CE and TG (Figure 5.1A). These lipids continued to increase 
over the subsequent 8 weeks on the HFHC diet. In contrast the addition of GW1516 to 
HFHC diet for 8 weeks decreased hepatic lipids by 30-50% demonstrating a significant 
slowing of steatosis progression (Figure 5.1A).  
We reasoned that GW1516 attenuates liver TG accumulation via increased fatty 
acid (FA) β-oxidation and/or reduced fatty acid synthesis. With respect to FA oxidation, 
Pgc1a expression was suppressed in livers of mice fed the HFHC-diet for 12 weeks (-
20% compared to chow-fed mice), which was not further affected by GW1516-treatment 
(Figure 5.1B). Furthermore, at 12 weeks, the expression of Ppara and the PPARα-target 
gene Acox were unaffected by any diet (Figure 5.1C,D). In contrast, Cpt1a mRNA 
abundance was significantly enhanced (35%) in livers isolated from GW1516-treated 
animals, which was associated with a 50% increase in FA oxidation as compared to 
HFHC-fed animals (Figure 5.1E,F). We next examined the expression of the PPARδ-
specific target gene Adfp to determine whether hepatic PPARδ was activated in 
response to GW1516-treatmend. Indeed, expression of Adfp was significantly increased 
(2-fold) in liver from GW1516-treated animals (Figure 5.1G). Collectively, these results 
suggest that GW1516 attenueates liver TG accumulation partly due to increased hepatic 
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Figure 5.1: GW1516 attenuates diet-induced hepatic steatosis, in part, via 
increased fatty acid oxidation.  
Ldlr-/- mice were fed a high-fat, cholesterol-containing diet (HFHC) for 4 weeks. For a 
subsequent 8 weeks, mice remained on HFHC alone or supplemented with GW50516 
(GW1516) (3mg/kg/day) (n=12/group). A, Hepatic triglyceride (TG), total cholesterol (TC) 
and cholesteryl ester (CE) mass. Abundance of hepatic Pgc1a (B) Ppara (C) Acox (D) 
Cpt1a (E) and Adfp (G) was measured via qRT-PCR and normalized to Gapdh. F, 
Hepatic fatty acid β-oxidation was determined as conversion of [3H]palmitate to 3H20. 
Energy expenditure (H) and respiratory exchange ratio (I) (RER=VO2/VCO2) were 
measured by indirect calorimetry (CLAMS system) during a 24hr period. Measurements 
were collected every 10 min. Mean of each parameter during the 24hr period shown. 
Data is presented as mean +/- SEM. Different letters indicate significant differences; 
ANOVA with post-hoc Tukey’s test (P<0.05). Asterisk (*) indicates significant different 
between two groups; student’s paired t-test (P<0.05)  
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FA β-oxidation, which does not involve the activation of PGC1α or PPARα.  
To further investigate the increase in hepatic FA oxidation by GW1516-treatment, 
we assessed energy balance in an animal metabolic monitoring system. Total energy 
expenditure (EE) was significantly higher (16%) in mice receiving GW1516 compared to 
mice remaining on the HFHC diet alone (Figure 5.1H). As there was no significant 
difference in caloric intake between the diet groups (Chapter 4, Figure 4.2B) increased 
energy expenditure likely contributed to the significant 30% attenuation of body weight 
gain observed in Chapter 4 (Figure 4.2A). Nevertheless, the respiratory exchange ratio 
(RER) profiles, which reflect the relative utilization of carbohydrate (RER~1) versus fat 
(RER~0.7), were similar between the HFHC-fed and GW1516-intervention groups 
(Figure 5.1I). Given the significant increase in total EE in GW1516-treated mice, the lack 
of difference in RER profiles suggests that both carbohydrate and fat utilization are 
increased by PPARδ activation. 
5.3.2 AMPK ACTIVATION IS NOT REQUIRED FOR THE GW1516-MEDIATED 
INCREASE IN FAT OXIDATION 
AMPK is a cellular energy sensor that regulates fat oxidation, in part, through 
phosphorylation of its downstream substrate ACC (O'Neill et al., 2012). Given that 
PPARδ activation stimulated hepatic FA oxidation in vivo, we hypothesized that AMPK 
activation may be involved. To evaluate the ability of GW1516 to directly stimulate acute 
hepatic AMPK activation in vivo, we employed a fasting, feeding, injection and re-fasting 
protocol (Hawley et al., 2012). In livers isolated 90min after the injection of GW1516, we 
observed a significant 2-fold increase in phosphorylation of AMPK and ACC (Figure 
5.2A). Mice were also injected with the potent synthetic AMPK activator A-769662 (Cool 
et al., 2006), which increased AMPK and ACC phosphorylation ~2.5-fold (Figure 5.2A).  
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Figure 5.2: GW1516 increases AMPK and ACC phosphorylation, which is not 
required for fatty acid oxidation. 
Eight to ten week-old Ldlr-/- mice fed a standard laboratory chow were fasted overnight, 
fed at 0700 for 2hrs and re-fasted at 0900. Intraperitoneal injection of vehicle, GW1516 
(3mg/kg) or A-769662 (30mg/kg) (n=6/group) occurred at the beginning of the re-fasting 
period at 0900. A, Immunoblots of AMPK and ACC in freeze-clamped liver lysates 90-
min post-injection. Representative immunoblots with quantitations shown. B-F, Primary 
hepatocytes isolated from WT and β1-/- mice. Cells were incubated for 1hr with or without 
GW1516 or A-769662 and lysates were immunoblotted for phosphorylated (p)AMPK and 
pACC (B). Representative immunoblots with quantitations are shown. C, Isolated 
hepatocytes were treated with 0.5mM palmitate (0.5μCi/mL [14C]palmitate) for 4hrs with 
or without GW1516 or A-769662 prior to determination of fatty acid oxidation. In isolated 
hepatocytes treated with or without GW1516 or A-769662 for 6hrs, mRNA abundances 
of Cpt1a (D), Adfp (E) and Acox (F) were measured by qRT-PCR and normalized to 
Gapdh. Data is presented as mean +/- SEM (n=3-4 from at least 3 independent 
experiments). In (A) asterisk (*) indicates significant difference between vehicle and 
treatment; student’s paired t-test (P<0.05). In (B) # and † indicate significant difference 
versus WT control; two-way ANOVA with post-hoc Bonferroni’s test (P<0.05). In (C-F) 
different upper case letters indicate statistical significance among treatments in WT 
hepatocytes, different lower case letters indicate statistical significance among 
treatments in β1-/- hepatocytes, and an asterisk (*) indicates statistical significance 
between WT and β1-/- within the same treatment group (P<0.05); two-way ANOVA with 
post-hoc Tukey’s test (P<0.05).  
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To investigate the requirement of AMPK in the GW1516-mediated stimulation of 
FA oxidation, we isolated primary mouse hepatocytes from wild type (WT) or AMPKβ1-/- 
mice (referred to as β1-/- mice). Deletion of the β1 subunit of AMPK results in 90% loss of 
hepatic AMPK activity (Dzamko et al., 2010). As depicted in Figure 5.2B, both GW1516 
and A-769662 increased phosphorylation of AMPK and ACC in isolated WT primary 
mouse hepatocytes but not β1-/- hepatocytes. Furthermore, GW1516 and A-769662 
stimulated a modest but significant 30% increase in FA oxidation in isolated WT 
hepatocytes (Figure 5.2C). The effect of A-769662 was lost in β1-/- hepatocytes, 
consistent with an AMPK-dependent effect (Hawley et al., 2012). However, in β1-/- 
hepatocytes GW1516 stimulated fat oxidation to the same extent as in WT cells (Figure 
5.2C). To reconcile this, we examined Cpt1a expression in WT and β1-/- hepatocytes and 
found that GW1516-treatment significantly enhanced Cpt1a expression (~2-fold) 
irrespective of genotype (Figure 5.2D). A-769662 treatment had no effect on Cpt1a 
mRNA abundance in WT or β1-/- hepatocytes (Figure 5.2D). The PPARδ-specific target 
gene Adfp was increased 2-fold in isolated hepatocytes from either genotype, whereas 
the PPARα-specific target Acox was unaffected by genotype or treatment (Figure 
5.2E,F). Taken together, these results provide evidence that the ability of GW1516 to 
increase FA oxidation does not require AMPK activation. Rather, GW1516 stimulates 
Cpt1a, an effect that does not require AMPK. Furthermore, the selected concentration of 
GW1516 does not activate PPARα. 
To evaluate whether increased hepatic FA oxidation would be reflected in a more 
rapid switch to fat utilization, we examined RER profiles in the fasting, acute feeding, 
injection and re-fasting protocol outlined above. Consistent with a faster switch to post-
prandial fat utilization, A-769662-injected mice exhibited more rapid depression of RER 
at 5 and 6 hours post-injection (Figure 5.3A). Accordingly, the calculated oxidation of 
carbohydrate was significantly decreased (~30%) during this period, whereas oxidation 
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Figure 5.3: GW1516 activates hepatic AMPK in vivo, yet stimulates carbohydrate 
utilization.  
Eight to ten week-old Ldlr-/- mice fed a standard laboratory chow were fasted overnight, 
fed at 0700 for 2hrs and re-fasted at 0900. Intraperitoneal injection of vehicle, GW1516 
(3mg/kg) or A-769662 (30mg/kg) (n=6/group) occurred at the beginning of the re-fasting 
period at 0900. A, Respiratory exchange ratio (RER) measured during a fasting, feeding, 
injection and re-fasting protocol with A-769662. B-C, Carbohydrate and fatty acid 
utilization, respectively, calculated from data shown in (A). D, Respiratory exchange ratio 
(RER) measured during a fasting, feeding, injection with GW1516 and re-fasting 
protocol. E-F, Carbohydrate and fatty acid utilization, respectively, calculated from data 
shown in (C). Data is presented as mean +/- SEM. * indicates significant difference 
versus vehicle; student’s paired t-test (P<0.05).  
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of fat was markedly increased by 2.5-fold (Figure 5.3B,C). On the other hand, injection of 
GW1516 resulted in a slower depression of RER (Figure 5.3D), which is consistent with 
enhanced post-prandial carbohydrate utilization (Figure 5.3E). In contrast to the mutual 
inhibition of substrate utilization observed in A-769662-injected mice, GW1516-injection 
did not supress post-prandial fat utilization (Figure 5.3F). Collectively, these data 
suggest that the ability of PPARδ activation by GW1516 to increase total body glucose 
oxidation is greater than its ability to increase liver FA oxidation. 
5.3.3 GW1516-TREATMENT ATTENUATES DE NOVO LIPOGENESIS, IN PART, VIA 
ACTIVATION OF AMPK AS WELL AS CORRECTION OF SELECTIVE HEPATIC 
INSULIN RESISTANCE 
In addition to regulating FA oxidation, AMPK is a critical regulator of de novo 
lipogenesis (Dzamko et al., 2010). We thus hypothesized that PPARδ activation inhibits 
FA synthesis via activation of AMPK. When incubated with WT hepatocytes, GW1516 
significantly inhibited de novo lipogenesis by ~30% (Figure 5.4A). This effect was 
strongly attenuated in β1-/- hepatocytes, in which the suppression was only 11% and not 
statistically significant (Figure 5.4A). Consistent with an AMPK-specific effect, the 80% 
reduction in lipogenesis by A-769662 in WT hepatocytes was lost in β1-/- hepatocytes 
(Figure 5.4A). Both compounds increased expression of Insig1 (Figure 5.4B), a known 
negative regulator of SREBP-1c (Qin et al., 2008). The induction of Insig1 by GW1516 
and A-769662 may have contributed to the residual 10% reduction in lipogenesis 
observed in β1-/- hepatocytes. Nevertheless, in primary mouse hepatocytes GW1516 
inhibits de novo lipogenesis, in part, through activation of AMPK. 
During selective hepatic insulin resistance, hyperinsulinemia drives mTORC1 
activation, resulting in enhanced SREBP-1c-mediated lipogenesis (Brown and Goldstein, 
2008). Thus, another possible mechanism for reduced hepatic steatosis in GW1516-
treated mice is correction of the mTORC1 branch of insulin signaling. 
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Figure 5.4: GW1516 inhibits hepatic fatty acid synthesis as a consequence of 
AMPK activation and correction of selective hepatic insulin resistance. 
A, Primary mouse hepatocytes isolated from WT and β1-/- mice were incubated with 
0.5mM sodium acetate (0.5μCi/mL 14C-acetate) for 4hrs with or without GW1516 or A-
769662 prior to determination of lipogenesis (n=3-4 from at least 3 independent 
experiments). In isolated hepatocytes treated with or without GW1516 or A-769662 for 
6hrs abundance of Insig1 (B) was measured by qRT-PCR and normalized to Gapdh. C, 
Plasma insulin at the end of the induction and intervention phases in Ldlr-/- mice fasted 
overnight (designated F) and fasted overnight followed by a 2hr re-feeding period 
(designated RF). D, Immunoblots of insulin signaling proteins phosphorylated (p) AKT 
and pmTOR in liver lysates from F and RF mice. Representative immunoblots with 
quantitations shown. mRNA abundance of Srebf1c (E) and Fasn (F) in liver lysates 
isolated from animals fasted for 4hrs (n=6-8/group). G, Synthesis of fatty acid in liver 
obtained 60 min post injection (i.p.) with [14C]acetic acid (n=6-8/group). Data is 
presented as mean +/- SEM. In (A) different upper case letters indicate statistical 
significance among WT treatments, different lower case letters indicate statistical 
significance among β1-/- treatments, and asterisk (*) indicates statistical significance 
between WT and β1-/- within the same treatment group (P<0.05); two-way ANOVA with 
post-hoc Tukey’s test (P<0.05). In (C,D) different upper case letters indicate statistical 
significance among fasted animals, different lower case letters indicate statistical 
significance among re-fed animals, and asterisk (*) indicates statistical significance 
between fasted and re-fed within the same diet (P<0.05); two-way ANOVA with post-hoc 
Tukey’s test (P<0.05). In (E-G) different letters indicate significant differences; one-way 
ANOVA with post-hoc Tukey’s test (P<0.05).  
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In contrast to chow-fed animals, HFHC-feeding resulted in continued progression of 
fasting hyperinsulinemia (Figure 5.4C). Fasting hyperinsulinemia in the HFHC-fed 
animals was strongly attenuated by intervention with GW1516 to the HFHC diet (Figure 
5.4C). Fasting hyperinsulinemia in the HFHC-fed animals was associated with increased 
phosphorylation of hepatic Akt and mTORC1 compared to chow-fed animals (Figure 
5.4D). In contrast, GW1516-intervention restored fasting phospho-Akt (partially) and 
phospho-mTORC1 (completely) to levels observed in chow-fed controls (Figure 5.4D). In 
all three diet groups, re-feeding elicited enhanced phosphorylation of Akt and mTORC1 
(Figure 5.4D). This is consistent with increased sensitivity in the lipogenic mTORC1 
branch of the insulin signaling cascade in HFHC-fed mice and its normalization following 
GW1516 treatment (Brown and Goldstein, 2008).  
Compared to chow-fed controls, the fasting hyperinsulinemia and increased 
phospho-mTORC1 observed in HFHC-fed mice at 12 weeks was associated with 
increased expression of Srebpf1c and Fasn (Figure 5.4E,F), as well as markedly 
enhanced fasting FA synthesis (Figure 5.4G). In contrast, the GW1516-intervention 
cohort exhibited significant attenuation of Srebf1c and Fasn expression (Figure 5.4E,F), 
which was coupled to a complete inhibition of the HFHC-induced progression of FA 
synthesis from 4- to 12-weeks of feeding (Figure 5.4G). Together with results in primary 
mouse hepatocytes, these data suggest that PPARδ activation inhibits hepatic 
lipogenesis through activation of AMPK as well as correction of selective hepatic insulin 
resistance, both of which contribute to the attenuation of ectopic liver TG accrual. 
5.3.4 PPARδ ACTIVATION RESTORES DYNAMIC REGULATION OF HEPATIC 
FoxO1 WHICH SLOWS THE DEVELOPMENT OF OF HYPERGLYCEMIA 
Given that PPARδ plays a role in hepatic insulin sensitivity (Lee et al., 2006), we 
hypothesized that this was perhaps a result of correcting the bifurcation in the insulin 
signaling cascade induced by the HFHC diet. At 12 weeks, livers isolated from HFHC-
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fed mice lost the ability to suppress Pck1 expression and stimulate FoxO1 
phosphorylation in the fasting-to-feeding transition (Figure 5.5A,B). This is consistent 
with previous hyperinsulinemic euglycemic clamp studies in which the liver of Ldlr-/- 
mice fed a high fat diet were insulin resistant (Mulvihill et al., 2011). In contrast, animals 
receiving the GW1516-intervention retained the ability to dynamically regulate fasting/re-
feeding Pck1 expression and FoxO1 phosphorylation, similar to that observed in chow-
fed mice (Figure 5.5A,B). We examined fasting blood glucose levels and found a 
significant 1.5-fold increase in fasting hyperglycemia in mice fed the HFHC for 12 weeks, 
which was partially attenuated by GW1516-intervention (Figure 5.5C). These data 
suggest that PPARδ activation corrects the gluconeogenic branch of insulin signaling 
during selective hepatic insulin resistance, which prevents exacerbation of diet-induced 
dysglycemia. 
5.3.5 GW1516 INHIBITS HEPATIC INFLAMMATION AND INDUCTION OF ER 
STRESS 
Inflammation is a prominent feature of hepatic insulin resistance and steatosis 
(Hummasti and Hotamisligil, 2010). Given that GW1516-intervention attenuated hepatic 
steatosis and corrected selective hepatic insulin resistance, we postulated that this 
would be associated with reduced hepatic inflammation. As shown in Figure 5.6A, 
expression of the proinflammatory M1 cytokines Tnf, Icam1, Il1b, Ccl2, Ccl3 and iNos 
were markedly induced (2-to 15-fold) in livers of mice fed the HFHC diet at 12 weeks.. In 
contrast, these cytokines were significantly attenuated (-50- to -65%) in livers excised 
from the GW1516-intervetion group (Figure 5.6A). Furthermore, HFHC-feeding strongly 
suppressed hepatic expression of the M2 anti-inflammatory marker Arg1, resulting in 
greatly exacerbated iNos/Arg1 ratio compared to chow-fed control mice (Figure 5.6B). 
GW1516 intervention completely prevented this expression pattern (Figure 5.6B). 
Together these data suggest that PPARδ activation promotes an anti-inflammatory
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Figure 5.5: GW1516 corrects the gluconeogenic branch of insulin signalling 
during selective hepatic insulin resistance which improves fasting hyperglycemia.  
A, mRNA abundance of Pck1 in liver lysates isolated from fasted (F) and re-fed (RF) 
animals (n=6-8/group). B, Immunoblots of insulin signaling protein pFoxO1 in liver 
lysates from F and RF mice (n=6-8/group). Representative immunoblots with 
quantitations shown. C, Blood glucose levels in F and RF mice (n=6-8/group). Data is 
presented as mean +/- SEM. Different upper case letters indicate statistical significance 
among fasted animals, different lower case letters indicate statistical significance among 
re-fed animals, and asterisk (*) indicates statistical significance between fasted and re-
fed within the same diet (P<0.05); two-way ANOVA with post-hoc Tukey’s test (P<0.05). 
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Figure 5.6: GW1516 attenuates hepatic inflammation and ER-stress.  
Ldlr-/- mice were fed a high-fat, cholesterol-containing diet (HFHC) for 4 weeks. For a 
subsequent 8 weeks, mice remained on HFHC alone or supplemented with GW50516 
(GW1516) (3mg/kg/day) (n=12/group). A,B Hepatic abundance of cytokines was 
determined at 12 weeks by qRT-PCR, and expression was normalized to Gapdh +/- 
SEM (n=8-12/group). C, Immunoblots of GRP78 and CHOP in liver lysates at 12 weeks. 
Representative immunoblots with quantitations shown. Data is presented as mean +/- 
SEM (8-12/group). Different letters indicate significant differences; one-way ANOVA with 
post-hoc Tukey’s test (P<0.05). 
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M2 cytokine milieu in the liver. 
 Inflammation is commonly interwoven with ER-stress in the development of 
hepatic insulin resistance (Hummasti and Hotamisligil, 2010, Van Beek et al., 2012). 
Accordingly, HFHC-feeding significantly increased hepatic GRP78 (Figure 5.6C), a 
marker of the unfolded protein response (UPR), which is the precursor to the ER-stress 
response (Kaplowitz et al., 2007). GW1516-intervention completely normalized the diet-
induced increase in GRP78 (Figure 5.6C). However, CHOP, the effector of the ER-
stress response was unaffected by any diet (Figure 5.6C) suggesting that although the 
UPR has been initiated, the ER-stress response has not. Nevertheless, PPARδ 
activation attenuates this diet-induced hepatic pathology 
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5.4 DISCUSSION 
In the current study, we evaluated the ability of intervention to a HFHC diet with a 
PPARδ agonist to attenuate the progression of hepatic steatosis. We show that 
GW1516-intervention inhibits the progression of diet-induced liver TG accumulation. 
Mechanistically, attenuation of hepatic steatosis was a result of reduced FA synthesis 
and increased FA oxidation. The loss of hepatic AMPK activity did not mitigate the ability 
of PPARδ activation to induce FA oxidation, whereas loss of AMPK partially prevented 
PPARδ agonist-mediated inhibition of lipogenesis. Selective hepatic insulin resistance 
was corrected by PPARδ activation, which was associated with reduced hepatic 
inflammation and ER-stress.  
 The role of PPARδ activation in liver TG metabolism has been controversial (Lee 
et al., 2006, Liu et al., 2011, Nagasawa et al., 2006, Qin et al., 2008). One study showed 
that GW1516 prevented diet-induced suppression of hepatic AMPK activation, which 
was associated with increased expression of genes involved in FA oxidation and 
increased plasma β-hydroxybutyrate. In spite of these observations, GW1516 had no 
effect on hepatic TG content (Barroso et al., 2011). Another study showed that injection 
of adPPARδ into Ldlr-/- mice significantly increased AMPK phosphorylation in the liver, 
which was thought to contribute to glucose lowering (Liu et al., 2011). The impact of 
increased hepatic AMPK activation on lipid metabolism was not explored (Liu et al., 
2011). Here we provide direct evidence that PPARδ activation increases AMPK and 
ACC phosphorylation in vivo as well as in primary mouse hepatocytes. The GW1516-
mediated increase in phospho-ACC was AMPK dependent as this effect was lost in β1-/- 
hepatocytes. With regard to lipid metabolism, we demonstrate that PPARδ activation in 
vivo stimulates hepatic FA oxidation through PPARδ-specific activation of Cpt1a. We 
recapitulated these results in primary mouse hepatocytes, and identified that AMPK 
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activation is not a requirement for GW1516 to stimulate FA oxidation, as enhanced 
Cpt1a expression and FA oxidation persisted in β1-/- hepatocytes.  
 Carbohydrate oxidation and fat oxidation are thought to be mutually inhibitory 
(Randle, 1998). Thus, an agent that induces liver fat oxidation would be predicted to 
stimulate a faster switch in post-prandial substrate utilization from carbohydrate to fat 
(Hawley et al., 2012). In the current study we show that in an acute setting, GW1516-
injection increased carbohydrate oxidation, yet fat oxidation during this period was not 
suppressed. Furthermore, in a setting of prolonged PPARδ activation, we demonstrate 
that intervention to the HFHC diet with GW1516 increases total EE, yet has no further 
effect on average RER through a 24hr period. Previous work has generated the 
hypothesis that PPARδ activation stimulates carbohydrate and fat utilization 
simultaneously (Kramer et al., 2007, Lee et al., 2006). The findings reported here are 
consistent with this hypothesis, and contribute direct evidence for simultaneous oxidation 
of both fuel sources in response to a synthetic PPARδ ligand. The increased oxidation of 
fat likely contributes to reduced liver TG accumulation. 
Studies which have examined the role PPARδ activation in hepatic de novo 
lipogenesis have yielded both positive and negative results (Lee et al., 2006, Liu et al., 
2011, Qin et al., 2008). On one hand, both adPPARδ injection and GW1516-treatment 
have been shown to increase hepatic expression of genes involved in lipogenesis, and 
consequently increase liver TG accumulation (Lee et al., 2006, Liu et al., 2011). On the 
other hand, delivery of adPPARδ or the synthetic PPARδ agonist GW0742 have 
demonstrated reduced SREBP-1c processing, reduced lipogenic gene expression and 
prevention of hepatic steatosis (Qin et al., 2008). The data presented here are consistent 
with, and extend this latter concept, as we provide evidence that intervention to a HFHC 
diet with GW1516 in mice, corrects selective hepatic insulin resistance, reduces 
lipogenic gene expression and prevents any further increase in fasting fatty acid 
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synthesis. Furthermore, GW1516 reduced de novo lipogenesis in WT primary mouse 
hepatocytes, but not in β1-/- hepatocytes, which demonstrated that a component of the 
inhibition of FA synthesis was AMPK-dependent. Given that two different mechanisms 
may contribute to the observed reduction in lipogenesis by GW1516-treatment, the 
relative contributions of these pathways requires further study.  
During selective hepatic insulin resistance, Akt loses its ability to phosphorylate 
and inactivate FoxO1, while maintaining its ability to phosphorylate and activate 
mTORC1 (Li et al., 2010). Coupled to hyperinsulinemia, this bifurcation in the insulin 
signaling cascade contributes to hepatic steatosis, dyslipidemia and hyperglycemia 
(Brown and Goldstein, 2008). In the present study, we provide evidence that hepatic 
insulin signaling does in fact bifurcate in a model of diet-induced insulin resistance. 
Importantly, we demonstrate that PPARδ activation attenuates the progression of the 
selective hepatic insulin resistant phenotype, as dynamic regulation of fasting-to-feeding 
phospho-FoxO1 and Pck1 expression was restored in the GW1516-intervention cohort. 
These data elaborate on the body of evidence that supports a role for PPARδ activation 
in protection from metabolic disease (Lee et al., 2006, Tanaka et al., 2003, Wang et al., 
2003), and further support the use of PPARδ agonists in management of insulin 
resistance. 
Liver inflammation has been linked to hepatic steatosis and insulin resistance 
(Gregor and Hotamisligil, 2011, Hummasti and Hotamisligil, 2010). Vascular chronic low-
grade inflammation is in part mediated by aortic lipid accumulation and insulin resistance 
(Chapter 2, Chapter 4, (Liang et al., 2007, Tabas et al., 2010)). Given the selective 
insulin resistant phenotype and TG acquisition in livers of HFHC-fed animals and 
correction by GW1516-intervention, it is tempting to hypothesize that similar 
mechanisms govern induction and attenuation of vascular and hepatic inflammation. 
Moreover, Kupffer cell-specific deletion of Pparδ resulted in increased proinflammatory 
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cytokine expression and reduced anti-inflammatory cytokine expression, which was 
coupled to increased liver TG accumulation and hepatic dysfunction (Odegaard et al., 
2008). Therefore, our results are consistent with an anti-inflammatory role for PPARδ 
activation in the liver. The relative impact of reduced inflammation versus correction of 
insulin sensitivity to the attenuation of hepatic steatosis cannot be discerned from the 
present experiments and requires further elucidation.  
In summary, the data reported here provide physiological and molecular 
evidence that intervention with PPARδ-specific activation in the liver alleviates diet-
induced hepatic steatosis, insulin resistance, inflammation and ER-stress. We conclude 
that PPARδ agonists may serve as therapeutic options for the treatment of patients with 
hepatic steatosis. 
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Chapter 6 
Discussion 
 
6.1 SUMMARY OF FINDINGS 
 Cardiovascular disease due to accelerated atherosclerosis is the primary cause 
of death in patients with dyslipidemia, insulin resistance and type 2 diabetes. Central to 
atherogenesis is the development of lipid-laden macrophage foam cells, which occurs in 
response to retention of apoB-containing lipoproteins within the arterial intima (Moore 
and Tabas, 2011). In addition to the accrual of lipid, macrophage foam cells synthesize 
and secrete proinflammatory effector molecules that potentiate lesion development 
(Libby et al., 2011). Therefore, a macrophage-targeted treatment that inhibits foam cell 
formation and the associated inflammatory responses would be desirable. In this thesis, 
two synthetic agonists for PPARδ were examined in vitro, one of which was extended to 
in vivo experiments. These studies were undertaken to: (1) identify the molecular 
mechanisms involved in macrophage foam cell-associated inflammatory responses, and 
(2) define the mechanism of action and therapeutic potential of PPARδ activation in the 
regulation of lipid metabolism, inflammatory signaling and protection from 
atherosclerosis in states of metabolic disturbance such as insulin resistance and 
dyslipidemia.  
 Elevated plasma TG-rich VLDL is an independent risk factor for the development 
of CVD, and can readily stimulate the development of macrophage foam cells (Evans et 
al., 1993, Whitman et al., 1999a, Whitman et al., 1999b). Paradoxically, VLDL-derived 
fatty acids also activate macrophage PPARδ resulting in up-regulation of genes involved 
in fatty acid and TG metabolism (Chawla et al., 2003). Thus, from an evolutionary 
standpoint, PPARδ serves as a fatty acid sensor in cells of the vasculature to prevent 
arterial lipid accumulation under normolipidemic conditions. The experiments described 
in Chapter 2 tested the hypothesis that synthetic ligand activation of PPARδ would 
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attenuate VLDL-induced macrophage foam cell formation in the context of 
hypertriglyceridemia. These in vitro studies confirmed that VLDL and synthetic PPARδ 
agonists each individually activated similar transcriptional programs (Chawla et al., 
2003). However, the VLDL-stimulated PPARδ-target gene expression was insufficient to 
prevent the 5-fold increase in VLDL-induced macrophage TG deposition. In contrast, 
macrophages incubated with VLDL in the presence of the potent synthetic PPARδ 
agonists GW0742 and GW1516 resulted in the attenuation of VLDL-induced TG 
accumulation. Mechanistically, the PPARδ ligands reduced TG accumulation, at least in 
part, by increasing expression of ANGPTL4, CD36 and CPT1α above VLDL-treatment 
alone, which resulted in: (1) reduced lipolysis, (2) enhanced FA uptake, albeit from a 
smaller FA pool, and (3) increased FA oxidation, respectively. Collectively, the net effect 
of synthetic ligand activation of PPARδ was to reduce intracellular TG accumulation 
(Figure 6.1). It is important to note that the concentrations of the PPARδ agonists used 
in these studies were specific for activating PPARδ, in the absence of activating PPARα 
or PPARγ. 
 In addition to increasing lipid accumulation, previous work has suggested that 
VLDL or VLDL-derived FAs can also stimulate or potentiate macrophage inflammatory 
responses (Saraswathi and Hasty, 2006, Stollenwerk et al., 2005, Su et al., 2009). The 
second hypothesis tested in Chapter 2 was that PPARδ agonists could attenuate VLDL-
induced macrophage inflammatory responses. In VLDL-treated macrophages, 
expression of the proinflammatory mediators IL-1β, MIP-1α and ICAM-1 was significantly 
enhanced, which was associated with increased MAPK activation as well as 
dysregulation of the insulin signaling cascade as evidenced by reduced phosphorylation 
of Akt and FoxO1 (Figure 6.1). In contrast, incubation with the PPARδ agonists almost 
completely inhibited VLDL-induced cytokine expression and MAPK activation, and 
restored the dysregulation of the insulin signaling cascade. These studies also revealed
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Figure 6.1: PPARδ activation inhibits macrophage foam cell formation and the 
inflammatory response. 
PPARδ activation attenuates VLDL-induced triglyceride (TG) accumulation by activating 
a transcriptional program resulting in enhanced CPT-1α-mediated fatty acid β-oxidation 
and ANGPTL4-mediated inhibition of lipoprotein lipase (LPL) activity. Furthermore, 
macrophage treatment with synthetic PPARδ ligands inhibits proinflammatory cytokine 
expression, by inhibiting VLDL-stimulated ERK1/2 activation and reversing VLDL-
mediated inhibition of Akt/FoxO1 phosphorylation. 
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that the PPARδ-mediated inhibition of the inflammatory response was not a 
consequence of increased FA oxidation, as both of the PPARδ agonists normalized 
VLDL-induced cytokine expression, MAPK activation and dysregulated insulin signaling 
even in the presence of etomoxir, a potent inhibitor of CPT1α (Galic et al., 2011).  
 Although hypertriglyceridemia is an independent risk factor for the development 
of CVD, the canonical foam cell-inducing lipoprotein is CE-rich LDL in both its native and 
modified forms. The studies in Chapter 3 addressed the ability of PPARδ activation to 
attenuate native and modified LDL-induced macrophage foam cell formation and the 
associated inflammatory response(s). Cellular CE accumulation in response to native 
and oxLDL was significantly attenuated by both GW0742 and GW1516. With regard to 
oxLDL, both PPARδ agonists increased CD36 mRNA abundance (Chapter 2), which 
would be predicted to enhance particle uptake (Moore and Freeman, 2006). However, 
PPARδ activation also increased ABCA1-mediated cholesterol efflux to apoAI, likely 
owing to increased ABCA1 mRNA and protein, which contributed to a net inhibition of 
CE-rich lipoprotein-induced macrophage foam cell formation. 
 Previous studies examining oxLDL-induced inflammatory responses have yielded 
both positive and negative results (Curtiss et al., 2012, Febbraio et al., 2000, Janabi et 
al., 2000, Kannan et al., 2012, Michelsen et al., 2004, Mullick et al., 2005, Qiu et al., 
2007). The studies in Chapter 3 contribute to the notion that cholesterol-loaded 
macrophages exhibit a dampened inflammatory phenotype, as evidence by reduced 
expression of TNFα and IL-6, which was not further affected by synthetic ligand 
activation of PPARδ. The anti-inflammatory effect of oxLDL was coupled to reduced 
DHCR24 expression, which is known to result in the accumulation of desmosterol, a 
known activator of LXR. Accumulation of desmosterol within cholesterol-loaded mouse 
peritoneal macrophages has recently been shown to have potent anti-inflammatory 
effects (Spann et al., 2012). Thus, the studies conducted in Chapter 3 agree with the 
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concept that cholesterol-loaded macrophages do not exhibit a proinflammatory 
phenotype, suggesting that other immune cells of the arterial intima are responsible for 
the atherosclerosis-associated inflammation observed in vivo. 
 The studies in Chapter 4 were undertaken to determine whether the ability of the 
PPARδ agonists to attenuate macrophage foam cell formation translated into reduced 
foam cell formation in vivo, and in turn, protection from diet-induced atherosclerosis. 
These studies tested the hypothesis that PPARδ activation attenuates the progression of 
diet-induced atherosclerosis and aortic inflammation in Ldlr-/- mice. Previous studies 
involving prevention protocols, in which the PPARδ agonist is administered at the same 
time as the atherogenic stimulus (a high-fat diet), have reported a preventative effect of 
PPARδ activation on atherogenesis (Barish et al., 2008, Graham et al., 2005). The 
studies in Chapter 4 involved an intervention approach, whereby Ldlr-/- mice were fed the 
HFHC diet for 4 weeks to induce dyslipidemia and insulin resistance, which predisposes 
the animals to atherosclerosis development. Subsequently, HFHC-fed animals either 
remained on the atherogenic diet, or were supplemented with GW1516 for a subsequent 
8 weeks. A subset of animals was fed standard laboratory chow for the 12-week period. 
The continued progression of dyslipidemia and hyperinsulinemia in HFHC-fed mice 
contributed to extensive lipid deposition within atherosclerotic plaques. In concert with 
increased lipid accumulation, HFHC-fed animals had significant enrichment of lesion 
macrophage, smooth muscle cell and collagen content. In contrast to the continued 
progression of dyslipidemia, insulin resistance and plaque development in HFHC-fed 
mice, GW1516-intervention induced regression of elevated plasma lipid and plasma 
insulin levels, which contributed to slowed progression of plaque lipid deposition. 
GW1516-intervention also reduced macrophage infiltration, yet had no effect on lesion 
smooth muscle cell content. Despite this, collagen deposition was increased in lesions of 
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GW1516-treated animals, suggesting the development of smaller, more stable 
atherosclerotic lesions. 
 Examination of cytokine expression in full-length aortae revealed that HFHC-
feeding stimulated a proinflammatory phenotype in the aorta, as the M1 cytokines, Ccl3, 
II1b, Icam1, Tnf, II6, iNos and Ccl2 were all markedly elevated. Additionally, the M2 anti-
inflammatory mediator Arg1 was substantially lower and the iNos/Arg1 ratio was greatly 
exacerbated in aortae excised from HFHC-fed animals as compared to those isolated 
from chow-fed animals. In contrast, GW1516-intervention attenuated the progression of 
aortic inflammation, as M1 cytokines were reduced, Arg1 expression was restored and 
the iNos/Arg1 ratio was reverted back to levels in chow-fed mice.  
 To further build on the translation of findings from Chapters 2 and 3 into the in 
vivo setting, aortic analyses of the signaling cascades known to regulate cytokine 
expression were performed. HFHC-feeding significantly increased aortic MAPK 
activation. Furthermore, Nfκb activation was also enhanced, which was correlated with 
the increased expression of aortic Tnf, Il6 and Ccl2. Both MAPK and Nfκb activation 
were attenuated by intervention with GW1516. To assess aortic insulin signaling, aortae 
excised from fasted and re-fed mice were examined for phosphorylated Akt and FoxO1. 
In contrast to the dynamic fasting-to-feeding regulation of pAkt and pFoxO1 observed in 
aortae isolated from chow-fed animals, this effect was lost in aortae from HFHC-fed 
mice. GW1516-intervention corrected aortic insulin signaling, which likely contributed to 
reduced aortic inflammation.  
In addition to exerting atheroprotective effects, the studies in Chapter 4 identified 
that PPARδ activation also corrects dyslipidemia and peripheral insulin resistance. 
Coupled to the fact that hepatic steatosis is a major clinical manifestation of insulin 
resistance that contributes to dyslipidemia (Farese et al., 2012), the studies in Chapter 5 
were undertaken to determine whether PPARδ activation inhibits diet-induced liver lipid 
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accumulation. To assess this, the same induction/intervention protocol used in Chapter 4 
was employed. The Chapter 5 studies demonstrated that the further 2-fold increase 
hepatic TG accrual in animals remaining on the HFHC diet was significantly attenuated 
by intervention with GW1516. The PPARδ agonist reduced cellular TG, in part, through 
increased FA oxidation, which was unrelated to activation of PGC1α, PPARα or PPARγ. 
This was evidenced by GW1516 having no effect on hepatic Pgc1a, Ppara, Acox or 
Fabp4 expression. Furthermore, the studies conducted in Chapter 5 identified that the 
stimulation of FA oxidation by a synthetic PPARδ agonist does not require the activation 
of AMPK. β-oxidation persisted in PPARδ agonist-treated primary mouse hepatocytes 
isolated from AMPKβ1-/- mice. 
Compared to chow-fed controls, the HFHC-fed animals were hyperinsulinemic, 
which was coupled to increased hepatic phosphorylation of the insulin signaling 
mediators Akt and mTORC1. Accordingly, Srebf1c and Fasn expression were 
significantly upregulated. Functionally, increased phospho-mTORC1, Srebf1c and Fasn 
expression was associated with significantly enhanced fasting FA synthesis. All of these 
parameters were markedly attenuated by intervention with GW1516 to the HFHC diet. 
These experiments demonstrated that part of the mechanism by which PPARδ activation 
attenuates hepatic steatosis is through correction of the lipogenic branch of the insulin 
signaling bifurcation. 
The studies in Chapter 5 also revealed that another mechanism by which PPARδ 
activation reduces FA synthesis is through increased AMPK activity. Treatment of 
isolated WT primary mouse hepatocytes with GW1516 resulted in a 30% reduction in 
basal de novo lipogenesis. This effect was lost in β1-/- hepatocytes. Consistent with an 
AMPK effect, the synthetic AMPK activator A-769662 reduced rates of lipid synthesis in 
hepatocytes isolated from WT mice. However, A-769662 was ineffective at inhibiting 
lipogenesis in β1-/- hepatocytes. 
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 In addition to stimulating the development of hepatic steatosis and 
hyperinsulinemia, HFHC-feeding also induced a state of fasting hyperglycemia. The 
hyperglycemia observed in HFHC-fed animals was at least partially a result of the 
inability of insulin to elicit further phosphorylation of FoxO1 during re-feeding. Reduced 
dynamic regulation of FoxO1 activity was associated with a loss of fasting-to-feeding 
suppression of Pck1 expression, as hepatic Pck1 in the 12-week HFHC cohort was 
similar between fasted and re-fed animals. Importantly, GW1516-intervention to the 
HFHC diet prevented the progression of resistance in the gluconeogenic FoxO1 branch 
of the insulin signaling cascade, which likely contributed to the attenuated progression of 
dysglycemia. 
Previous work has suggested that inflammation in the liver is linked to hepatic 
steatosis and insulin resistance (Gregor and Hotamisligil, 2011, Hummasti and 
Hotamisligil, 2010). The Chapter 5 studies confirmed a proinflammatory state of the liver 
during insulin resistance, and showed that intervention to the HFHC-diet with a PPARδ 
agonist was able to completely prevent progression of this inflammatory phenotype. 
Moreover, HFHC-feeding induced the UPR, which is the precursor to ER-stress often 
linked to inflammation and progression of insulin resistance (Gregor and Hotamisligil, 
2011, Hummasti and Hotamisligil, 2010). Importantly, UPR induction was completely 
normalized by GW1516-intervention. 
6.2 CONCLUSIONS AND FUTURE DIRECTIONS 
6.2.1 CHAPTER 2 CONCLUSIONS 
The studies in Chapter 2 demonstrated that although VLDL-derived FAs activate 
PPARδ, potent synthetic agonists for this receptor are required to attenuate VLDL-
induced macrophage lipid accumulation and the associated inflammatory responses. 
Moreover, these studies revealed that the anti-inflammatory and lipid lowering 
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capabilities of PPARδ are discrete. That PPARδ activation was associated with reduced 
LPL activity and increased β-oxidation would suggest that the normalization of the VLDL-
induced inflammatory response by the PPARδ agonists was a result of reduced TG 
accumulation. However, inhibition of TG accumulation with low-dose tetrahydrolipstatin 
to the same extent as that achieved by PPARδ activation failed to normalize VLDL-
induced cytokine expression. Furthermore, GW0742 and GW1516 completely inhibited 
VLDL-induced cytokine expression, even when β-oxidation was inhibited by etomoxir. 
Whether PPARδ activation can attenuate VLDL-induced inflammatory responses in 
ANGTPL4-/-, CPT1α-/- or ANGPTL4/CPT1α double knockout macrophages would be the 
more definitive experiment to confirm the findings here. However, the data presented in 
Chapter 2 strongly suggest that the anti-inflammatory and lipid lowering properties of 
PPARδ activation are distinct.  
 A growing body of evidence indicates that lipid-induced macrophage 
inflammation is a consequence of increased MAPK signaling as well as impaired 
signaling through the Akt/FoxO1 pathway (Han et al., 2006, Saraswathi and Hasty, 
2006, Senokuchi et al., 2008, Su et al., 2009). It is also thought that VLDL-derived FAs 
can stimulate macrophage inflammation through TLR-Nfκb signaling (Nguyen et al., 
2007, Shi et al., 2006). However, this hypothesis has more recently been challenged 
(Anderson et al., 2012, Erridge and Samani, 2009). The studies conducted in Chapter 2, 
performed in the complete absence of LPS, contribute to the paradigm that VLDL-
derived FAs themselves stimulate macrophage inflammatory responses are a 
consequence of macrophage insulin resistance, rather than activation of the TLR-Nfκb 
pathway. This is supported by: (1) reduced pAkt and pFoxO1, increased nuclear FoxO1 
and enhanced MAPK signaling by VLDL treatment, (2) canonical Nfκb target genes 
TNFα and IL-6 being unaffected by VLDL treatment, and (3) the inability of parthenolide 
(an inhibitor of Nfκb signaling) to block VLDL-stimulated expression of IL-1β, MIP-1α, 
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and ICAM-1. Importantly, we found that PPARδ activation blocks VLDL-induced MAPK 
activation as well as the VLDL-mediated inhibition of the insulin signaling cascade.  
6.2.2 CHAPTER 2 FUTURE DIRECTIONS  
Going forward, it will be important to identify the mechanism(s) by which VLDL 
induces MAPK activation and the mechanism(s) by which PPARδ activation normalizes 
VLDL-induced MAPK signaling. It has been suggested that PPARδ activation stimulates 
the expression of Rgs4 and Rgs5 in mouse macrophages, which reduces angiotensin II-
induced phosphorylation of ERK1/2 and p38 (Takata et al., 2008). It remains unknown 
whether this mechanism applies to prevention of VLDL-induced MAPK activation and 
downstream inflammation. If this were the mechanism, it would imply that VLDL-induced 
inflammation through the MAPK pathway involves activation of G-protein coupled 
receptor signaling, which may uncover novel candidates in the inhibition of macrophage 
inflammation and atherogenesis. We propose to examine RGS4 and RGS5 expression 
in macrophages treated with PPARδ agonists. Concurrently, we propose studies in 
which the ability of GW0742 and GW1516 to inhibit VLDL-induced MAPK activation will 
be compared in PPARδ agonist treated control, RGS4, RGS5 and combined 
RGS4/RGS5 knockdown macrophages. We hypothesize that the ability of PPARδ 
activation to attenuate VLDL-induced MAPK activation and cytokine expression will be 
strongly attenuated in the absence of RGS4 and/or RGS5.  
 Another important avenue of investigation will be to identify how VLDL-treatment 
dysregulates insulin signaling, and the mechanism(s) by which the PPARδ agonists 
restore this VLDL-induced dysregulation. One possibility is that VLDL induces negative 
regulators of one or more steps of the cascade. For example, the suppressor of cytokine 
signaling (SOCS)-3 negatively regulates insulin signaling by targeting IRS-1 and IRS-2 
for proteosomal degradation, thereby diminishing signaling to PI3-K and to Akt 
(Emanuelli et al., 2000, Rui et al., 2002). Another example is the c-Jun N-terminal kinase 
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(JNK), which phosphorylates the insulin receptor on serine residues, and in doing so, 
inhibits the intrinsic autophosphorylation of insulin receptor tyrosine residues. In turn, 
JNK-mediated serine-phosphorylation of the insulin receptor dampens the propagation 
of the insulin signal through the IRS-proteins, PI3-K and Akt (Ozcan et al., 2004). The 
hypotheses that SOCS-3 and/or JNK play a role in the impairment of insulin signaling 
during VLDL-induced macrophage inflammation can be tested using knockdown 
experiments for SOCS-3 and inhibitor studies for JNK.  
Regarding the mechanism by which PPARδ activation restores VLDL-mediated 
impairment of insulin signaling, both PPARδ agonists used in the Chapter 2 studies 
stimulated enhanced Akt and FoxO1 phosphorylation in the absence of VLDL. We 
concluded from these experiments that PPARδ activation primes the insulin signaling 
cascade to prevent its downregulation by VLDL-treatment. It has been suggested that 
PPARδ activation can directly activate Akt activity through the induction of integrin-like 
kinase (ILK) and 3-phosphoinositide-dependent kinase 1 expression (PDK1) (Di-Poi et 
al., 2002). These transcripts encode kinases that are known to directly phosphorylate 
Akt and, in turn, FoxO1. However, we and others have observed PPARδ activation-
induced enhancement of Akt and FoxO1 phosphorylation, without increased ILK or 
PDK1 expression (Chapter 2, (Han et al., 2008)). Another series of candidates may be 
phosphatases that are known to downregulate the insulin signaling. One such example 
is the phosphatase and tensin homolog (PTEN), which catalyses the dephosporylation of 
the 3` phosphate of PIP3, resulting in the biphosphate product PIP2. This 
dephosphorylation event inhibits PI3-K activity, thereby mitigating signaling to Akt 
(Nicholson and Anderson, 2002). In keratinocytes, PPARδ plays a role in the 
downregulation of PTEN, thus relieving the impediment on the PI3-K to Akt signal (Di-
Poi et al., 2002). Whether this mechanism applies to the GW0742 and GW1516-
mediated reversal of VLDL-induced insulin resistance in macrophages is unknown. If this 
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were the case, one would hypothesize that macrophages treated with PPARδ agonists 
would exhibited reduced PTEN expression. Additionally, one would hypothesize that 
VLDL and PPARδ agonist treatment of macrophages transfected with constitutively 
active PTEN, would attenuate the ability of PPARδ activation to reverse VLDL-induced 
downregulation of Akt and FoxO1 phosphorylation, resulting in sustained 
proinflammatory cytokine expression. If the converse were true, this would identify that 
activation of insulin signaling by the PPARδ agonists occurs downstream of PI3-K. This 
latter scenario would warrant experiments involving treatment of macrophages 
expressing dominant-negative Akt or phosphorylation-resistant FoxO1, with or without 
PPARδ agonists. 
6.2.3 CHAPTER 3 CONCLUSIONS 
The studies in Chapter 3 showed that PPARδ activation attenuates both native 
and oxLDL-induced macrophage foam cell formation. Although the PPARδ agonists 
increased LDLR and CD36 expression (Chapter 2), these compounds also increased 
cholesterol efflux. We concluded from these studies that PPARδ agonists, similar to 
PPARγ ligands (Argmann et al., 2003), induce a transcriptional program that increases 
cholesterol uptake and concomitantly increases cholesterol efflux, which collectively 
leads to a net depletion of cellular CE and FC. Induction of cholesterol efflux to apoAI 
was significantly increased, whereas efflux to HDL3 was not. The fact that macrophage 
foam cell formation was reduced despite no apparent increase in ABCG1 activity agrees 
with the paradigm that ABCA1 is a more critical efflux transporter in the regulation of 
cholesterol homeostasis in hematopoetic cells of the arterial intima (Tarling et al., 2010, 
Yvan-Charvet et al., 2007). 
 With regard to CE-rich lipoprotein-induced inflammatory responses, we observed 
decreased cytokine expression in macrophages treated with oxLDL compared to vehicle 
controls. Reduced cytokine expression was not further affected by the PPARδ agonists. 
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One interpretation of these data is that the PPARδ agonists require the induction of 
cytokine expression in order to exert their inhibitory effects. In Chapter 2, we observed 
no change in basal cytokine mRNA abundance when macrophages were treated with 
GW0742 or GW1516, yet a complete inhibition of cytokine expression by these 
compounds in the presence of the VLDL-stimulus. A study that supports this hypothesis 
demonstrated that in adipocytes, GW1516 had no effect on basal IL-6 mRNA and 
protein but completely inhibited LPS-induced IL-6 synthesis and secretion (Rodriguez-
Calvo et al., 2008). Another line of evidence that supports this interpretation is that 
GW0742 had no effect on the inhibitors of Nfκb (IκBα and IκBβ) in cardiomyocytes 
unless an LPS-stimulus was present (Ding et al., 2006).   
 Previous studies have suggested that oxLDL-treated macrophages or FC-loaded 
macrophages exhibit a proinflammatory phenotype, characterized by increased TLR 
and/or Nfκb signaling (Curtiss et al., 2012, Febbraio et al., 2000, Janabi et al., 2000, Li et 
al., 2005, Michelsen et al., 2004, Mullick et al., 2011, Stewart et al., 2010). However, 
other studies have provided contrary evidence (Kannan et al., 2012, Qiu et al., 2007, 
Spann et al., 2012). In our hands, oxLDL treatment reduced cytokine expression, and 
inhibition of ACAT activity to significantly increase FC accumulation failed to reverse the 
anti-inflammatory phenotype of oxLDL-treated macrophages. These results suggest that 
oxLDL treatment or FC accumulation in macrophages is not a stimulus for the 
inflammatory response. Furthermore, oxLDL-mediated reduction in cytokine expression 
was coupled to markers of (1) oxysterol accumulation (reduced SREBP-1c and FAS 
expression), (2) LXR activation (increased ABCA1, ABCG1 and MYLIP), (3) PPARγ 
activation (FABP4), and (4) PPARδ activation (ADFP). The activation of LXR, PPARγ or 
PPARδ is known to be anti-inflammatory (Im and Osborne, 2011, Straus and Glass, 
2007). Therefore, oxLDL-mediated activation of all three of these nuclear receptors may 
elicit a combination of effects that contributes to reduced cytokine expression.  
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6.2.4 CHAPTER 3 FUTRE DIRECTIONS 
The association between oxLDL treatment, increased expression of LXR-target 
genes and reduced inflammatory cytokine expression is most likely linked to 
desmosterol accumulation as a consequence of reduced DHCR24 expression. However, 
it will be critical to determine whether desmosterol does in fact accumulate in THP-1 
macrophages exposed to oxLDL. We propose to conduct experiments in which oxLDL-
treated macrophages with or without the PPARδ agonists are examined for intracellular 
desmosterol concentrations by liquid chromatography tandem mass spectrometry 
(Honda et al., 2009, Honda et al., 2008). We hypothesize that oxLDL-treatment will 
stimulate an increase in desmosterol accumulation, which will not be further enhanced 
by the PPARδ agonists. The latter portion of this hypothesis is driven by the fact that the 
PPARδ agonists did not further suppress TNFα and IL-6 expression beyond oxLDL-
treatment alone.  
Although enhanced intracellular desmosterol is the most likely driving factor 
behind the oxLDL-mediated anti-inflammatory response, other mechanisms are certainly 
possible. In fact, Spann et al. reported that in mouse peritoneal macrophages elicited 
from LXR-double knockout mice, the anti-inflammatory phenotype was attenuated, but 
not eliminated, compared to macrophages elicited from LXR-wild type mice (Spann et 
al., 2012). Thus, LXR-independent anti-inflammatory mechanisms must also play a role 
in this context. In the Chapter 3 studies, oxLDL stimulated the expression of the PPARδ-
specific target gene ADFP, implying that oxLDL may induce the accumulation of PPARδ 
ligands. Fatty acids are known to activate PPARδ (Chawla et al., 2003). Spann et al. 
observed increases in oleic acid accumulation in cholesterol-loaded and desmosterol-
treated mouse peritoneal macrophages which were in the picomolar range (Spann et al., 
2012). The studies in Chapter 2 revealed that in the micromolar range, oleic acid 
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induces macrophage inflammatory responses. However, picomolar concentrations of 
oleic acid may be sufficient to activate PPARδ but insufficient to stimulate the 
inflammatory response.  
The hypothesis that oxLDL-mediated anti-inflammatory responses are partially 
the result of PPARδ activation can be tested by examining cytokine expression in 
macrophages treated with oxLDL in the presence or absence of PPARδ antagonists 
(GSK0660 or GSK3787). It is important to note that genetic ablation of PPARδ would not 
be an appropriate model system for these experiments, as PPARδ deletion mimics the 
liganded state of the receptor. This is due to genetic ablation of PPARδ resulting in the 
transrepression of inflammatory cytokine expression and derepression of PPARδ target 
genes (Lee et al., 2003, Lee et al., 2006a). Hence, this would create an experimental 
confounder for the proposed studies. Continuing with the proposed PPARδ inhibitor 
experiments, one would hypothesize that antagonizing PPARδ would result in partial 
reversal of the oxLDL-mediated reduction of TNFα and IL-6. If this hypothesis is correct, 
another series of experiments could perhaps determine whether oleic acid or other fatty 
acid ligands for PPARδ accumulate in oxLDL-treated macrophages. Subsequently, 
experiments may also include, but are not limited to, determining the expression of 
cytokines under the following conditions: (1) oxLDL in the presence of both PPARδ and 
LXR antagonists, (2) exogenous addition of the determined fatty acid PPARδ ligand, (3) 
in the presence or absence of PPARδ antagonist(s). The proposed experiments would 
determine the relative contribution of LXR and PPARδ activation to the oxLDL-mediated 
anti-inflammatory response in macrophages, and possibly identify a novel mechanism 
responsible for the reduced proinflammatory responses observed in oxLDL-treated 
macrophages. 
Given that TNFα and IL-6 expression is regulated, at least in part, by Nfκb 
signaling (Ding et al., 2006, Li et al., 2005, Rodriguez-Calvo et al., 2008), one would be 
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inclined to hypothesize reduced phosphorylation of the Nfκb signaling mediators IKK and 
IκB in oxLDL-treated macrophages. However, the anti-inflammatory effects of LXR occur 
as a result of ligand-induced small ubiquitin-like modifier (SUMO)-dependent 
modification of the receptor. The SUMOylation of LXR results in the recruitment of co-
repressor complexes to promoter regions of proinflammatory genes, which inhibit Nfκb 
from binding to its response elements within these targets (Im and Osborne, 2011). 
Hence, it is unlikely that oxLDL-treated macrophages would display reduced phospho-
IKK and IκB. On the other hand, PPARδ inhibits Nfκb signaling through increased 
expression of the IκB proteins, suggesting that oxLDL-treated macrophages may exhibit 
higher IκBα and IκBβ than untreated controls. In oxLDL-treated macrophages with or 
without LXR and PPARδ antagonists, we propose to examine nuclear co-repressor 
occupancy of the TNFα and IL-6 promoters via chromatin immunoprecipitation (Ghisletti 
et al., 2007), as well as phospho- (as a control) and total-IKK, IκBα and IκBβ via 
immunoblotting. These experiments would expand on the mechanism by which oxLDL-
mediates reduced TNFα and IL-6 expression. 
6.2.5 CHAPTER 4 CONCLUSIONS 
The studies in Chapter 4 revealed that, intervention with a synthetic PPARδ 
agonist to a diet-induced setting of pre-established dyslipidemia and insulin resistance 
attenuates the progression of early stage lesions to more complex lesions. A significant 
contributor to this effect was likely the reduction in plasma lipids, thus reducing the 
atherogenic stimulus. However, aortae excised from GW1516-treated mice exhibited 
significantly increased expression of the PPARδ-target genes Adrp, Angptl4 and Cpt1a, 
which we showed in Chapter 2 are important regulators of VLDL-induced macrophage 
foam cell formation. Coupled to the fact that aortic TG in mice receiving the GW1516-
intervention regressed from the 4-week baseline levels, these data suggest that this 
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compound has direct vessel wall effects that contribute to the PPARδ-mediated 
reduction in lesion lipid deposition.  
 In HFHC-fed animals, the markedly increased aortic expression of Ccl3, II1b, 
Icam1, Tnf, II6, iNos and Ccl2 coupled to substantially lower Arg1 and a greatly 
exacerbated iNos/Arg1 ratio strongly suggests the polarization of these aortae towards 
the M1 proinflammatory phenotype. That GW1516-intervention attenuated the 
progression of this M1 polarization demonstrates that PPARδ activation exerts anti-
inflammatory effects in the aorta, which likely contribute to protection from lesion 
progression. Furthermore, GW1516 prevented the induction of aortic MAPK, which was 
associated with increased Rgs4 and Rgs5 expression. Additionally, the PPARδ agonist 
inhibited HFHC diet-induced aortic Nfκb activation, through mechanisms that remain to 
be elucidated.  
The studies in Chapter 4 also revealed that dynamic fasting-to-feeding regulation 
of aortic pAkt and pFoxO1 is lost in a diet-induced model of atherosclerosis. These data 
suggest that nuclear FoxO1 activity is chronically active in the aorta, which likely 
contributes to the sustained accumulation of FoxO1 target genes such as Il1b (Su et al., 
2009), Icam1 and Ccl3 (Chapter 2). This hypothesis is supported by the paradigm that 
atherogenesis is a longitudinal process associated with chronic low-grade inflammation 
(Glass and Witztum, 2001, Libby et al., 2011). Importantly, we found that GW1516-
intervention to the HFHC diet completely reversed the fasting-to-feeding regulation of 
aortic pAkt and pFoxO1 back to levels in chow-fed controls. These data suggest that 
part of the ability of PPARδ activation to protect mice from lesion progression is 
mediated by restoration of normal aortic insulin signaling. 
6.2.6 CHAPTER 4 FUTURE DIRECTIONS 
A caveat to the conclusions from the findings in Chapter 4 is the leap from drug-
treatment to causal relationship. In other words, the ability of GW1516 to lower plasma 
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lipids is unequivocally a major contributor to protection from lesion progression. 
However, the data also provide compelling evidence that GW1516 exerts lipid lowering, 
anti-inflammatory and insulin-sensitizing at the level of the aorta. The relative 
contribution of lipid lowering and direct vessel wall effects cannot be deciphered from the 
experiments performed. Furthermore the lesions after 4-weeks of induction were early 
lesions, which were prevented from further development. Moving forward it will be 
important to determine if PPARδ activation improves the pathology of more advanced 
lesions, and whether extended treatment is able to achieve regression.  
 Given that the use of Pparδ-/- mice results in the experimental confounder 
discussed above, alternative strategies will need to be employed to reconcile the issue 
of lipid lowering versus direct vessel wall effects. To address this issue, and to determine 
if extended treatment is able to achieve regression, one potential experiment would be to 
induce lesion development with HFHC feeding for 12-weeks prior to a 12-week 
intervention with GW1516. Additionally, the introduction of HFHC-fed mice transferred to 
chow with or without GW1516 would provide unique insight into the contribution of 
PPARδ activation within the aorta to improved lesion pathology. The justification for this 
statement arises from ongoing experiments in our laboratory, in which 12-weeks of 
HFHC feeding prior to the introduction of chow for the remaining 12-weeks, completely 
normalizes all metabolic parameters back to levels observed in 24-week chow-fed mice. 
Thus, examining lesion pathology in GW1516-intervention during chow feeding would 
eliminate the variable of drastic lipid lowering contributing to inhibition of plaque 
progression or stimulation of plaque regression. The reversa mouse (Cre-induced 
deletion of hepatic Mttp) provides a similar platform to test the impact of a drug on 
atherosclerosis development independent of lipid lowering (Feig et al., 2011), but is 
unfortunately commercially unavailable.  
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Another strategy to help reconcile lipid lowering versus direct vessel wall effects 
is the utilization of laser-capture microdissection (LCM). Analysis of gene expression 
from LCM samples would allow us to determine the contribution of a particular cell-type 
to the changes we observed in full-length aorta. Specifically, LCM of MOMA-2 positive 
macrophages would provide a tool for the macrophage-specific measurement of Adrp, 
Angptl4 and Cpt1a expression. Additionally, the measurement of cytokines in MOMA-2 
positive macrophages isolated by LCM would provide a more definitive conclusion of 
lesion macrophage polarization in all diet groups. Answering these questions would 
provide a PPARδ-specific mechanism in macrophages for reduced foam cell formation 
and inhibition of inflammatory cytokine expression, particularly in the condition of HFHC 
transferred to chow plus GW1516. 
GW1516 increased lesion collagen deposition without altering lesion SMC 
content. This observation is possibly due to a direct effect of PPARδ activation on plaque 
SMCs, enhancing their capacity to synthesize and deposit extracellular matrix. This 
hypothesis is supported by a report that PPARδ activation in vascular smooth muscle 
cells (VSMCs) inhibits IL-1β-induced matrix metalloproteinase (MMP)-2 and MMP-9 
expression (Kim et al., 2010). Although reduced lipid deposition in VSMCs restores their 
capacity to synthesize extracellular matrix (Beyea et al., 2012, Frontini et al., 2009), the 
ability of PPARδ agonists to improve VSMC function in response to a lipid load is 
unknown. In addition, LCM of smooth muscle cells from aortic lesions would allow us to 
determine whether GW1516-treatment enhanced collagen and elastin expression 
specifically in VSMCs, thus contributing to enhanced matrix deposition.  
An interesting and novel finding in the Chapter 4 studies was the increased aortic 
expression of Ptpn6 and Trib3, which are known negative regulators of hepatic insulin 
signaling (Du et al., 2003, Dubois et al., 2006). While it has recently been demonstrated 
that silencing Trib3 using siRNA suppresses atherosclerosis in diabetic mice (Wang et 
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al., 2012), the role of Ptpn6 in atherogenesis has not been reported. Experiments using 
siRNA against Ptpn6 in a setting of HFHC diet-induced atherosclerosis would identify the 
contribution of induced Ptpn6, and its protein product SHP-1, to atherogenesis. 
Moreover, the ability of GW1516 to inhibit lesion progression in a setting of already 
improved (vascular) insulin signaling (such as Trib3 and/or Ptpn6 knockdown) would 
help determine the impact of improved aortic insulin signaling on atherosclerosis. 
Alternatively, examining the ability of GW1516 to inhibit plaque progression in the setting 
of bone marrow transplantation from Insr-/- mice to Ldlr -/- recipients would also provide 
valuable information regarding the contribution of improved vascular insulin sensitivity by 
PPARδ activation to the atheroprotective effect. If in this scenario GW1516 can still 
inhibit atherogenesis, it will be important to determine the mechanism by which PPARδ 
activation reverses insulin resistance, as discussed in Chapter 2 future directions 
(Section 6.2.2).  
6.2.7 CHAPTER 5 CONCLUSIONS 
In Chapter 5 we demonstrated that intervention to a HFHC diet with a synthetic 
PPARδ agonist attenuates the progression of hepatic steatosis, as evidenced by a 
complete halting of liver TG accumulation from 4-week baseline levels. The addition of 
GW1516 to the HFHC diet did not affect hepatic expression of Pgc1a, Ppara, Acox or 
Fabp4, which led us to conclude that GW1516 did not activate PGC1α, PPARα or 
PPARγ. However, GW1516-treatement enhanced the hepatic expression of Adfp and 
Cpt1a in the liver, which was coupled to increased FA oxidation. These data strongly 
suggest that GW1516 increases CPT1α-mediated β-oxidation in the liver, and that with 
respect to PPARs, this effect is PPARδ specific.  
 The studies in Chapter 5 also revealed that AMPK is not required for PPARδ-
mediated stimulation of liver fat oxidation, as the increase in β-oxidation observed in 
isolated WT primary mouse hepatocytes persisted in AMPKβ1-/- hepatocytes. 
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Irrespective of AMPKβ1 genotype, GW1516-treatment significantly increased Cpt1a 
expression, further demonstrating that PPARδ activates CPT1α-mediated FA oxidation 
independent of AMPK.  
As alluded to above, GW1516-intervention inhibited hepatic fatty acid synthesis, 
which is partially attributable to AMPK activation. We also found that intervention to a 
HFHC diet with GW1516 in mice, corrected selective hepatic insulin resistance, which 
reduced lipogenic gene expression and prevented any further increase in fasting FA 
synthesis. Our findings are supported by a number of studies reporting that PPARδ 
plays a role in improving whole-body insulin sensitivity, which reduces metabolic 
disturbance (Lee et al., 2006b, Tanaka et al., 2003, Wang et al., 2003). However, we 
extended this concept in Chapter 5, as we provided evidence that improved insulin 
signaling specifically in the liver contributes to reduced hepatic steatosis. 
A previous study demonstrated that transplanatation of bone marrow from Pparδ-
/- mice into WT mice polarized hepatic Kupffer cells to the proinflammatory M1 
phenotype, which resulted in increased liver TG accumulation and hepatic dysfunction 
(Odegaard et al., 2008). Given that deletion of PPARδ mimics the liganded state of the 
receptor as discussed in Section 6.2.4, the study by Odegaard and colleagues would 
imply that PPARδ activation in hepatic Kuppfer cells is proinflammatory. Although the 
studies performed in Chapter 5 cannot distinguish between the effects of PPARδ 
activation in hepatocytes versus Kuppfer cells, the results suggest an anti-inflammatory 
rather than a proinflammatory effect. This is consistent with the notion that activation of 
PPARδ in hepatocytes protects from inflammatory responses induced by non-lipid 
stimuli such as cytokines or LPS (Serrano-Marco et al., 2011). Even so, it remains to be 
determined whether the inhibition of hepatic inflammation by GW1516 contributed to 
correction of hepatic insulin signaling, FA synthesis and hepatic steatosis, or was a 
secondary effect of reduced liver TG accumulation. 
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6.2.8 CHAPTER 5 FUTURE DIRECTIONS 
Moving forward it will be important to determine the mechanism by which PPARδ 
activation corrects insulin signaling. The discussion in Chapter 2 highlighted the fact that 
GW1516 activated Akt and FoxO1 phosphorylation in macrophages. Here, the situation 
is vastly different. If GW1516 activated hepatic insulin signaling, mTORC1 
phosphorylation and Srebf1c expression would have been increased compared to 
HFHC-fed mice. Furthermore, fatty acid synthesis would have been increased, or 
perhaps unchanged due to activation of AMPK mitigating the increase in insulin-
stimulated lipogenesis, but certainly not decreased. The simplest explanation for the 
correction of hepatic insulin signaling is improved peripheral insulin sensitivity, which 
would result in enhanced peripheral glucose uptake and a reduction in hyperinsulinemia. 
This hypothesis is supported by: (1) the known ability of PPARδ activation to enhance 
glucose uptake in skeletal muscle (Kramer et al., 2005), (2) the fact that GW1516 treated 
mice exhibit increased insulin stimulated glucose disposal under hyperinsulinemic-
euglycemic clamps (Lee et al., 2006b) and (3) that PPARδ activation in pancreatic islet 
cells increases glucose stimulated insulin secretion (Iglesias et al., 2012). Taken 
together, these studies suggest that the PPARδ-mediated correction of peripheral insulin 
resistance may contribute to reduced fasting hyperinsulinemia, and therefore the lower 
drive on hepatic insulin receptor signaling to stimulate the mTORC1-SREBP1c lipogenic 
axis. Hence, examining the contribution of corrected selective hepatic insulin resistance 
to reduced liver TG accumulation in GW1516-treated animals is not particularly 
straightforward. 
Considering AMPK activation by GW1516 is required for the inhibition of 
lipogenesis, but is not required for the induction of FA oxidation, AMPKβ1-/- mice provide 
an appropriate platform to test the relative contribution of these parameters in the 
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GW1516-mediated inhibition of liver TG accumulation. Furthermore, AMPKβ1-/- mice are 
protected from diet-induced hepatic insulin resistance (Dzamko et al., 2010). Therefore, 
AMPKβ1-/- mice also represent a model which can be used to decipher the relative 
contribution of corrected insulin signaling and AMPK activation to reduced lipogenesis by 
PPARδ activation. We propose to examine the ability of GW1516 intervention to a HFHC 
diet to attenuate hepatic steatosis in AMPKβ1-/- mice. We hypothesize that the ability of 
GW1516 to inhibit liver TG accumulation will be partially attenuated in AMPKβ1-/- mice. 
Furthermore, the addition of a group of mice treated with adenoviral Cpt1a siRNA in the 
presence or absence of GW1516 would inhibit PPARδ activation induced FA oxidation. 
The proposed experiments would provide unique insight into the mechanism of 
GW1516-mediated inhibition of hepatic steatosis. 
In the fasting, acute feeding, injection and re-fasting protocol we found that 
GW1516 acutely stimulated carbohydrate oxidation, while not suppressing fat oxidation. 
Furthermore, in the intervention study, a setting of prolonged PPARδ activation, 
GW1516 increased total EE yet had no further effect on average RER through a 24hr 
period. Taken together, these results suggest that PPARδ activation can simultaneously 
stimulate carbohydrate and fat oxidation. The mechanism by which this occurs has been 
postulated to involve increased glucose flux through the pentose phosphate pathway 
coupled to increased hepatic fatty acid synthesis (Lee et al., 2006b). The consequence 
of these processes being upregulated in response to a PPARδ agonist is that the former 
can consume up to 20% of hepatic glucose, while providing reducing power to stimulate 
fatty acid synthesis (Lee et al., 2006b); hence increased simultaneous carbohydrate and 
fat utilization. Although we did not measure activity of the pentose-phosphate pathway in 
livers of GW1516-treated animals, we did observe a significant reduction in the rate of 
hepatic fatty acid synthesis, thus challenging the theory of Lee and colleagues with 
respect to the liver. However, preliminary experiments in our lab have revealed that in 
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muscle, GW1516 does not inhibit HFHC feeding-induced fatty acid synthesis despite the 
resolution of hyperinsulinemia. Importantly GW1516-treatment significantly increases 
muscle FA oxidation (~2-fold). Together, these data suggest that PPARδ activation may 
stimulate the pentose-phosphate shunt and fatty acid synthesis in muscle, where the 
oxidative machinery to utilize the newly synthesized FAs is upregulated. This would 
create futile cycling of FA synthesis and oxidation which: (1) increases carbohydrate 
consumption as a consequence of increased pentose-phosphate activity to provide 
reducing power for FA synthesis, and (2) simultaneously increases fat oxidation to 
deplete the newly synthesized FAs. However, this is highly speculative and substantial 
experimentation would be required to test this hypothesis. Nevertheless, identifying the 
mechanism by which PPARδ activation stimulates simultaneous utilization of 
carbohydrate and fat is exciting and warrants further study. 
6.3 OVERALL THESIS CONCLUSION 
A substantial body of preclinical evidence supports the hypothesis that PPARδ 
activation represents a favourable therapeutic strategy for the treatment and prevention 
of dyslipidemia, insulin resistant syndromes and atherosclerosis. Despite this wealth of 
knowledge, a significant gap between preclinical and clinical studies has stalled the 
development of PPARδ agonists. The studies described in this thesis have contributed 
to the narrowing of this gap by elaborating on how PPARδ activation confers protection 
from metabolic insult in macrophages, in the aorta and in the liver (Figure 6.2). 
Specifically, Chapters 2-5 of this thesis provided molecular and physiological evidence 
that PPARδ activation favourably regulates lipid metabolism and inflammatory signaling, 
which results in the protection from atherosclerosis and hepatic steatosis in states of 
metabolic disturbance such as dyslipidemia, insulin resistance and type 2 diabetes.
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Figure 6.2: Thesis Summary. 
PPARδ activation in macrophages attenuates TG and CE accumulation in response to 
lipoproteins, corrects impaired insulin signaling and inhibits the inflammatory response 
(Chapters 2 and 3). The ability of PPARδ activation to inhibit foam cell formation, likely 
contributes to attenuation of diet-induced aortic insulin resistance and atherosclerosis in 
vivo (Chapter 4). In the liver, PPARδ activation attenuates hepatic steatosis via 
increased FA oxidation and inhibition of de novo lipogenesis, which is associated with 
the correction of hyperlipidemia, hyperglycemia and hyperinsulinemia (Chapter 4 and 5).  
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